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PREFACE  
 
The chemotherapy, a branch of pharmacology that develops drugs for therapeutic 
purposes can be divided into antiviral and antitumor chemotherapy. In both case the 
primary requirement for a chemotherapeutic agent must be the selectivity for the 
diseased cells in order to preserving healthy ones, so preventing the occurrence of 
possible side effects.  
Inspired by postulate of Paul Ehrlich, the pioneer of selective chemotherapy, which 
is based on the creation of a ‘magic bullets’ to be used in the fight against human 
diseases, scientists have pointed a lot of attention on the development of powerful 
molecular therapeutics. In particular, in the antitumor chemotherapy field, current 
efforts are devoted to the construction of new and efficient targeted-drug delivery 
systems which allow a controlled drug release once reached cancerous tissue. This 
approach has been realized thanks to the use of controlled release carriers which include 
liposomes, monoclonal antibody, drug loaded biodegradable microspheres and drug 
polymer conjugates.  
On the other side, the antiviral chemotherapy has take advantage of the advent of 
gene silencing strategies based on the development of synthetic MOs that promise to 
achieve the specificity and efficacy that Ehrlich thought. This strategies for regulating 
the expression of a gene results completely selective, and of universal applicability, 
compared to traditional therapies. Strong motivations for this research have been the 
promising results obtained with antisense, antigene, aptamer, and, in more recent times, 
RNAi and miRNA strategies. 
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1.1 INTRODUCTION 
With the exception of coronary and heart diseases, cancer remains the major cause of 
death in the Western world. Despite the significant progress in the development of 
cancer detection, prevention, surgery, and therapy, there is still no efficient cure for 
patients with malignant diseases. The greater part of clinically approved anticancer 
drugs are characterized by a narrow therapeutic window that results mainly from a high 
systemic toxicity of the drugs in combination with an evident lack of tumor selectivity 
causing undesirable severe side effects, such as hair loss and damage to the liver, 
kidney, and bone marrow.  
One strategy aimed at providing substantial increases in the clinical efficacy of 
such drugs, is the development of relatively non-toxic prodrug forms of these cytotoxins 
that can be selectively activated in tumor tissue. The term prodrug was first introduced 
in 1958 by Adrien Albert1 to describe compounds that undergo biotransformation prior 
to eliciting their pharmacological effects. In accordance with this definition, prodrugs 
are derivatives of drugs that are metabolized or activated after administration in the 
body to release or generate the pharmacologically active species; if possible at the site 
of action. They could be designed to overcome pharmaceutical, pharmacokinetic, or 
pharmacodynamic barriers such as insufficient chemical stability, poor solubility, 
unacceptable taste or odor, irritation or pain, insufficient oral absorption, inadequate 
blood-brain barrier permeability, marked presystemic metabolism, and toxicity.2 
Inadequate aqueous solubility is an important factor limiting parenteral, 
percutaneous, and oral bioavailability of common drugs. In such cases, a prodrug 
strategy may bring great pharmaceutical and pharmacokinetic benefit. Charged 
promoieties (esters: phosphates, hemisuccinates, aminoacyl conjugates, dimethylamino 
acetates) and neutral promoieties (poly(ethylene glycol)s, PEG) can be used. Some 
examples of this prodrugs are reported in Figure 1 such as Fosphenytoin,3 a hydrophilic 
phosphate prodrug of the anticonvulsant phenytoin which is rapidly hydrolyzed by 
phosphatases. Another example is Parecoxib Sodium, a water soluble and injectable 
prodrug of Valdecoxib that is a selective inhibitor COX-2 (enzyme responsible for 
inflammation or pain). It can be used when patients are unable to take oral drug. 
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Figure 1. Examples of prodrug designed to improve aqueous solubility. 
 
A classic and clinically successful example of such a prodrug is N4-pentyloxycarbonyl-
5′-deoxy-5-fluorocytidine (Figure 2), more commonly known as Capecitabine or 
Xeloda, a cytotoxic agent orally administered and preferentially activated in tumor cells. 
This carbamate of fluoropyrimidine was synthesized4 in the 1990s as an oral 
formulation designed to circumvent the unacceptable toxicity of 5’-deoxy-5-
fluorouridine. The main limitation of the latter derives from its gastrointestinal toxicity, 
attributed to liberation of 5-fluoruracil in the small intestine under the action of 
thymidine phosphorylase, a tumor-associated angiogenesis factor. Capecitabine was 
thus designed to be not metabolized by thymidine phosphorylase; indeed, after oral 
administration, it crosses the gastrointestinal barrier intact and is rapidly and almost 
completely absorbed. It is subsequently converted into 5-fluoruracile in a three-step 
process involving several enzymes (Figure 2). In theory, this prodrug of 5-fluoruracil 
should have two main advantages, which may translate into an improved therapeutic 
index. First, it should increase the concentration of the active principle at the tumor site, 
and so, should have greater activity; second, it should decrease the concentration of 
drug in healthy tissues with a consequent reduction in systemic toxicity. 
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Figure 2. Structure of a Capecitabine prodrug converted by three enzymes to 5-
fluorouracil. 
 
Another well-know example of an enzyme-activated prodrug is L-Dopa. This agent is a 
precursor of the dopamine neurotransmitter and so has been the mainstay of Parkinson’s 
disease therapy since its discovery in the early 1960s. It has the usefulness to cross the 
protective blood-brain barriers (BBB) by amino acid transporters, whereas dopamine 
itself cannot. After brain entry, L-Dopa is decarboxylated by aromatic L-amino acid 
decarboxylase to dopamine (Figure 3), which can act locally, being no longer a 
substrate for neutral amino acid transporter.5
NH2
OH
HO
OH
HO
NH2
L-Dopa
Dopamine
decarboxylation
O
OH
  
 
Figure 3. L-Dopa: example of prodrug targeting the brain. 
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1.1.1 CARRIER-LINKED PRODRUG STRATEGIES 
One approach that has now been validated by clinical success aimed at improving 
selectivity of anticancer agents is currently being pursued:6 it is mostly based on the 
subtle biochemical differences discriminating healthy from malignant cells. This 
approach involved the conjugation of the drug to tumor-specific ligands, and was called 
“magic bullet” by pioneer of chemotherapy Paul Ehrlich on 1900.
1.1.1.1 PASSIVE TARGETING 
7 
Carrier-linked prodrug strategy is based on passive or active targeting. Differences 
in the biochemical and physiological characteristics of healthy and malignant tissue are 
responsible for the passive tumor accumulation of macromolecules. Active targeting 
relies on the interaction of the carrier-linked prodrug with a tumor-associated cell 
surface marker such as a receptor or antigen. 
 
 
Passive targeting exploits anomalies of malignant tissue at vasculolymphatic level that 
result from the tumor’s phathophysiology. Indeed, it’s know that at a size of 2–3 mm, 
tumor cell clusters induce angiogenesis to satisfy their increasing demands for nutrition 
and oxygen. During this process newly formed blood vessels often greatly differ from 
those of normal tissue. Neovasculature generated by the tumor is characterized by an 
irregular shape and dilated, leaky or defective vessels. The endothelial cells are poorly 
aligned or disorganized with large fenestrations. Other differences affect the 
perivascular cells, the basement membrane, and the smooth-muscle layer which are 
frequently absent or abnormal. These anatomical features make the vasculature of tumor 
tissue permeable to macromolecules or even larger nanometer-scale particles, whereas 
in the blood vessels of healthy tissue only small molecules can pass the endothelial 
barrier. Furthermore, whereas smaller molecules were shown to be rapidly cleared from 
the tumor interstitium, large molecules are retained, thus showing high intratumor 
concentrations even after 100h post-application. This enhanced retention of 
macromolecules in tumor tissue is primarily caused by a lack of lymphatic drainage due 
to an impaired or absent lymphatic system. Hence, it is the combination of both 
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enhanced permeability and retention (EPR)6 that is responsible for the accumulation of 
macromolecules in solid tumors, as illustrated in Figure 5. 
 
Figure 5. Representation of the anatomical and physiological characteristics of normal 
and tumor tissue and EPR effect.i 
 
Thus, an accumulation of drugs in tumor tissue is simply achieved by employing large 
molecules (synthetic or biopolymers) or nanoparticles (liposomes, nanospheres) 8
1.1.1.2 ACTIVE TARGETING 
 as 
inert carriers that do not necessarily interact with tumor cells but strongly influence the 
drug’s biodistribution. 
Appropriate carrier molecule has to fulfill following requirements: it should be 
sufficiently water soluble, nontoxic, nonimmunogenic and should ideally be 
biodegradable and have low polydispersity.  
 
 
Active targeting is based on differences in cell surface antigen or receptor expression 
between normal and cancer tissue. The aim of active targeting is to develop drug 
conjugates with tumor-specific ligands that interact specifically with their cellular 
target. Among such approaches, so called “guided molecular missiles” or “molecular 
Trojan horses” have been widely and successfully reported over the last years.9,10
                                                 
iFigure adapted from “Prodrug Strategies in Anticancer Chemotherapy”, ChemMedChem 2008, 3, 20–53. 
 A 
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typical structure of a tumor-targeting drug-delivery system is characterized by four 
modules as shown in Figure 6:11  
 a ligand capable of detecting cancer cells  
 a linker that functions as a spacer and helps to improve the pharmacokinetics 
and pharmacodynamics of antitumor agent resulting  
 a cleavable bond, located between the spacer and the drug that would allow the 
release of the latter 
 
linker
ligand
cleavable
bond
antitumor
agent
unit 1
unit 2
unit 3 unit 4
an antitumor agent. 
 
Figura 6. Typical structure of antitumor carrier-linked prodrug. 
 
 
UNIT 1: LIGAND 
A rapidly growing tumor requires various nutrients and vitamins. Thus, tumor cells 
overexpress many tumor-specific receptors, which can be used as targets to deliver 
cytotoxic agents into tumors. 
Ligands that have been exploited for this approach to tumor targeting include 
monoclonal antibodies and low molecular weight receptor-binding molecules such as 
peptide hormones, receptor antagonists and agonists, oligosaccharides, oligopeptides, 
and vitamins. (vitamin B12,12 biotin13 and riboflavin14). Moreover, it has long been 
recognized that folate receptors (FRs) are excellent biomarkers to this end.15
FOLIC ACID 
  
 
 
Folic acid is an important member of water-soluble B-group vitamins functioning as co-
factors in one-carbon transfer reactions including de novo biosynthesis of nucleotides 
and plays a key role in metabolic processes involved in DNA and RNA synthesis, 
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epigenetic processes, cellular proliferation and survival. The human membrane FR has 
three main isoforms, namely FR-α, FR-β and FR-γ. This receptors belong to a special 
class of glycopolypeptides of apparent Mr in the range of 38-45 kDa and are attached to 
the plasma membrane by a GPI anchor. FRs are expressed in a limited number of 
normal tissues but are overexpressed in a large number of epithelial malignancies. 
Since folic acid enters cells by receptor-mediated endocytosis (Figure 7), a striking 
consequence is that those FRs expressed by cancer cells can be exploited to selectively 
convey specific anticancer drugs. 
 
Figure 7. FR-mediated endocytosis of a folic acid drug conjugate. 
 
Tumor-targeting folic acid conjugates, covalently linked via folate’s γ-carboxyl moiety, 
maintain a high affinity for the FRs,16 and the mechanism of cellular uptake of folic acid 
conjugates by FRs is as effective as that displayed by folic acid in its free form.17 
Despite their molecular complexity, folic acid conjugates can still enter cells by FR-
mediated endocytosis18 and move through many organelles supplying transported 
materials to cell cytoplasm. The drug is then released in the endosomes/lysosomes 
mainly by enzymatic cleavage or owing to the acidic environment occurring in 
lysosomes. The uptake process can be reiterated because of the recycling of the 
unligated FR back to the cell surface, allowing continuous supplies of folate-linked 
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drugs into the cell19 (Figure 7). Folate as a targeting ligand offers many potential 
advantages over macromolecules such as monoclonal antibodies; these include:  
 small size (M 441.4) of the targeting ligand, which often leads to favorable 
pharmacokinetic properties of the folate conjugates and reduced probability of 
immunogenicity thus allowing for repeated administration;  
 convenient availability and low cost;  
 relatively simple and defined conjugation chemistry;  
 high binding affinity for the FRs (KD ~ 0.1-1.0 nmol/L) even after conjugation 
to its therapeutic/diagnostic cargo;  
 the receptor/ligand complex can be induced to internalize via endocytosis, which 
may facilitate the cytosolic delivery of therapeutic agents;  
 high frequency of overexpression among human tumors thus a wide range of 
tumor targets. 
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Figure 8. Examples of drug folate-conjugates. 
 
The conjugation of folic acid with various anticancer agents, such as taxol20, platinum 
compounds21 or fluorouracil,22 has been the subject of recent researches; some examples 
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were reported in Figure 8. Preliminary experimental studies in animal models 
confirmed the regression of tumor23
UNIT 2: LINKER 
. 
 
 
Direct conjugation of the drug to folic acid has been observed to affect the affinity of 
resultant derivative. Experimental data reported in the literature24 have shown that for 
folate conjugates, the linker (unit 2), which allows to anchor the drug to the ligand, 
plays an important role. For this purpose the use of polymeric linker is often frequent in 
this type of prodrugs. However, it is unknown the requested length of the linker able to 
determine an effective recognition of these molecular systems by receptor. The choice 
of macromolecular systems working as spacer units is also dictated by the fact that these 
compounds are not efficiently eliminated by the kidneys, thus showing a better retention 
of prolonged half-life in plasma. Although the permeability of a molecule depends on 
several factors as size, shape, charge and deformability of the molecule,24 a general rule 
that can be applied to most of the macromolecular carrier, provides that: neutral or 
negatively charged molecules with weight greater than 40 kDa are able to avoid renal 
clearance.25 Oligomeric or polymeric spacers with these prerequisites are already widely 
used in prodrug formation, mainly as carriers. Table 1 shows an overview of various 
synthetic polymers used for this purpose. Usually, an ideal carrier must meet following 
requirements: 
 to be non-toxic or immunogenic, 
 to posses good biodegradability and low polydispersity, 
 to be sufficiently soluble to be administered. 
 
Polyether and peptide spacers meet these requirements and indeed are frequently used 
as a polymeric carriers.26  
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Name Structure 
polyethylene glycol (PEG) 
HO O H
n  
methoxypolyethylene glycol 
(mPEG) HO
O CH3
n  
polyglutamic acid (PG) 
H
H
N OH
O
COOH
n
 
copolymer of  
CH2C CH2
CH3
C
CH3
n m
ON
H
HO OHO
N-(2-hydroxypropyl) 
methacrylamide (HPMA).   
O
HO
HO
OH
HO
O
O
HO
HO
OH
OH
O
O
HO
HO
OH
n
Dextran 
 
Table 1. Some synthetic polymers 
UNIT 3: CLEAVABLE
used in prodrug strategies. 
 
 
Following endocytosis of the drug in the 
 BOND 
cell membrane the next phase involves the 
release of the drug in its active form, due to some intracellular event so that it can 
effectively explicit its antitumor activity. The release is usually performed by inserting a 
cleavable bond between the drug and the carrier. The concept of “programming” 
molecular separation to occur between the ligand and the ‘‘drug’’ is not new. In fact, 
this process occurs naturally with many bacterial, plant and fungal protein toxins that 
bind to receptors on target cells through specialized domains. For many toxins (ricin, 
diphtheria toxin) this bond consists of a disulfide one. Linkers containing disulfide 
bonds are common in carrier-linked prodrug systems due to their stability in blood 
circulation; moreover they are efficiently cleaved by glutathione-S-transferase enzyme, 
particularly overexpressed in tumor cells allowing the release of the active therapeutic 
agent.27 As an example, an efficacious tumor-targeting drug conjugate is reported in 
Scheme 1, which exhibited extremely promising results in human cancer xenografts in 
SCID mice. The glutathione-triggered cascade drug release takes place to generate the 
free anticancer agent, taxol via thiolactone formation and ester bond cleavage. 
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Scheme 1. Release of drug by glutathione. 
 
However, cellular environment of tumors offers a wide choice of intervention as it is 
characterized by a lot of specific enzymes and intense lysosomal activity. To this regard 
it was found a more high content of specific lysosomal glycosidases such as β-
galactosidase, β-glucuronidase and β-N-acetilglucosamminidasi, specific esterase, 
reductase inhibitors and protease inhibitors, than in healthy cells.28
UNIT 4: ANTICANCER AGENTS  
  
 
 
The available anticancer drugs have distinct mechanisms of action which can 
differentiate in their effects on
FDA-APPROVED ANTICANCER DRUGS 
 different normal and cancer cells types. There are about 
50 drugs approved by the Food and Drug Administration; some examples are following 
reported.  
 
 
Methotrexate29 is used as maintenance therapy for childhood acute lymphoblastic 
leukemia, where it can be given intrathecally for central nervous system prophylaxis. It 
is also useful in choriocarcinoma, non-Hodgkin’s lymphoma, and a number of solid 
tumors. Methotrexate competitively inhibits dihydrofolate reductase which is 
responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the 
biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon 
Introduction                                                                                                        Chapter 1 
15 
 
transfer reactions occur which require specific coenzymes synthesized in the cell from 
tetrahydrofolic acid. Methotrexate acts specifically during DNA and RNA synthesis, 
and thus it is cytotoxic during the S-phase of the cell cycle. Logically, it therefore has a 
greater toxic effect on rapidly dividing cells (such as malignant and myeloid cells, and 
gastrointestinal and oral mucosa), which replicate their DNA more frequently, and thus 
inhibits the growth and proliferation of these noncancerous cells.  
N
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Gemcitabine
 (Gemzar) is a pyrimidine nucleoside analogue. In comprehensive 
preclinical and clinical studies, it has shown activity against a wide spectrum of human 
solid tumors including non small cell lung, pancreatic, colon, breast, bladder, ovarian, 
head and neck, cervical and hepatocellular tumours. It exerts its antiproliferative activity 
via multiple mechanisms of action. Gemcitabine is phosphorylated intracellularly by 
deoxycytidine kinase and subsequently by nucleotide kinases to its active metabolites, 
diphosphate and triphosphate gemcitabine. The triphosphate is then incorporated into 
DNA, blocking DNA synthesis and inducing apoptosis. 
 
Paclitaxel31 (Taxol) is a highly complex tetracyclic diterpene found in the needles and 
bark of Taxus brevifolia, the Pacific yew tree. The cytotoxic nature of extracts of Taxus 
brevifolia was first demonstrated in 1964 through a screening program coordinated by 
the National Cancer Istitute; pure paclitaxel was isolated in 1966 and its structure 
published in 1971. Together with docetaxel, it forms the drug category of the taxanes.  
Taxol is now used to treat patients with lung, ovarian, breast cancer, head and neck 
cancer, advanced forms of Kaposi's sarcoma and for the prevention of restenosis. 
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Paclitaxel is a mitotic inhibitor, it 
HOO
O
H
OH
O
O
HO
NH
O
O
O
O
O
O
O
Paclitaxel
stabilizes microtubules and as a result, interferes with 
the normal breakdown of microtubules during cell division.  
 
Doxorubicin32 (Adriamycin) is a type of anthracycline antibiotic, made from the 
bacterium Streptomyces. Adriamycin can be used to treat early-stage or node-positive 
breast cancer, HER2-positive breast cancer, and metastatic disease. It is sometimes 
combined with cytoxan and 5-fluorouracil to make a cocktail of breast-cancer fighting 
chemotherapy drugs. 
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Chloroambucil
 (Leukeran) is a bifunctional alkylating chemotherapeutic agent of the 
mustards type, clinically used for the treatment of chronic lymphatic leukemia, 
lymphomas, and advanced ovarian and breast carcinomas. Like all alkylating agents, 
CLB toxicity stands on its oxidative stress-inducing properties that are exerted equally 
toward healthy and cancer tissues.  
 
Introduction                                                                                                        Chapter 1 
17 
 
                                                 
1 Albert, A. Nature 1958, 182, 421-422 
2 Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. J. Med. Chem. 2004, 47, 2393-
2404 
3 Gerber, N.; Mays, D. C.; Donn, K. H.; Laddu, A.; Guthrie, R. M.; Turlapaty, P.; Quon, 
C.Y. J. Clin. Pharmacol. 1988, 28, 1023-1032. 
4 Arazaki, M.; Ishitsuka, H.; Kuruma, I.; Miwa, M.; Murasaki, C.; Shimma, N.; Umeda , 
I. Eur. Patent Appl., 1992, n° 92121538.0. 
5 Anderson B.D. Adv. Drug. Deliv. Rev. 1996, 19, 171-202 
6 Kratz, F.; Müller, I.A.; Ryppa, C.; Warnecke, A. Chem.Med.Chem. 2008, 3, 20–53. 
7 Ehrlich, P. Angew. Chem. 1910, 23, 2-8. 
8 Matsumura, Y.; Maeda, H. Cancer Res. 1986, 46, 6387-6392. 
9 a) Jaracz, S.; Chen, J.; Kuznetsova, L.V.; Ojima, I. Bioorg. Med. Chem. 2005, 13, 
5043–5054; b) Allen, T. M. Nat. Rev. Cancer 2002, 2, 750–763. 
10 Chari, R. V. J. Adv. Drug Delivery Rev. 1998, 31, 89–104. 
11 Leamon, C.P.; Reddy, J.A. Adv. Drug Delivery Rev. 2004, 56, 1127-1141 
12 a) Gupta, Y., Kohli D.V.; Jain, S.K. Crit. Rev. Ther. Drug Carrier Syst. 2008, 25, 
347-379; b) Waibel, R.; Treichler, H.; Schaefer, N.G.; van Staveren, D.R.; Mundwiler, 
S.; Kunze, S.; Küenzi, M.; Alberto, R.; Nüesch, J.; Knuth, A.; Moch, H.; Schibli, R.; 
Schubiger, P.A. Cancer Res. 2008, 68, 2904-2911. 
13 a) Ojima, I. Acc. Chem. Res. 2008, 41, 108-119; b) Chen, S.; Zhao, X.; Chen, J.; 
Chen, J.; Kuznetsova, L.; Wong, S.S.; Ojima, I. Bioconjugate Chem. 2010, 21, 979–
987; c) Yang, W.; Cheng, Y.; Xu, T.; Wang, X.; Wen, L.P. Eur. J. Med. Chem. 2009, 
44, 862–868; d) Chen, J.; Chen, S.; Zhao, X.; Kuznetsova, L.V.; Wong, S.S.; Ojima, I. 
J. Am. Chem. Soc. 2008, 130, 16778-16785. 
14 a) Bareford, L.M.; Swaan, P. W. Adv. Drug Deliv. Rev. 2007, 59, 748-758; b) 
Foraker, A.B.; Khantwal, C.M.; Swaan, P.W. Adv. Drug Delivery Rev. 2003, 55, 1467-
1483. 
15 a) Xia, W.; Low, P.S. J. Med. Chem. 2010, 53, 6811–6824; b) Low, P.S.; Henne, W. 
A.; Doorneweerd, D. D. Acc. Chem. Res. 2008, 41, 120–129; c) Low, P.S.; Kularatne, 
S. A. Curr. Opin. Chem. Biol. 2009, 13, 256-262; d) Hilgenbrink, A.R.; Low, P.S. J. 
Pharm. Sci. 2005, 94, 2135–2146. 
Introduction                                                                                                        Chapter 1 
18 
 
                                                                                                                                               
16 Lee, J.W.; Lu, J.Y.; Low, P.S.; Fuchs, P.L. Bioorg. Med. Chem. 2002, 10, 2397-2414. 
17 Wang, S.; Low, P.S. J. Control. Release 1998, 53, 39-48. 
18 Leamon C.P.; Low, P.S. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 5572-5576. 
19 Parker, N.; Turk, M.J.; Westrick, E.; Lewis, J.D.; Low, P.S.; Leamon, C.P. Anal. 
Biochem. 2005, 338, 284-293. 
20 Lee, J.W.; Lu, J.Y.; Low, P.S.; Fuchs, P.L. Bioorg. Med. Chem. 2002, 10, 2397-2414. 
21 Aronov, O.; Horowitz, A.T.; Gabizon, A.; Gibson, D. Bioconjug. Chem. 2003, 14, 
563-574. 
22 Liu, J.; Kolar, C.; Lawson, T.A.; Gmeiner, W.H. J. Org. Chem. 2001, 66, 5655-5663. 
23Kukowska Latallo, J.F.; Candido, K.A.; Cao, Z.; Nigavekar, S.S.; Majoros, I.J.; 
Thomas, T.P.; Balogh, L.P. Khan, M.K.; Baker, J.R. Cancer Res. 2005; 65, 5317-5324. 
24 Venturoli, D.; Rippe, B. Am. J. Physiol. Renal. Physiol. 2005, 288, F605-F613. 
25 Maeda, H. Adv. Enzyme Regul. 2001, 41, 189-207. 
26 Pasut, G.; Veronese, F.M. Prog. Polym. Sci. 2007, 32, 933-961. 
27 Feener, E. P.; Shen, W.C.; Ryser, H.J.P. J. Biol. Chem. 1990, 265, 18780-18785. 
28 Devalapally, H.; Navath, R.S.; Yenamandra, V.; Akkinepally, R. R.; Devarakonda, 
R.K. Arch. Pharm. Res. 2007, 30, 723-732. 
29 Haenseler, E.; Esswein, A.;Vitols, K.S.; Montejano. Y.; Mueller, B.M.; Reisfeld, 
R.A.; Huennekens, F.M. Biochemistry 1992, 31, 891-897. 
30 Song, X.; Lorenzi, P.L.; Landowski, C. P.; Vig, B.S.; Hilfinger, J.M.; Amidon, G.L. 
Mol. Pharm. 2005, 2, 157-167 
31 Sinhababu, A.K.; Thakker, D.R. Adv. Drug Delivery Rev.  1996, 19, 241-273 
32 a) Panasci, L.; Paiement, J. P.; Christodoulopoulos, G.; Belenkov, A.; Malapetsa, A.; 
Aloyz, R. Clin. Cancer Res. 2001, 7, 454-461; b) Reux, B.; Weber, V.; Galmier, M.J.; 
Borel, M.; Madesclaire, M.; Madelmont, J.C.; Debiton, E. Bioorg. Med. Chem. 2008, 
16, 5004-5020. 
Results and Discussion                                                                                        Chapter 1 
19 
 
1.2 RESULTS AND DISCUSSION 
On the basis of the results discussed in the previous section, this work is focused on the 
synthesis of carrier-linked prodrug systems to use in anticancer therapeutic strategies 
involving the active transport of drug (Figure 1). The tumor-specific ligand is the folic 
acid, the linker consists of a polyether or polyamide system and the anticancer agent, 
Chlorambucil, chosen from those of more modern application, is anchored to the spacer 
by cleavable bond that can release the drug by action of specific 
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Figure 1. Carrier linked prodrug system. 
 
As already mentioned, folic acid has proven to be one of the most promising ligand 
because its receptors are overexpressed on the surface of a large number of tumor cells, 
including cancer breast, lung, liver, ovaries, brain and myelogenous cells.1,2,3 Objective 
of a part of my PhD thesis was the synthesis and biological evalutation of novel folate-
conjugates 1-2 (Figure 2) trough straightforward and versatile synthetic routes. 
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Figure 2. Folic acid conjugates 1-2. 
 
It must be noted that the choice of an aminoether linker (conjugate 1) offers a twofold 
advantage: a) it is biocompatible and hydrophilic as the most commonly employed 
polymeric linkers NH2PEG (NH2PEG2000, NH2PEG1000, etc.) and b) it’s cheaper 
than other NH2PEG linkers.4 On the other hand, the wear of a β-amino acid-based 
linker (conjugate 2) is due of their structural characteristics. Indeed, they should ensure 
a good solubility and stability of our molecular systems in biological medium. It is 
known that β-amino acids systems are highly innovative alternative to the systems 
studied so far. They appear to be promising constituents of potential therapeutic agents, 
because they are appreciably more stable than their α-analogues to proteolytic 
degradation in vivo.5,6 The majority of β-peptides reported in literature is not toxic,7 thus 
they seem to be a good compromise between solubility, biocompatibility and localized 
release of the drug through a prolonged systemic circulation, so they can to be 
interesting candidates as carriers for such strategies.  
In particular we used the 4,7,10-trioxa-1 ,13-tridecandiamine and a linker 
consisting of two β-amino acid units separated by a ethylenediamine moiety. These 
linkers present amine functions at both ends so that they can bind, on the one hand folic 
acid via an amide bond and the other hand a cleavable unit or the drug.  
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Figure 3. Polyether and polyamide linker. 
 
The preparation of conjugates 1 and 2 was carried out by synthetic methodology that 
consists of following key steps
1.2.1 SYNTHESIS OF CLB-DELIVERY SYSTEM 1 
: 1) preparation of the linkers; 2) linkers conjugation with 
folic acid through an amide bond formation; 3) removal of protective groups; 4) 
coupling reaction with the anticancer agent. 
 
 
The synthetic strategy of conjugate 1 involved the use of 4,7,10-trioxa-1,13-
tridecandiamine (3), commercially available at low cost, and consists of a few stages. 
The first synthetic step (Scheme 1) provided N-Boc-monoprotection of amine 3 by 
reaction with Boc2O in MeOH under refluxing conditions to obtain carbamate 4 with 
86% yield. 
At this point, we are interested to prepare 7 by a coupling reaction of resulting 
carbamate 4 with folic acid (5). It was attempted usual synthetic routes (DCC/HOBT, 
DCC/NHS), but unfortunately we didn’t obtained the expected product. Instead, amide 
7 was successfully obtained by means of the activated folate anhydride 6, in turn 
prepared in situ by treatment of 5 with dicyclohexylcarbodiimide (DCC) in 
DMF/pyridine (5:1) for 30 min in an ultrasonic bath. When it was observed formation 
of intermediate 6 thanks to presence of white crystals of DCU in the reaction vessel, 
amine 4 (1 eq) was added, smoothly leading to amide 7. The concentrate DMF solution 
containing the reaction product was dropwise added to a cold mixture of acetone and 
diethyl ether (30:70 v/v ratio), from which the desired 7 was isolated by precipitation 
(85% yield).  
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Scheme 1. Synthesis of folic derivate 8. 
 
In such conditions the γ-conjugate is the only product formed, because γ-position 
carboxyl function of folate is more reactive than the α-one (Figure 4), indeed, as 
reported in the literature,8 common amidation reactions were carried out preferably in 
this position, so no protections were necessary. The exclusive formation of γ-carboxyl-
linked compound was confirmed by 1
COOH
NH
NN
N
O
NH2
HN
O
N
H COOH
left unprotected
reactive group
left unprotected
α β
γ
H and COSY NMR experiments. 
 
Figure 4. Folic acid. 
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Finally, amide 8 was quantitatively obtained via N-Boc group removal, by treatment of 
conjugate 7 with TFA in CH2Cl2 (Scheme 1). At this point, with the product 7 in hand, 
our interest was focused on preparation of desired conjugate 1 by reaction with 
PyBOP/DIPEA and CLB (9) in DMSO. The crude product, purificated by precipitation, 
gave a brownish yellow compound with 75% yield.  
 
Scheme 2. Coupling reaction to obtain final compound 1. 
 
It’s noteworthy that the same coupling reaction in common condition using DCC was 
found to be not convenient, due to difficulty to remove the resulting DCU from reaction 
mixture.  
 
 
1.2.2 SYNTHESIS OF CLB-DELIVERY SYSTEM 2 
To synthesize conjugate 2 in which a linker consisting of two β-alanina units bridged by 
ethylenediamine spacer is included, we planned to start from folic acid and a linker as 
14 using the same methodology as for 1. Linker 14 was prepared in a single step using 
N-Boc-β-Alanine (2 eq) and free ethylendiamine. Amide bond formation was carried 
out activating carboxyl acid function of N-Boc-β-alanine (11) by treatment with PPh3/I2 
complex and imidazole (Scheme 3). The use of this reagent, as widely reported in the 
literature9 leads to formation of acyl iodide, like intermediate, which in the presence of 
ethylenediamine gave compound 13. Subsequent deprotection of amino functions under 
usual conditions (TFA/CH2Cl2) afford diamine 14 in quantitative yield. (Scheme 3). 
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Scheme 3. Synthesis of pseudo-β-dipeptide 14. 
 
Unfortunately, 14
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 coupled with folic acid did not lead to the desidered conjugate but to 
a bis-folate derivate unsuitable for our purposes. An alternative approch was next 
attempted using a monoprotected linker. Both attempts to obtain 15 from 14 (by 
selective protection) or from 13 (by selective deprotection) failed due to the almost 
exclusive formation respectively of bis-protected (13) or free diamine 14. 
 
Scheme 4. Synthetic efforts to obtain linker 15. 
 
To overcome these problems, we planned to prepare an orthogonally protected diamine 
linker starting from N-Boc-β-Ala (11) and N-Fmoc-β-Ala (17). The Fmoc group is 
Results and Discussion                                                                                        Chapter 1 
25 
 
stable under acidic conditions and may be selectively removed in basic conditions, the 
Boc-protecting group is acid-labile but stable under basic conditions.10 
Amidation reaction of 11 with ethylenediamine (12) (Scheme 5) was carried out 
under the same conditions as described for 13 (carboxyl acid activation with 
PPh3/I2/ImH), in this case, using a large excess of amine (ratio 1:15), the compound 16 
was obtained in high yields 
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(75%). 
The latter was then used in the coupling reaction with N-Fmoc-β-alanine (17) 
prepared trough a well note procedure; the reaction was quantitative and provided 
orthogonally protected 18 (Scheme 5). Finally the selective removal of Fmoc group 
under common reaction conditions (5% piperidine / DMF) gave desired linker 15. 
 
Scheme 5. Synthesis of pseudo-β-dipeptide 15 by Boc/Fmoc strategy. 
 
Monoprocted linker 15 allowed, the preparation of folate 19, via coupling reaction with 
folic acid (Scheme 6), in presence of DCC, Py in DMSO. Conjugate 19 was obtained 
with 82% of yield. N-Boc group removal with TFA at 0 °C gave then amine 20 that was 
finally coupled with CLB (9) using PyBOP/DIPEA in anhydrous DMSO, to allowed 
conjugate 2 as a brownish purple solid (79% yield). 
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Scheme 6. Synthesis of conjugate 2. 
 
 
1.2.3 BIOLOGICAL ASSAYS 
Following the biological assays performed on these molecular systems are reported, 
these assays were realized in collaboration with Prof. Giuseppe Palumbo research group 
(Dip. di Biologia e Patologia Cellullare e Molecolare "L. Califano). 
Cytotoxicity studies with CLB. CLB is an alkylating agent that has been mainly 
used in the treatment of chronic lymphocytic leukemia (CLL).11 It has been 
demonstrated that CLB may induce different effects in in vitro systems, spanning from 
growth arrest to cell death.12 In light of these observations, our initial experiments were 
aimed at establishing the effective CLB concentrations against the specific cell lines 
used in this work. To this purpose, we incubated undifferentiated U937 and TK6 cells 
for 48 and 72 h with CLB at concentrations ranging from 0 to 60 µM. As shown in 
Figure 4, metabolic activity of both cell lines was inhibited as drug concentrations and 
incubation times were increased. In all cases, however, changes in cell metabolic 
activity were less pronounced at CLB concentrations in the order of 30 µM. 
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Figure 4. Metabolic activity of FR--U937 (left) and FR+-TK6 cells (right) treated with 
increasing doses of CLB at different incubation times. 
 
Cytotoxicity studies with CLB conjugates 1 and 2. A first comparison between the 
efficacy of CLB and our FA-conjugates was obtained by observing the 
presence/absence of statistically significant changes in metabolic activities of 
undifferentiated U937 and TK6 cells incubated for 24, 48 and 72 h with media 
containing 30 µM of CLB (to which both cell lines should presumably respond in a 
similar manner) or 30 µM FA-conjugates 1 and 2 (to which receptor positive cells 
should preferentially respond). 
 
Figure 5. Effects of FA-CLB conjugates 1 and 2 on metabolic activity (XTT assay) of  
FR--U937 (upper panel), FR+-TPA-activated U937 (middle panel) and FR+-TK6 cells 
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(lower panel). Significant differences (p<0.0001, three asterisks) are referred to 
controls. 
 
As shown in Figure 4 (upper panel), the metabolic activity of undifferentiated U937 
cells treated with FA-CLB conjugates did not differ appreciably from the control except 
for long incubation time (72 h). Conversely, we observe that the metabolic activity of 
TK6 cells, incubated in 30 µM FA- conjugates 1 or 2, decreased from nearly 50% to 
about 70% (as compared to controls) as the incubation time was increased from 48 to 72 
h, respectively (Figure 5, lower panel). 
We hypothesized that a different expression level of FRs may account for such a 
divergent behavior. Indeed, it has been demonstrated that while FR expression is 
restricted to only a few cell types,13 Branda et al. reported14 that this expression level in 
TK6 human lymphoblast cells is very high. At variance, while Antony has reported15 
that such receptors are essentially absent in undifferentiated U937 cells, nevertheless 
remarkably elevated levels have been demonstrated in macrophagic TPA-activated 
U937 cells.16 This presence in macrophages has been largely exploited for drug 
targeting.17 In line with these remarks, to finally proof that our folate conjugates 1 and 2 
exerted antitumor activity by FR recognition and endocytosis, we differentiated the 
U937 FR- into FR+ activated macrophages. This was achieved by incubating the U937 
with 20 nM of TPA (as outlined in the experimental section). The U937 cells, which 
normally grow in suspension, when differentiate into macrophages become adherent to 
each other and to the surface of the culture vessel and cease to proliferate. We found 
that the metabolic activity of TPA-activated U937 incubated with 1 and 2 (30 µM) 
differed significantly from that of undifferentiated U937 cells. As shown in Figure 4 
(middle panel), cell viability of activated cells decreased significantly and progressively 
from 48 and 72 h. We also observed that differences in therapeutic efficacy of FA-
derivatives in responsive cells were scarcely perceptible and, in any case, were similar 
to that of CLB at the longest incubation time (Figure 6). 
Interesting enough, the addition of FA-conjugates to responsive cells (104) 
pretreated for 1 h with 50 fold excess (1.5 mM) free FA, prevented appreciable changes 
in metabolic activities even after 72 h of incubation (Figure 6). At variance, the same 
pre-treatment resulted wholly ineffective when cells were exposed to 30µM CLB.  
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Figure 6. TK6 and TPA-differentiated U937 cells were pretreated with 1.5 mM free FA 
for 1 h and incubated with FA-conjugates 1 and 2. The XTT assay was performed after 
72 h of incubation. 
 
Stability of FA-CLB conjugates 1 and 2 (shelf life and stability in human serum). 
The shelf life (at 4 °C) of 1 and 2 in human serum was established in vitro in U937 and 
TK6 cell lines. Activity of our FA-CLB conjugates did not change over a 5 weeks 
storage period (data not shown). Similarly, when conjugates 1 and 2 were incubated in 
fresh human serum, their activity was preserved with negligible activity loss as 
determined by XTT assay.  
 
Figure 7. Stability studies of FA-CLB conjugates 1 and 2 pre-incubated for 12 h in 
fresh human serum. Details in the Methods section. 
 
As shown in Figure 7, change in cell viability of both cell lines was similar to that 
observed by treating cells with equimolar concentrations (30 µM) of FA-CLB 
conjugates 1 and 2 or CLB free form. The abatement of metabolic activity of TK6 cells 
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resulted similar to that observed in the absence of pre-incubation of the compounds with 
human serum. The U937 cells retain their unresponsiveness to both conjugates. 
 
Molecular studies. Although it is generally acknowledged that the bifunctional 
alkylating agent chlorambucil (CLB) is not cell cycle specific, it has been demonstrated 
that it may induce G2/M arrest and apoptosis in several human cell lines. Clarification 
of the molecular mechanisms of cell cycle arrest and cell death induced by different 
DNA-damaging chemicals, including chlorambucil, has considerable implications for 
molecule-targeted cancer therapy. For this reason, it was of interest to investigate at 
cellular and molecular level how FA-CLB conjugates 1 and 2 exert their effects in 
undifferentiated U937 (FR-), TPA-U937 activated (FR+), and TK6 (FR+) cells in 
comparison to their parent molecule CLB. To this purpose, we studied the cell cycle 
distribution and apoptosis upon sublethal treatments. To this aim we analyzed the 
cytofluorimetric profiles and analyzed the protein expression patterns of cells incubated 
for 48 h with 30 µM CLB in its free form or in conjugated forms 1 and 2. In agreement 
with general literature data, we confirmed in both FR+ cell lines two major aspects: first, 
CLB promotes visible cell accumulation in G2 phase and, as also suggested by the 
presence of a consistent sub-G1 phase, this drug induces apoptosis (Figure 8). The 
increase of the sub-G1 phase appears to be also associated to an appreciable up-
regulation of the proapoptotic BAX and Clusterin (Figure 8). This protein has been at 
the core of a long-lasting debate, as conflicting data demonstrated both pro- and 
antiapoptotic effects. However, the controversy on Clusterin function in tumors has 
been clarified in that it has been demonstrated that two different mRNA transcripts 
(generated by alternative splicing) can be found in cells, one secretory and the other one 
coding for the a nuclear form. The activation of the latter form has proapoptotic aptitude 
and a regulative (negative) function in cell cycle progression.i
                                                 
i However, the controversy on Clusterin function in tumors has been clarified in that it has been 
demonstrated that two different mRNA transcripts (generated by alternative splicing) can be found in 
cells, one secretory and the other one coding for the a nuclear form. The activation of the latter form has 
proapoptotic aptitude and a regulative (negative) function in cell cycle progression. See ref. 18. 
,18 
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Figure 8. Cell cycle profiles for FR--U937 (panel a), differentiated FR+-U937 (panel b) 
and FR+-TK6 cells (panel c) in response to treatments (48 h) with CLB-conjugates 1, 2 
and free CLB (30 µM). 
 
As the FR- cells (undifferentiated U937) are concerned, we found that treatment with 
FA-CLB conjugates did not roughly change the cell cycle profile and, at variance with 
the effect of pure CLB, it did not determine amassing of cells in the sub-G1 fraction. 
The lack of apoptosis in cells incubated for 48 h with both conjugates was also inferred 
by Western blot experiments, showing no changes in the expression levels of Bax and 
Clusterin (Figure 9, left panel, lanes 2 and 3). 
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Figure 9. Protein expression in FR--U937, TPA-differentiated FR+-U937 and FR+-TK6 
cells in response to treatments (48 h) with CLB-conjugates 1, 2 and free CLB (30 µM). 
 
On the contrary, once incubated with FA-CLB conjugates (30 µM), the cell cycle 
profile of TK6 and TPA-differentiated U937 cells, both expressing FRs, showed a 
modest accumulation in G2 phase while visibly activating apoptosis (Figure 8, panel b 
and c). The sub-G1 fractions in fact amounted to ≤ 20 in TK6 cells and up to ≥ 25% of 
the total in TPA-treated U937 cells. The differentiation to macrophages that occurs in 
TPA-treated U937 cells induced synchronization in G0/G1 phase and in the meanwhile 
proliferation was switched off. This cytofluorimetric scenario was mirrored by Western 
blot experiments. Apoptosis was declared by the augmented levels of BAX and of the 
propapoptotic form of Clusterin (Figure 9, middle and right panels, lanes 2 and 3) in 
both cell lines and, as the TK6 cells are concerned, of p53 (Figure 9, right panel, lanes 
2 and 3). Notably, once incubated with 30 µM free CLB, TK6 cells were characterized 
by a time-dependent increase in the expression level of p53. This observation agrees 
with literature data that point to an ongoing up-regulation of p53 protein expression to 
explain the onset of lymphocytic cell resistance to CLB.19 
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1.3 CONCLUSION 
Cellular uptake of vitamin folic acid occurs via folate-receptor mediated endocytosis. 
Many types of cancer cells express high levels of folate receptors as they need 
continuous supply of this vitamin for their proliferation. With an objective to use folic 
acid as a ‘Trojan Horse’ to transport anticancer drugs into cancer cells, we prepared two 
tumor-targeted drug delivery systems 1 and 2, which bear a FA unit as the tumor 
recognition moiety and the CLB as the cytotoxic agent, the two bioactive units having 
been jointed by aminoether (4,7,10-trioxadecane-1,13-diamine) and pseudo-β-dipeptide 
(β-Ala-ED-β-Ala) linkers. Preparation of the two molecular systems has been devised 
by a straightforward and efficient route (34-54% o.y.). When evaluated using both FR- 
(undifferentiated U937) and FR+ (TK6 and TPA-differentiated U937) leukemic cells, 
both conjugates exhibited activity only against FR+
 
 cells (particularly TK6), exerting 
antitumor effects which are comparable to that displayed by CLB in its free form. Our 
in vitro results, then, show that the FA-derivatives specifically bind folate-receptor-
positive cells, that this binding is significantly higher than in folate-receptor negative 
cells, and that the interaction is inhibited by free FA. 
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1.4 EXPERIMENTAL SECTION 
CHEMISTRY 
All moisture-sensitive reactions were performed under nitrogen atmosphere using oven-
dried glassware. Solvents were dried over standard drying agents and freshly distilled 
prior to use. Triethylamine (TEA) and N,N-diisopropylethylamine (DIPEA) were 
redistilled from NaOH. N,N’-Dicyclohexylcarbodiimide (DCC) and folic acid (FA) 
were purchased from Sigma-Aldrich Inc. Chlorambucil (CLB), dimethyl sulfoxide 
(DMSO, anhydrous) and pyridine (Py, anhydrous) were used as purchased (Fluka 
Chemical Co.) without further purification. Reactions were monitored by TLC 
(precoated silica gel plate F254, Merck). Column chromatography: Merck Kieselgel 60 
(70–230 mesh); flash chromatography: Merck Kieselgel 60 (230–400 mesh). 
Combustion analyses were performed by using CHNS analyzer. 1H and 13
SYNTHETIC PROCEDURES AND CHARACTERIZATION DATA FOR 
INTERMEDIATES AND CONJUGATES 
C NMR 
spectra were recorded with the following instruments: Varian Gemini (200 MHz), 
Varian Gemini (300 MHz), Bruker DRX (400 MHz) and Varian Inova (500 MHz) 
spectrometers. MALDI spectra were recorded on a Voyager DE-PRO MALDI-TOF 
mass spectrometer. 
 
O
O
OH2N
H
N O
O
4  
Compound 4. A stirring solution of 4,7,10-trioxa-1,13-tridecanediamine (3, 2.0 g, 9.1 
mmol) in anhydrous CH3OH (152 mL) was treated with Boc2O (2.0 g, 9.1 mmol) and 
TEA (2.9 mL, 21 mmol). The reaction mixture was left at reflux for 16 h. The solvent 
was removed under reduced pressure and the resulting yellow oil was purified by silica 
gel chromatography (CHCl3/CH3OH/NH4OH = 89:10:1) to give the pure 4 (2.5 g, 86% 
yield). Oily; 1H NMR (300 MHz, CD3OD) δ: 1.44 (s, 9H), 1,73-1,78 (m, 2H), 1.90-1.96 
(m, 2H), 2.03 (bs, 2H), 2.90 (t, 2H, J = 6.7 Hz), 3.12 (t, 2H, J = 6.0 Hz), 3.52 (t, 2H, J = 
6.0 Hz), 3.56-3.68 (m, 10H), 5.1 (bs, 1H). 13C NMR (100 MHz, CDCl3) ppm: 28.2, 
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29.3, 32.7, 38.3, 39.3, 69.2, 69.8, 69.9, 70.2, 70.3 78.2, 156.2. MALDI-TOF MS: m/z 
320.23 (calcd); 321.20 [M+H]+ (found). Anal. calcd for C15H32N2O5
COOH
N
H
O
N
H
N
O
HN
H2N N N
H
N
O
O
O
O
BocHN
7
: C, 56.23; H, 
10.07; N, 8.74. Found: C, 56.40; H, 10.03; N, 8.71. 
 
Compound 7. To a stirring solution of folic acid (5, 0.25 g, 0.56 mmol) in an anhydrous 
DMF:Py (5:1, 24 mL) solution, DCC (0.70 g, 3.4 mmol) was added in one portion. The 
reaction mixture was kept in an ultrasound bath in the dark for 30 min. Then the 
resulting suspension was quickly filtered over a sintered funnel and the precipitate 
washed with the minimum amount of anhydrous DMF:Py solution. The N-Boc-4,7,10-
trioxa-1,13-tridecanediamine (4) (0.18 g, 0.6 mmol) was then added to the filtrate. The 
resulting reaction was further stirred in the dark for 16 h. Afterwards, the mixture was 
poured dropwise into a stirred solution of cold diethylether/acetone (70:30): a yellow 
precipitate was formed and collected on a sintered glass funnel. After washing several 
times with acetone and ether, the material was dried to give 7 as a yellow powder (0.35 
g, 85% yield) which was used in the next step without further purification. Mp 206-210 
°C; 1H NMR (200 MHz, DMSO-d6) δ: 1.34 (s, 9H), 1.49-1.65 (m, 4H), 1.80-2.05 (m, 
2H), 2.12-2.34 (m, 2H), 2.86 (dd, 2H, J = 6.5, 12.4 Hz), 3.05 (bt, 2H, J = 6.1 Hz), 3.25-
3.40 (m, 4H), 3.41-3.50 (m, 8H), 4.20-4.38 (m, 1H), 4.46 (bd, 2H, J = 5.4 Hz), 6.61 (bd, 
2H, J = 7.6 Hz), 6.75-6.98 (m, 3H), 7.63 (bd, 2H, J = 7.6 Hz), 7.76-7.86 (m, 1H), 7.90 
(bd, 1H, J = 8.4 Hz), 8.62 (bs, 1H), 11.4 (s, 1H). 13C NMR (100 MHz, DMSO-d6): ppm 
29.4, 30.0, 30.4, 31.2, 36.6, 37.9, 46.7, 52.9, 68.8, 70.4, 70.5, 78.1, 111.1, 122.2, 128.7, 
129.7, 149.3, 151.5, 154.5, 156.3, 156.7, 161.7, 166.9, 172.4, 174.6, 174.9. MALDI-
TOF MS: m/z 743.36 (calcd); 766.20 [M+Na]+, 782.20 [M+K]+ (found). Anal. calcd for 
C34H49N9O10: C, 54.90; H, 6.64; N, 16.95. Found: C, 55.05; H, 6.61; N, 16.89. 
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COOH
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H
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Compound 8. TFA (1.7 mL) was added to 7 (250 mg, 0.33 mmol) at 0 °C and under 
magnetic stirring. The resulting mixture was stirred at room temperature for 2 h, then 
TFA was evaporated under high vacuum and the resulting residue was dissolved in a 
small amount of anhydrous DMF. Pyridine was added dropwise until complete 
formation of a yellow precipitate, which was collected by filtration, washed with Et2O 
and dried under vacuum to yield amine 8 (0.421 g, 99% yield). Yellow powder, M.p. 
203-207 °C; 1H NMR(500 MHz, CD3OD) δ: 1.44-1.62 (m, 2H), 1.70-1.80 (m, 2H), 
1.82-2.00 (m, 2H), 2.05-2.17 (m, 2H), 2.84 (bt, 2H, J = 7.4 Hz), 2.98-3.07 (m, 2H), 
3.18-3.38 (m, 2H), 3.40-3.57 (m, 10H), 4.20-4.37 (m, 1H), 4.46 (d, 2H, J = 5.8 Hz), 
6.63 (d, 2H, J = 7.4 Hz), 6.80-6.98 (m, 3H), 7.65 (bd, 2H, J = 7.4 Hz), 7.85 (bd, 1H, J = 
8.0 Hz), 8.65 (s, 1H), 11.38 (bs, 1H). 13C NMR (100 MHz, DMSO-d6): ppm 27.2, 29.3, 
30.6, 35.6, 36.9, 46.2, 53.8, 67.4, 68.0, 69.5, 69.6, 69.7, 111.2, 121.4, 128.3, 129.4, 
148.3, 151.0, 153.3, 158.5, 160.8, 166.5, 172.1, 174.4. MALDI-TOF MS: m/z 643.31 
(calcd); 666.40 [M+Na]+, 682.34 [M+K]+ (found). Anal. calcd for C29H41N9O8
N
NN
N
HO
NH2
HN
O
N
H
COOH
O
H
N O
O
O NH
O N
Cl
Cl
1
: C, 
54.11; H, 6.42; N, 19.58. Found: C, 54.30; H, 6.39; N, 19.51. 
 
Compound 1. To a stirring solution of CLB (9) (0.46 g, 1.5 mmol) in anhydrous 
DMSO (5.0 mL), DIPEA (0.26 mL, 1.5 mmol), 8 (0.32 g, 0.5 mmol) and PyBOP (0.78 
g, 1.5 mmol) were sequentially added. The resulting mixture was stirred for 16 h at 
room temperature. Then the mixture was poured dropwise into a stirred solution of cold 
diethyl ether/acetone (70:30): a yellow precipitate was formed and collected on a 
sintered glass funnel. After washing several times with acetone, ether and finally 
chloroform, the material was dried to give 1 as a brownish yellow solid (0.38 g, 75% 
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yield). 1H NMR (500 MHz, DMSO-d6) δ: 1.48-1.63 (m, 4H), 1.63-1.78 (m, 2H), 1.79-
1.98 (m, 2H), 2.05 (appt, 2H, J = 7.3 Hz), 2.30 (t, 2H, J = 6.7 Hz), 2.36-2.45 (m, 2H), 
2.99-3.09 (m, 2H), 3.15-3.50 (m, 14H), 3.78 (bs, 4H), 4.21-4.35 (m, 1H), 4.46 (bs, 2H), 
6.63 (m, 4H), 6.93 (m, 1H), 6.98 (d, 2H, J = 7.0 Hz), 7.65 (d, 2H, J = 8.0 Hz), 7.76-7.87 
(m, 2H), 7.93 (bd, 1H, J = 6.6 Hz), 8.02-8.23 (m, 1H), 8.63 (s, 1H), 11.43 (bs, 1H). 13C 
NMR (100 MHz, DMSO-d6): ppm 27.0, 29.4, 30.6, 32.0, 33.8, 34.8, 35.6, 35.9, 40.4, 
45.8, 52.2, 53.6, 58.5, 67.3, 68.0, 69.5, 69.7, 111.1, 111.9, 121.4, 127.9, 128.9, 129.5, 
138.4, 144.4, 148.4, 150.7, 153.4, 155.1, 159.0, 160.9, 166.3, 171.8, 173.8, 174.0. 
MALDI-TOF MS: m/z 928.38 (calcd); 951.03 [M+Na]+, 967.04 [M+K]+ (found). Anal. 
calcd for C43H58Cl2N10O9
N
H
OH
O
O
O
11
: C, 55.54; H, 6.29; Cl, 7.63; N, 15.06. Found: C, 55.75; H, 
6.25; Cl, 7.57; N, 14.98. 
 
Compound 11. To a stirring solution of β-alanina (2.5 g, 28 mmol) in H2O (55 mL) 
was added KOH (3.2 g, 57 mmol) in one portion and Boc2O (2.0 g, 9.1 mmol) 
dissolved in CH3CN (10 mL) at 0 °C. After 24 h at room temperature to the mixture of 
reaction HCl (1M) was added until to obtained a pH ~ 4 and then the reaction was 
extracted with EtOAc2. The organic layer was washed with H2O until neutrality and 
dried over Na2SO4. The solvent was removed under reduced pressure to give the pure 
product 11 (5.0 g, 95% yield): p.f. 76-77 °C; 1H NMR (200 MHz, CDCl3) δ: 1.43 (s, 
9H), 2.50 (bt, 2H, J = 5.4), 3.32 (bd, 2H, J = 6.0, J = 11.8), 5.18 (bs, 1H), 10.95 (bs, 
1H). 13C NMR (50 MHz, CDCl3) ppm: 28.0, 34.1, 35.6 (CH2NH), 84.8, 155.8, 175.9. 
ESI-MS: m/z 189.10 (calcd); 190.1 [M+H]+ (found). Anal. calcd for C8H15NO4
N
H
N
H
O
H
N
O
H
NO
O
O
O
13
: C, 
50.91; H, 7.96; N, 7.37. Found: C, 50.78; H, 7.99; N, 7.40. 
 
Compound 13. To magnetically stirred solution of I2 (503 mg, 1.98 mmol) in dry 
CH2Cl2 (15 mL), under nitrose atmosphere at room temperature a solution of 
triphenylphosphine dissolved in the same solvent (15 mL) was added dropwise (520 
mg, 1.98 mmol). After 15 min, imidazole (273 mg, 4.0 mmol) was added and after a 
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few min N-protected β-amino acid 11 (300 mg, 1.6 mmol) in CH2Cl2 (5 mL) was added 
to the mixture of reaction. The reaction was kept at room temperature until starting 
material was consumed to form acyl iodide (TLC: CHCl3:CH3OH = 8/2). After 3 h, 
ethylenediamine (0.053 mL, 0.8 mmol) was added in one portion; the resulting mixture 
was left at room temperature until TLC analysis indicates complete formation of 
compound 13 (TLC: CHCl3:CH3OH = 8/2). The solution was diluted with CH2Cl2 (20 
mL), washed with a solution of sodium thiosulfate 5 N and neutralized with brine. The 
organic phase reunited and dried over dry Na2SO4 was evaporated under reduced 
pressure to give the pure 13 (450 mg, 75% yield): pf. 182.8-184.4 °C, 1H NMR (200 
MHz, CD3OD) δ: 1.43 (s, 18H), 2.34 (t, 4H, J = 6.7), 3.22-3.38 (m, 8H), 5.22 (bs, 2H, 
NHuret), 6.63 (bs, 2H).13C NMR (50 MHz, CD3OD) ppm: 25.0, 33.8, 34.3, 36.3, 76.3, 
152.8, 172.9. ESI-MS: m/z 402.25 (calcd); 403.01 [M+H]+ (found). Anal. calcd for 
C18H34N4O6
NH2NH
O
H
N
O
H2N
14
: C, 53.71; H, 8.51; N, 13.92. Found: C, 53.90; H, 8.47; N, 13.87. 
 
Compound 14. To a magnetically stirred solution of dry CH2Cl2 (3 mL) and TFA (1.5 
mL) at room temperature compound 15 (500 mg, 1.2 mmol) was added. After 1 h 
starting material was completely consumed (TLC, CHCl3/CH3OH=8:2) and the solvent 
was evaporated under vacuum to give the pure compound 14 (230 mg, 95% yield):p.f. 
182.8-184.4 °C, 1H NMR (200 MHz, CD3OD) δ: 2.63 (t, 4H, J=6.5,), 3.21 (t, 4H, J = 
6.5), 3.31 (s, 4H). 13C NMR (50 MHz, CD3OD) ppm: 29.2, 33.4, 36.2, 168.9. Anal. 
calcd for C8H18N4O2
N
H
N
H
O
O
O
NH2
16
: C, 47.51; H, 8.97; N, 27.70;. Found: C, 47.68; H, 8.93; N, 27.61. 
 
Compound 16. To a solution of I2 (990 mg, 3.9 mmol) in dry CH2Cl2 (10 mL), under 
dry nitrogen atmosphere at room temperature, triphenylphosphine (1.1 g, 3.9 mmol) was 
added dropwise in the same solvent (10 mL). After 15 min imidazole (708 mg, 10.4 
mmol) was added in one portion. Then, compound 11 (500 mg, 2.6 mmol), in CH2Cl2 
(5 mL) was added to the mixute. The reaction was kept at room temperature for 3 h 
(TLC monitoring: CHCl3:CH3OH = 8/2) until all the starting amino acid was 
completely consumed in favor of acyl iodine. After 3 h, ethylenediamine (2.6 mL, 39 
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mmol) was added in one portion; the resulting mixture of reaction was kept at room 
temperature. When acyl iodine was consumed (TLC: CHCl3:CH3OH = 8/2) the solution 
was diluted with CH2Cl2 (20 mL), washed with a solution of sodium thiosulfate 5 N and 
brine. The organic layer was extracted with a mixture of CHCl3/MeOH (95/5, 3 x 75 
mL) and dried (Na2SO4) and evaporated under vacuum to give the pure 16 (450 mg, 
75% yield): 1H NMR (200 MHz CD3OD) δ: 1.38 (s, 9H), 1.62 (bs, 2H), 2.32 (t, 2H, J = 
6.0), 2.76 (t, 2H, J = 6.0), 3.15-3.42(m, 4H), 5.52 (bs, 1H), 6.78 (bs, 1H). 13C NMR (50 
MHz, CH3OD) ppm: 28.2, 36.2, 41.2, 41.9, 79.2, 156.2, 171.9. ESI-MS: m/z: 231.16 
(calcd); 232.37 [M+H]+ (found). Anal. calcd for C10H21N3O3
N
H
OH
O
O
O
17
: C, 51.93; H, 9.15; N, 
18.17. Found: C, 51.72; H, 9.19; N, 18.25. 
 
Compound 17. To a stirring solution of β-alanina (2.5 g, 13.3 mmol) in H2O (8 mL), at 
0 °C, a 10 mL of a mixture of sodium carbonate (9%) was added slowly and then Fmoc-
O-Su (2.69 g, 7.9 mmol) dissolved in DMF (25 mL) was added in one portion. After 30 
min the reaction was diluited with H2O (400 mL) and extracted with EtOAc (100 mL). 
The aqueous phase was acidified (pH ~ 2) with a cold solution of HCl 1M and extraxted 
several times with EtOAc. The organic phase reunited was washed with brine, dried on 
dry Na2SO4 and evaporated under vaccum to obtain the pure 17 (3 g, 9.7 mmol, 73% 
yield): 1H NMR (200 MHz, CD3OD) δ: 2.62 (bt, 2H, J = 5.7), 3.18-3.40 (m, 2H), 4.22 
(t, 1H, J = 6.4), 4.42 (d, 2H, J = 6.6), 5.32 (bt, 1H, J = 5.6), 7.20-7.46 (m, 4H), 7.58 (d, 
2H, J = 7.3), 7.76 (d, 2H, J=7.1), 9.54 (bs, 1H). 13C NMR (50 MHz) ppm: 34.2, 36.4, 
47.2, 66.8, 120.0, 125.0 127.1, 127.7, 141.3, 143.8, 156.4, 176.7. Anal. calcd for 
C18H17NO4
N
H
N
H
O
O
O
H
N
O
H
NO
O
18
: C, 69.44; H, 5.50; N, 4.50. Found: C, 69.57; H,5.48; N, 4.48. 
 
Compound 18. To a solution of PPh3/I2/Him complex in dry CH2Cl2 anidro (30 mL), 
prepared with the same procedure used to prepare 13, Fmoc-β-Ala 17 (150 mg, 0.65 
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mmol, 1 eq) was added at room temperature and under nitrogen atmosphere. When it 
was observed the formation of acyl iodide (TLC: CH2Cl2/MeOH = 8:2), to mixture of 
reaction the compound 13 (450 mg, 1.94 mmol) in CH2Cl2 anidro (5 mL), was added in 
one portion. After 24 h, the mixture was treated with a solution of sodium thiosulfate 
5N (25 mL) e brine (25 mL) and extracted with CHCl3:CH3OH = 95/5. The organic 
phases were reunited, dried over Na2SO4 and evaporated under reduced pressure. The 
crude product (350 mg) was purified by crystallization (EtOAc) to give the pure 18 as 
white crystals (230 mg, resa 88%): 1H NMR (200 MHz, DMSO-d6) δ: 1.38 (s, 9H), 
2.11-2.29 (m, 4H), 2.99-3.26 (m, 8H), 4.14-4.32 (m, 5H.), 6.75 (bt, 2H, J = 5.5), 7.22-
7.42 (m, 4H), 7.67 (d, 2H, J = 7.1), 7.87 (d, 2H, J = 6.8). 13C NMR (50 MHz, DMSO-
d6) ppm: 28.2, 35.8, 36.7, 38.6, 39.5, 40.2, 40.7, 77.6, 40.7, 109.7, 120.0, 121.4, 127.2, 
128.9, 137.4, 139.4, 155.4, 157.2, 170.5, 171.5. ESI-MS: m/z 524.26 (calcd); 525.44 
[M+H]+ (found). Anal. calcd for C28H36N4O6
NH2NH
OH
N
O
H
NO
O
15
: C, 64.10; H, 6.92; N, 10.68. Found: C, 
64.25; H, 6.89; N, 10.64. 
 
Compound 15. To a magnetically stirred solution of Py in DMF (5%) product 12 (230 
mg, 0.44 mmol) was added at room temperature. After 2h starting material was 
consumed (TLC: CHCl3:CH3OH = 7/3) and the solvent was evaporated under vacuum. 
Purification of the crude product by crystallization (Et2O/AcOEt) gave the pure 15 as 
white crystals (126 mg, yield 95%): 1H NMR (200 MHz, CH3OD) δ: 1.40 ( s, 9H), 
2.10-2.30 (m, 6H), 2.32-2.47 (m, 2H), 3.20-3.45 (m, 6H), 4.30-4.60 (m, 1H), 5.45 ( bs, 
1H), 6.78 (bs, 1H). 13C NMR (50 MHz, CH3OD) ppm: 28.3, 34.0, 34.2, 36.4, 39.8, 
41.1, 41.7, 79.0, 156.0, 171.8. ESI-MS: m/z 302.20 (calcd); 303.19 [M+H]+ (found). 
Anal. calcd for C13H26N4O4
COOH
N
H
O
N
H
N
O
HN
H2N N N
H
N
O
H
N
NH
BocHN
O
O
19
: C, 51.64; H, 8.67; N, 18.53. Found: C, 51.82; H, 8.63; N, 
18.47. 
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Compound 19. Conjugate 15 was obtained (82% yield) under the same conditions 
reported for the synthesis of compound 7 from folic acid and amine 15.1 Yellow solid, 
M.p. 207-209 °C; 1H NMR (200 MHz, DMSO-d6) δ: 1.38 (s, 9H), 1.82-2.01 (m, 2H), 
2.08-2.32 (m, 6H), 2.98-3.18 (m, 4H), 3.21-3.42 (m, 4H), 4.22-4.38 (m, 1H), 4.52 (bs, 
2H), 6.62 (d, 2H, J = 7.5 Hz), 6.68-6.78 (m, 1H), 6.82-7.05 (m, 3H), 7.65 (d, 2H, J = 7.5 
Hz), 7.81 (bs, 2H), 7.91-8.02 (m, 1H), 8.69 (s, 1H), 11.42 (bs, 1H). 13C NMR (100 
MHz, DMSO-d6): ppm 28.3, 30.7, 31.8, 35.4, 36.0, 36.6, 39.0, 39.1, 46.0, 51.8, 77.6, 
111.2, 121.4, 128.0, 129.0, 148.5, 148.7, 150.8, 153.7, 155.5, 156.6, 160.9, 166.4, 
170.5, 171.7, 173.8, 174.1. MALDI-TOF MS: m/z 725.32 (calcd); 748.66 [M+Na]+, 
764.68 [M+K]+ (found). Anal. calcd for C32H43N11O9
COOH
N
H
O
N
H
N
O
HN
H2N N N
H
N
O
H
N
NH
H2N
O
O
20
: C, 52.96; H, 5.97; N, 21.23. 
Found: C, 52.84; H, 5.96; N, 21.31. 
 
Compound 20. Folate conjugate 20 was obtained (82%) under the same conditions 
reported for the preparation of compound 8. Yellow solid, M.p. 204-207 °C; 1H NMR 
(500 MHz) (DMSO-d6) δ: 1.79-2.15 (m, 2H), 2.18-2.30 (m, 6H), 2.99-3.32 (m, 8H), 
4.38 (bs, 1H), 4.50 (bd, 2H, J = 5.0 Hz), 4.52 (bs, 2H), 6.58 (d, 2H, J = 7.3 Hz), 6.78-
7.02 (m, 4H), 7.62 (d, 2H, J = 7.3 Hz), 7.78-7.98 (m, 1H), 8.02-8.08 (m, 1H), 8.65 (s, 
1H), 11.40 (bs, 1H). 13C NMR (100 MHz, DMSO-d6): ppm 31.6, 32.1, 36.0, 36.8, 37.0, 
38.8, 39.1, 46.5, 52.4, 111.7, 121.4, 128.0, 129.6, 148.2, 148.4, 151.8, 156.0, 157.5, 
161.6, 167.1, 171.0, 172.6, 173.6, 174.0. MALDI-TOF MS: m/z 625.45 (calcd); 648.49 
[M+Na]+, 664.45 [M+K]+ (found). Anal. calcd for C27H35N11O7
N
NN
N
HO
NH2
HN
O
N
H
COOH
O
H
N
H
N
N
HO
O
NH
O N
Cl
Cl
2
: C, 51.83; H, 5.64; N, 
24.63. Found: C, 51.96; H, 5.62; N, 24.57. 
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Compound 2. Folate-CLB conjugate 2 was obtained (79% yield) under the same 
conditions reported for the synthesis of compound 1. Brownish purple solid, M.p. 220 
°C (dec.); 1H NMR (400 MHz) (DMSO-d6) δ: 1.65-1.69 (m, 2H), 1.79-1.98 (m, 2H), 
2.03 (appt, 2H, J = 7.2 Hz), 2.14-2.26 (m, 5H), 2.30 (t, 1H, J = 6.4 Hz), 2.32-2.42 (m, 
2H), 2.97-3.18 (m, 4H), 3.19-3.37 (m, 4H), 3.60 (t, 2H, J = 6.3), 3.67 (s, 2H,), 4.23-4.38 
(m, 1H), 4.48 (bd, 2H, J = 5.9 Hz), 6.57-6.69 (m, 4H), 6.78-7.02 (m, 4H), 7.58-7.62 (d, 
2H, J = 7.3), 7.82-7.94 (m, 2H), 7.98 (t, 1H, J = 7.6), 8.10 (d, 1H, J = 7.8), 8.60 (bs, 
1H), 11.41 (bs, 1H). 13C NMR (100 MHz, DMSO-d6): ppm 26.4, 30.9, 31.8, 33.5, 35.2, 
35.6, 35.7, 39.0, 39.1, 40.1, 46.2, 52.6, 53.8, 111.5, 112.2, 121.7, 128.3, 129.4, 129.6, 
148.9, 149.0, 151.0, 153.8, 154.1, 156.9, 161.1, 166.7, 169.9, 170.8, 172.0, 174.2. 
MALDI-TOF MS: m/z 910.34 (calcd); 933.11 [M+Na]+, 949.13 [M+K]+ (found). Anal. 
calcd for C41H52Cl2N12O8
BIOLOGY 
: C, 54.01; H, 5.75; Cl, 7.78; N, 18.43. Found: C, 54.19; H, 
5.73; Cl, 7.75; N, 18.35. 
 
Cell lines. The p53-null U937 human leukemic monocyte lymphoma and the p53-
positive isogenic human lymphoblast TK6 cell lines were obtained from American Type 
Culture Collection (Rockville, MD). Both cells were grown in Dulbecco's Modified 
Eagle Medium, 2 mM L-glutamine, 100 µg/mL streptomycin, 100 units/mL penicillin, 
and 10% Foetal Calf Serum (FCS). All media and cell culture reagents were purchased 
from Life Technologies (San Giuliano Milanese, Italy).  
Cell differentiation. Differentiation of the promyelocytic cell line U937 cells into 
macrophages was achieved according to Sordet et al.2
Stock solutions of the same concentration (75 mM) of folate-trioxa-CLB and folate-
(βAla-ED-βAla)-CLB stock solutions (both) were also obtained by dissolving the 
 by treating the cells with 20 nM 
12-O-tetradecanoylphorbol-13-acetate (TPA) for 24 h. At the end of this time the 
differentiation process was considered complete as indicated by the massive attachment 
of cells to the plate. TPA was obtained by Sigma Aldrich. A 100 µM stock solution was 
prepared in 100% DMSO. 
CLB and CLB-folate conjugates stock solutions. CLB was dissolved in 100% 
DMSO to obtain a concentrated (75 mM) stock solution. Before measurements, 
appropriate aliquots of this solution were diluted to the desired concentration. 
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powders in 100% DMSO under continuous stirring at room temperature overnight in the 
dark. These concentrated solutions were stored at 4 °C wrapped in aluminium foil. 
Before use, appropriate amounts of each stock solution were diluted to the desired 
concentration. 
Cell viability. Cell viability was assayed by using the Cell Proliferation Kit II 
(XTT, Roche, Milan Italy). The assay is based on the cleavage of the yellow tetrazolium 
salt XTT to form an orange formazan dye by metabolic active cells.3 Therefore, this 
conversion only occurs in viable cells. 
Normally 1x104
Flow cytometry. The undifferentiated or TPA-activated U937 cells and TK6 cells 
were incubated individually for 48 h with CLB or with its folate conjugated forms (30 
µM). After incubation, cells were washed twice with 1 mL phosphate saline buffer pH 
 cells/well were seeded into 96-well plates and incubated for 24, 48 
and 72 h with CLB, folate-trioxa-CLB or folate-(βAla-ED-βAla)-CLB at established 
concentrations and then analyzed in triplicate. 
Stability of CLB-folate conjugates in DMSO solutions. To assess the time-
stability of CLB-folate derivatives stock solutions we evaluated their biological effects 
on cell viability immediately after their preparation or after several weeks of storage. 
The changes in cytotoxic activity on U937 and TK6 cells of freshly-prepared or long 
stored (5 weeks) stock solutions (both 75 mM) were evaluated by comparing the 
residual viability of these cells (XTT assay) following 48 h treatment with scalar doses 
(normally 0-50 µM) of each compound. As concentrated solutions are normally more 
stable than the diluted ones, the check of stability and full retention of cytotoxic activity 
was also performed starting from stock solutions 100 times more diluted (i.e. 0.75 mM 
in 33% DMSO). Even in this case, the assays were performed immediately after their 
preparation or after several weeks of storage at 4 °C (5 weeks).  
Stability of CLB-folate conjugates in human serum. To test the stability of CLB-
folate-conjugates in human serum, we have diluted appropriate amounts of stock 
solutions of folate-trioxa-CLB or folate-(βAla-ED-βAla)-CLB in human serum so that 
the final concentrations of the drugs were in both cases 0.5 mmol/L. These CLB-
containing solutions, used as drug sources, were then incubated at 37 °C for 12 h and 
finally used to treat undifferentiated U937 and TK6 cells. The analysis of cell viability 
by XTT assay was performed 48 h later. In these experiments, CLB in free (control) or 
conjugated forms was 30 µM. 
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7.4 (PBS), and re-suspended and fixed in 70% ethanol. Before analysis, fixed cells were 
washed, centrifuged, and re-suspended in 1 mL PBS containing 1µg RNase and 100 µg 
propidium iodide.4 Samples were stored in the dark for 20 min at room temperature 
before final readings. The cellular orange fluorescence of propidium iodide was 
detected in a linear scale using a CyAn ADP Flow Cytometer (DAKOCytomation, Ely, 
UK) and analyzed by using ModFit/LT Software (Verity Software, Topsham, ME). 
About 30,000 events (i.e., fluorescence readings, corresponding to not less than 20,000 
cells) were recorded for each sample. 
Electrophoresis and Western blot analysis. Total cellular protein extracts were 
obtained by lysing cells in 50 mM Tris (pH 7.5), 100 mM NaCl, 1% NP40, 0.1% Triton 
X 100, 2 mM EDTA, 10 µg/mL aprotinin, and 100 µg/mL phenylmethylsulfonyl 
fluoride. Protein concentration was routinely measured with the Bio-Rad protein assay.5 
Polyacrylamide gels (10 or 15%) were prepared essentially as described by Laemmli.6 
Molecular weight standards were from New England Biolabs (Beverly, MA, USA). 
Proteins separated on the polyacrylamide gels were blotted onto nitrocellulose filters 
(Hybond-C pure, Amersham Italia, Milan, Italy). Filters were washed and stained with 
specific primary antibodies and then with secondary antisera conjugated with 
horseradish peroxidase (Bio-Rad; diluted 1:2,000). Filters were developed using an 
electro-chemiluminescent Western blotting detection reagent (Amersham Italia, Milan, 
Italy); profiles were acquired and grossly quantified by scanning with a Discover 
Pharmacia scanner equipped with a Sun Spark Classic Workstation. The anti-p53 
(DO1), anti-BAX (P-19) and anti-Clusterin (N-18) were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Anti-tubulin (MCA77G) was from Serotec 
(Kidlington, UK). 
Statistical analysis. All data are expressed as mean ± SD. Significance was 
assessed by the Student's t test for unpaired data for comparisons between two means. 
Statistical significance was defined as *, p<0.01; **, p< 0.001; ***, p<0.0001. 
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2.1 INTRODUCTION 
As reported in Chapter 1 traditional cancer therapies such as surgical treatment, 
radiation therapy and chemotherapy lack selectivity in removing or destroying diseased 
tissue and sparing normal healthy cells. These conventional treatments result in serious 
side effects caused by the loss of normal cell functions as a result of having relatively 
indiscriminate cytotoxic properties. Thus it is necessary the development of new 
therapeutic approach that display more accurate and effective discrimination of normal 
and diseased tissue. Currently, one of the most widely used cancer therapies is 
photodynamic therapy (PDT). The PDT is a minimally invasive therapeutic modality 
used in the cure of various cancerous and pre-malignant diseases1
2.1.1 HISTORY OF PHOTODYNAMIC THERAPY  
 because it involves 
the systemic administration of a non-toxic photosensitizing drug (PS), which 
preferentially accumulates in host and tumor cells and then gets activated by the 
exposure of light in presence of oxygen to generate very reactive cytotoxic species. 
Furthermore, PDT is a cold photochemical process, which can be applied before, or 
after chemotherapy, ionizing radiation or surgery, without compromising these 
treatments or being compromised itself. Unlike other modalities like radiotherapy and 
surgery it can be applied repeatedly many times at the same site without risking the 
integrity of surrounding tissues. Response rates and its durability are better than other 
traditional therapeutic tools and it has better functional outcome. The possibility of 
interstitial light delivery where light is fed directly into solid tumors allows PDT to be 
used for large tumors and in treating residual microscopic disease left behind by other 
treatment modalities like surgery. Hence in many ways this treatment modality is 
superior to thermal laser techniques, chemotherapy and surgery.  
 
 
Utility of light in the medical field as a therapeutic tool traces its origin back to several 
thousand years. For example it’s know that ancient Egyptian, Indian and Chinese 
civilization used light to treat various diseases such as psoriasis, rickets, vitiligo and 
skin cancer.2 Indeed in one of India’s sacred books Atharva-veda (1400 BC) the use of 
seeds of the plant Psoralea corylifolia for the treatment of vitiligo is described. 
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Psoralens are photoactive components of these seeds, just as in the extracts of the plant 
Ammi majus, which grows on the banks of the Nile, and was used by Egyptians to treat 
vitiligo.3  
In the 18th and 19th centuries sunlight was used for treating various disease like 
tuberculosis or rheumatism paralysis. In 1903 a Danish scientist named N. Finsen was 
awarded a Nobel Prize for his work in phototherapy,4 he used the red light treatment for 
small pox5 and also ultraviolet light to treat tuberculosis.  
In those years Hermann von Tappeiner, director of the Institute of Pharmacology at 
the University of Munich, coined the term ‘photodynamic reaction’. According to the 
observations of Oscar Raab, his doctoral student, the reaction was characterized as an 
oxygen-dependent tissue reaction following photosensitization and irradiation with 
light.6 Oscar Raab could show in his experiments that in the presence of daylight the 
organic photosensitizer Acridine orange was cytotoxic for paramecia.6b
O
Br
-O
Br
O
BrBr
Na+
COO-
Na+
N
In 1898, O. Raab showed the cytotoxic effects
of the combination of acridine and light
on infusoria (Paramecium caudatum)
Acridine Eosin
Eosin is a fluorescent red
dye resulting from the action
of bromine on fluorescein
 The assays 
displayed that its toxicity was not only dependent on the concentration of the dye but 
also on the intensity of illumination. Furthermore in collaboration with the 
dermatologist Jesionek, von Tappeiner successfully treated patients suffering from 
lupus vulgaris, stage II syphilis and superficial skin cancer with topical Eosin red 
solution (1–5%) (Figure 1). 
 
Figure 1: Acridine and Eosin: promoters of phodynamic reactions. 
 
In 1913, F. Meyer-Betz investigated the porphyrins, class of compounds most often 
used today for their application in photodynamic therapy. He studied the accumulation 
of hematoporphyrin (HP) and its derivatives in rat tumors and PDT effects following 
systemic administration.7 The fluorescence from these compounds was further studied 
for diagnostic and tumor margin delineation between 1940 and 1950 by F.H.J. Figge 
and colleagues.8 Modern photodynamic therapy was initiated by R.L. Lipson and E.J. 
Blades. They established that an impurity in HP was the tumor-localizing agent, and not 
the parent compound. This led to the synthesis of hematoporphyrin derivative (HPD), a 
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mixture of porphyrins produced by the acid treatment of HP.9 The exact chemical 
composition and structure of this mixture remains unclear, although there is general 
consensus that the active portions consist of porphyrin oligomers with ether and ester 
linkages along with monomeric porphyrins. HPD was further developed for laboratory 
and clinical investigations through the efforts of T. J. Dougherty and colleagues in 
1970s and 1980s.10 
Tumors in virtually every anatomic site have been treated with PDT, and most are 
responsive to this therapy to some extent. Although, to date, several thousand patients 
have been treated with PDT for a variety of neoplasms, randomized clinical trials of this 
mode of cancer treatement were initiated only in 1987, using a purified form of HPD, 
called porfirmer sodium (Photofrin®)11
N
NH N
HN
CH3
CH3H3C
H3C
H3C
OH
CH3
OH
HOOC COOH
N
NH N
HN
CH3
CH3H3C
H3C
-OOC COO-
Na+ Na+
O
O
n
n=1-9
Hematoporphyrin Photofrin
 (Figure 2). Currently, PDT with Photofrin® is 
approved in 10 countries.  
 
Figure 2: First generation photosensitizers. 
 
The understanding of the biology of PDT has advanced, and efficient, convenient, and 
inexpensive systems of light delivery are now available. Moreover, encouraging results 
from randomized phase III trials are becoming published, and improved 
photosensitizing drugs are under development. Besides, porfirmer sodium (Photofrin®), 
temoporfin (meso-tetra (hydroxyphenyl) porphyrin (m -THPP) (Foscan®) has now been 
approved for systemic administration, and aminolevulinic acid and ethyl 
aminolevulinate have been approved for topical use. 
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Figure 3. Historical development of photodynamic therapy. 
 
 
2.1.2 MECHANISM OF PHOTODYNAMIC THERAPY  
The photochemical and photophysical principles of PDT have been schematically 
represented in a modified Jablonski diagram (Figure 4).12 PDT is the result of 
combination of three non-toxic elements namely light, oxygen and photosensitizer. A 
photosensitizer is administered, usually intravenously; after a period of time the 
sensitizer accumulates in tumor tissue. It remain inactive until exposed to light. Visible 
light, most relevant to PDT, covers the limited range of 400–700 nm. Sensitizer 
molecule exposed to light, gets excited from its singlet state S0 to short-lived (~10–6 
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seconds) electronically excited singlet state S1, which can undergo radiative 
(fluorescence 2) and nonradiative (internal conversion 3) decay to come back to the 
ground state (S0). A good photosensitizer will at this stage undergo a spin forbidden 
inter system crossing (ISC 4) which requires a spin inversion, converting the 
photosensitizer to a triplet state T1 (10-2 seconds) with high efficiency. Triplet state 
relaxes back to ground state via spin forbidden radiative pathway (phosphorescence 5) 
which imposes relatively long life time for triplet state or by internal conversion, 
radiationless transitions during collisions with other molecules. In oxygenated 
environments chromophores can undergo Type II photochemical process 6 which 
involves an energy transfer between excited triplet state of photosensitizer and stable 
triplet oxygen 3O2 producing short lived and highly reactive excited singlet oxygen 1O2. 
Singlet oxygen is actually a highly polarized zwitterion and is considered to be a 
proficient cytotoxic agent. Type I process involves electron or hydrogen transfer 
process where the triplet state of photosensitzer interacts with biological substrates 
resulting in the formation of radicals and radical ions which on interaction with 
molecular oxygen gives rise to cytotoxic species like superoxide ion (O2-) 7.13 It is 
generally thought that Type II mechanism predominates during PDT but it was found 
that Type I mechanism plays an important role at low oxygen concentrations and in 
more polar environments.13 The short lifetime of singlet oxygen (100-250 ns) limits the 
range of propagation to approximately 45 nm in cellular medium and hence cannot 
diffuse more than a single cell length (diameter of human cell ranges from 10-100 
mm).13,14 Hence, the primary generation of 1O2 warrants for the subcellular structures 
that can be accessed and destroyed. The photosensitizer is usually administered using an 
aqueous buffer solution or liposomes, the activating light is often generated by simple 
and economical lasers, which produce a coherent monochromatic light. Localization 
and biodistribution of photosensitizer in tissue and tumors depend on various factors 
such as hydrophobicity, pH, lymphatic drainage and lipoprotein binding. Other possible 
mechanisms which contributes to the tumor localization include aggregation, molecular 
charge and membrane potential of tumor cells. Many subcellular targets can be attacked 
during PDT, including mitochondria, lysosomes, plasma membrane and nuclei and it is 
the exact target, which decides whether cell death occurs by necrosis or apoptosis.15  
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Figure 4. Jablonski energy level diagram for photodynamic therapy. 
 
Thus in treating cancer with PDT (Figure 5), first step is the drug administration, 
followed by a period of incubation depending on the nature of photosensitizer used and 
is extremely necessary for the normal cells to get rid of the drug and the tumor cells to 
accumulate it. Third step is the illumination using laser which bring about the 
therapeutic effect. Finally, the exact method of PDT induced cell death relies primarily 
on the nature of the photosensitizer used and on the condition being treated and the light 
dose used.  
Figure 5. Schematic representation for PDT.i
                                                 
i Figure adapted from “Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and 
Optimization”, Chem Rev. 2010, 110, 2795–2838. 
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2.1.3 PHOTOSENSITIZERS 
Among the several photosensitizers available, very few have been selected for clinical 
trials owing to many important factors. They include selectivity in terms of target cells 
against healthy cells, suitable extinction coefficients and accumulation rates in target 
tissues, stable composition and a chemical nature that may facilitate the entrance in the 
cell avoiding precipitation in aqueous environments.16 The recent introduction of 
nanocarriers has partially modified this view, in that the properties of the PS may be not 
so important and that specificity toward target tissues may be improved using specific 
drug delivery strategies.19
2.1.3.1 FIRST AND SECOND GENERATION PHOTOSENSITIZERS 
 Photosensitizers are generally classified as porphyrins or non-
porphyrins. Porphyrin-derived PS, in turn are classified as first, second or third 
generation PS. 
 
 
First-generation PS are hematoporphyrin, its derivative HpD, and the purified, 
commercially available and yet largely employed Photofrin. This molecule originally 
approved for use in humans in 1993 in Canada, is now the PS most commonly used for 
the treatment of advanced stage lung, oesophageal, gastric and cervical cancer.17 Beside 
the absence of intrinsic toxicity, other advantages offered by Photofrin include the 
possibility of using small drug doses, the good clearance from normal tissue and 
possibility of repeated administrations without serious consequences, but prolonged 
photosensitivity, for the neoplastic patient.18 
Second generation PS include benzoporphyrin derivative, chlorins, phthalocyanines 
and texaphrins, as well as, naturally occurring compounds, such as hypericin, and 
substances that promote the production of the endogenous protoporphyrin IX (PpIX) as 
5-aminolevulinic acid (5-ALA) and some ester derivatives.19 5-Aminolevulinic acid is a 
stable molecule20
An extremely potent second generation PS approved in Europe for the palliative 
treatment of neck and head cancers is Foscan. This compound, which has been shown to 
have a short plasma half-life in humans, is an hydrophobic molecule, is strongly 
 that behaves as a prodrug, since it is metabolically converted to the 
photo-sensitizable protoporphyrin IX.  
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photoactivable (652 nm) with very high singlet oxygen yield while appearing to 
preferentially accumulate in tumor cells.21 In addition, beside a direct damage to tumor 
cells, the curative effect of this drug is also attributed to its pharmacokinetic behavior 
that causes intense and sustained vascular damage.22 Another PS that deserves particular 
mention is Talaporfin sodium (TS) a second-generation PS with a core chlorin structure 
containing a highly aromatic system. Its high water solubility and shorter half-life make 
it an attractive drug.23 In preclinical experiments, activation of Talaporfin sodium with 
laser light (664 nm) generated singlet oxygen in a drug dose-dependent fashion. The 
depth of treatment is dependent on the ability of light to penetrate the target tissue with 
enough photons to activate the drug. Singlet oxygen causes significant alteration of 
macromolecules via oxidation of biological substrates such as DNA, membrane lipids, 
cholesterol and solvated molecules.24 Preclinical studies have demonstrated that TS 
activation induces also systemic, tumor-specific immuno-modulation mediated by 
CD8+ T cells which involves up-regulation of both cytolytic and memory cells25 and 
microvessels closure that may help in overcoming tumor resistance.26
5-AMINOLEVULINIC ACID  
  
 
 
A new approach to PDT based on the use of endogenous photosensitizer protoporphyrin 
IX (Scheme 1), precursor in the biosynthesis of heme, was introduced in 1990. It made 
use of the above mentioned 5-aminolevulinic acid (Figure 6), which represent the first 
intermediate for the biosynthesis of heme.  
COO-
O
+H3N
 
Figure 6. 5-Aminolevulinic acid. 
 
 
HEME BIOSYNTHESIS  
It’s important to note that almost all cells in the body have a requirement for heme, 
because it forms the reactive centre of a number of enzymes and proteins. These cells 
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must preserve a capacity for heme biosynthesis that occurs by the porphyrin 
biosynthetic pathway shown in Scheme 1. The synthesis of ALA is the first and rate-
limiting step in the biosynthesis of heme. ALA is normally synthesized in mitochondria 
in the condensation reaction between glycine and succinyl-CoA27 (Scheme 1), in 
presence of ALA synthase (ALAS) and pyridoxal-5-phosphate (PLP) as cofactor.28 
ALA so synthesized achieves cytosol, where it undergoes a condensation reaction with 
aminolevulinate dehydratase (ALAD), a zinc-dependent enzyme, and leads to the 
formation of porphobilinogen (PBG). The next step in heme biosynthesis involves 
combining four molecules of PBG to form an unstable tetrapyrolle 
(hydroxymethylbilane HMB), catalyzed by porphobilinogen deaminase (PBDG), which 
is covalently linked a cofactor, dipyrromethane, that consist of two PBG molecules. 
Four additional molecules of PBG attach to dipyrromethane leading to the formation of 
hexapyrolle. Afterwards, in the hydrolytic reaction, cleavage of the distal tetrapyrolle 
occurs, resulting in the release of HMB.29 Uroporphyrinogen III synthase (URO3S) 
close HMB macrocycle leading to conversion of tetrapyrolle to uroporphyrinogen III.
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Scheme 1. Most important steps in the heme biosynthesis. 
 
Uroporphyrinogen decarboxylase (UROD) catalyzes decarboxylation of all four acetate 
side chains of uroporphyrinogen III to methyl groups.31 Coproporphyrinogen III so 
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formed, is transported into the membrane of mitochondria probably by peripheral-type 
benzodiazepine receptors (PBR).32 Coproporphyrinogen oxidase (CPO) then catalyzes 
the conversion of coporoporphyrinogen III to protoporporphyrinogen IX with the 
release of H2O2 and CO2, the reaction provides vinyl groups by oxidative 
decarboxylation of propionate groups.33 The next intermediate in heme biosynthesis, 
protoporphyrin IX (PpIX), is synthesized in the mitochondria and requires FAD-
containing protoporphyrinogen oxidase (PPO),34 that catalyzes the conversion of 
protoporphyrinogen IX to PpIX in the six-electron oxidation. Ferrochelatase (FECH), 
another rate-limiting enzyme, is responsible for insertion of Fe2+ into PpIX. The 
reaction occurs on the internal surface of the mitochondrial membrane.35
The use of 5-ALA in PDT take the advantage of the fact that these compound is a small, 
in contrast to porphyrins, soluble molecule able to penetrate the abnormal stratum 
corneum overlying skin tumors. For this reasons, it can be applied topically unlike other 
photosensitizers. Moreover, in contrast to most tetrapyrrole photosensitizers, ALA-PpIX 
localizes in cells during the biosynthesis, rather than in the tumor vasculature. ALA and 
ALA-PpIX are rapidly cleared from the system, which results in an acceptably short 
period compared to HpD and Photofrin® of cutaneous photosensitivity or skin 
phototoxicity. This is viewed as an advantage over some of the other photosensitizers 
 This stage 
leads to the formation of the final product so completing the heme biosynthetic 
pathway. 
At present, knowledge about the mechanisms involved in ALA-based PDT is 
limited, particularly it is not clear the reason for preferential ALA uptake and 
conversion by tumors and dysplastic tissue. Various theories have been put forward to 
account for this selectivity, one of these suggested that tumors contain lower levels of 
ferrochelatase than the surrounding normal tissue, resulting in less efficient conversion 
of PpIX into heme within tumor cells and hence the build-up of PpIX. Moreover it is 
well established that tumors have a lower pH than normal cells and this may result in 
more PpIX retention in the tumor cells due to the various protonated species which may 
be formed from PpIX.  
 
 
ADVANTAGES AND DISADVANTAGES OF 5-ALA  
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where light protection may be required for several weeks. This allows multiple 
treatment regims and thereby increases the efficacy of PpIX. Furthermore ALA can be 
easily synthesized unlike other porphyrin based photosensitizers, and the technique 
ALA-PDT is noninvasive, can be used to treat multiple lesions by short treatment 
sessions, produces excellent cosmetic results by not causing damage to surrounding 
tissue, has no side effects beyond slight pain during irradiation, and is well accepted by 
patients.36  
On the contrary a significant shortcoming of ALA is its limited ability to cross 
certain biological barriers, such as cellular membranes due to its low lipid solubility.37 
PpIX is active at 630 nm, which should give adequate depth penetration; when topically 
administered, ALA does not penetrate thoroughly; it has limited input. The drawback 
associated with PDT is that, when ALA was administered systemically, patients have 
reported mild nausea.38 Though multiple treatment regimens are possible, the efficacy 
of PpIX generation is decreased in the subsequent regimen if taken within 24 hours.39 
ALA is stable at acidic pH. In aqueous solutions buffered to a physiological pH, ALA 
dimerises to give pyrazine derivatives while at higher pH pseudo-porphobilinogen may 
be formed40
COO-
O
+H3N
NH
N
H
HOOC
COOH
O
O
Lactam Pyrazine
COOH
HOOC
NH2
Pseudo
porphoobilinogen
 and conversion to ester derivatives appears to worsen these problems. 
Esters are known to increase the potential for formation of lactam type derivatives 
(Scheme 2). 
 
Scheme 2: ALA degradation products. 
 
 
5-ALA DERIVATIVES: ESTERS  
In order to overcome the shortcomings of ALA and improve its bioavailability, ALA 
can be derivatized. ALA has two principal functional groups, a carboxylic acid and an 
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amino moiety which are both easily accessible for derivatization. The simplest way to 
alter the lipophilicity of ALA is via esterification of carboxylic function. The use of 
ALA derivatives as good candidates for the treatment of skin cancer has been 
extensively reviewed.41  
Amongst ALA-derivatives that may have improved pharmacological properties 
compared with ALA, ALA esters were widely studied. They are more 
hydrophobic/lipophilic than ALA, and it was believed that they might be taken up into 
cells by different mechanisms, which might improve the efficiency of the therapy. The 
rationale was, that once inside cells ALA esters may be hydrolysed to ALA, which 
could then enter the heme biosynthetic pathway. Esters with various chain lengths42,43 
(Table 1) have indeed proved to be effective in both phototherapy and photodetection.44 
However, the mechanisms involved in the production of PpIX from ALA esters may not 
be as simple as first thought. Certainly the uptake is different from that of ALA itself.45 
Increased cellular uptake of lipophilic ALA esters resulting in enhanced PpIX 
concentrations has been demonstrated in a number of in vitro and in vivo systems.46 
Though these esters are incorporated into the cells at higher rate than ALA, studies 
conducted show that they also efflux at an increased rate mediated by passive 
diffusion.
O
H
N O
R2
O
R1
47 
Table1. ALA derivatives. 
 
ALA-derivatives R R1 2 
ALA-methyl (Metvixia® -H ) -CH
ALA-ethyl 
3 
-H -C2H
ALA-propyl 
5 
-H -C3H
ALA-butyl 
7 
-H -C4H
ALA-pentyl 
9 
-H -C5H
ALA-hexyl (Hexvix
11 
® -H ) -C6H
ALA-octyl 
13 
-H -C8H
R-S-ALA-2-
(hydroxymethyl) tetra-
hydrofuranyl 
17 
-H 
O  
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R-S-ALA-2-
(hydroxymethyl) tetra-
hydropyranyl 
-H 
O  
ALA-benzyl (Benzvix® -H ) 
 
N-acetyl-ALA CH3 -H CO 
N-acetyl-ALA-ethyl CH3 -CCO 2H
N-acetyl-ALA-butyl 
5 
CH3 -CCO 4H
N-butanoyl-ALA 
9 
CH3(CH2)2 -H CO- 
N-pentyl-ALA CH3(CH2)3 -H CO- 
N-hexanoyl-ALA CH3(CH2)4 -H CO- 
N-heptanoyl-ALA CH3(CH2)5 -H CO- 
 
The most widely used ALA ester for in vitro work is ALA-hexyl ester.48 Under the 
commercial name of Hexvix, it has been successfully used in the detection of bladder 
cancer and has already been approved in most countries of the European Union and 
European Economic Area countries. In addition, the new European guidelines 
recommended recently the use of blue light cystoscopy and Hexvix, for the diagnosis of 
bladder cancer.49 On the other hand, it was shown that ALA methyl ester (Me-ALA) is 
very useful in the treatment of highly keratinised human lesions such as solar keratoses, 
reaching a higher ratio of porphyrins against normal skin after topical application.50 A 
highly selective and homogeneous distribution of Me-ALA-induced porphyrin 
fluorescence was seen in human malignant lesions such as thick basal cell carcinomas.51
2.1.3.2 THIRD GENERATION PHOTOSENSITIZERS 
 
Me-ALA, under the commercial name of Metvix is an approved drug for most of the 
European countries, USA, New Zealand, Australia and Brazil for certain non melanoma 
skin cancers such as superficial and nodular basal cell carcinomas, and actinic 
keratoses. Instead Benzvix is undergoing clinical trials for gastrointestinal cancers. 
 
 
Most therapeutic drugs distribute through the whole body, which results in general 
toxicity and poor acceptance of the treatments by patients. The targeted delivery of 
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chemotherapeutics to defined cancer cells is one of the main challenges and a very 
active field of research in the development of treatment strategies to minimize side-
effects of drugs. Disease-associated cells express molecules, including proteases, 
receptors, or adhesion molecules, that are different or differently expressed than their 
normal counterparts. Therefore one goal in the field of targeted therapies is to develop 
chemically derivatized drugs or drug vectors able to target defined cells through specific 
recognition mechanisms.52 This approach should also be able to overcome biological 
barriers.  
Four different strategies of improving selectivity (targeting) in PDT have been 
practiced so far.53 First strategy for selective photosensitizer (PS) delivery utilizes 
targeting moieties, such as monoclonal antibodies (MAbs),54 directed against antigens 
or ligands that are specifically overexpressed on cancer cells.  
A second strategy which is commonly used, to improve the delivery of PS to target 
tissue involves their encapsulation in colloidal carriers, such as liposomes, oil-
dispersions, polymeric particles, and polymers to facilitate drug delivery.55  
Thirdy strategy to selectively enhance PS levels in a disease site is to facilitate PS 
uptake more in the target tissue than the surrounding normal areas, through, for example 
several modification of PS taking advantage of certain properties of these cells, which 
either distinguish them from other cell or tissue types, or differentiate, malignant from 
normal cells. An note approach, is based on the altered sugar metabolism of cancer 
cells.56 Rapidly growing tumors are able to maintain high glucose catabolic rate by 
upregulation of the enzyme hexokinase. This enzyme phosphorylates glucose to 
glucose-6-phosphate, which is then retained in the cell. Photosensitizers have been also 
functionalized with a large quantity of different sugars. Saccharides-porphyrin or –
chlorin conjugates are probably the most active field of research in the targeting of 
photosensitizers.57 The efficiency of the saccharide composition has been evaluated 
using xylosyl, arabinosyl, glucosyl, galactosyl or 2-aminoglucosamide groups.38 When 
linked to a photosensitizer, uptake and accumulation in the endoplasmic reticulum and 
photoxicity were increased in cancer cells. The length of the oligosaccharide is also an 
important factor for the membrane penetration.
Fourthy strategy is to conjugate photosensitizer (PS) with specific receptors which 
are over expressed in cancer cells. This helps in receptor mediated endocytosis. One 
ligand suited for this purpose is folic acid thanks to the features reported in the Chapter 
58 
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1. For example tetraphenylporphyrin (TPP) has been conjugated to folic acid (Scheme 
3) to target tumor cells overexpressing its receptors.59 Cellular uptake and 
photodynamic activity of the conjugate on human nasopharyngeal cell line were greatly 
increased compared to free TPP and competitive assays using free folic acid 
demonstrated folate-receptor dependent uptake of the conjugate.  
 
Scheme 3: Tetraphenylporphyrin (TPP) has been conjugated to folic acid. 
 
On the contrary of this conjugated with tetraphenylporphyrin, on the basis of what just 
described, our attention has been concerned in the synthesis of folate-conjugated 
(reported in the next section) with 5-ALA and its methyl ester derivative precursors of 
porphyrin. 
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2.2 RESULTS AND DISCUSSION 
On the basis of the considerations given in the introduction and the promising results 
obtained for folate-conjugates described in the Chapter 1, the present work is focalized 
on development of new folate-based drug delivery systems for the selective transport of 
photosensitizers (FA-PS) in tumor cells.  
These systems (as described in Chapter 1) consist of 4 modules: folic acid, a linker, 
a cleavable bond and a photosensitizer as 5-ALA and its methyl ester derivative (Figure 
1). Beside the linkers already used for molecular systems previously cartooned, in this 
work we considered a third β-peptide-based linker prepared by solid phase synthesis in 
collaboration with Dr Giovanni Roviello (CNR of Napoli). The synthesis of this new 
compound are reported below.  
NH
NN
N
O
NH2
HN
O
N
H
COOH
O
unit 1
Folic Acid
unit 2
Linker
unit 3
Cleavable
Linkage unit 4
Photosensitizer
H
N O
O
O
H
N
H
N
H
N
N
H
N
HO
O
or
H2N OR
O
O
R = H, CH3
N
H
N
H
N
H
N
H
N
H
OOOOO
O NH2
or
 
Figure 1. Carrier linked prodrug system for photodynamic therapy. 
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2.2.1 SYNTHESIS OF FA-5-ALA CONJUGATES 1 AND 2. 
The synthesis of conjugates 1 and 2 (Figure 2) was carried out through an easy 
procedure starting from folate derivatives 4 and 5 prepared as previously described in 
Chapter 1, and 5-ALA suitably protected by reaction with Boc2O and NaOH in a 
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Figure 2. Folate conjugate 1-2 
 
The omologation reaction between N-Boc-5ALA 3 and the compounds 4 and 5 was 
carried out by testing different reaction conditions including the in situ activation of the 
carboxyl function of 3 using reagents such as DCC or PyBOP. In all cases, the results 
were not satisfactory, indeed the conjugation products was formed only in low yield 
(Scheme 1).  
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Scheme 1. Synthesis of folic acid-conjugates 6 and 7. 
 
With the aim to get the 5-ALA conjugates 6 and 7 with a better chemical yield, N-Boc-
5-ALA was first converted in corresponding succinimidyl ester 8 by reaction of 3 with 
NHS, DCC and TEA in dichloromethane (71% yield, Scheme 2). It’s interesting to note 
that in presence of a slight excess of NHS (1.2 eq) and extended reaction times (3h), the 
desired product N-Boc-5-ALA-OSu (8) was transformed quantitatively in the lactone 
compound (9). 
OH
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BocHN O
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71%3 8
 
Scheme 2. Formation of N-Boc-5-ALA-OSu. 
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In Scheme 3 the hypothesized mechanism for the formation of this product is shown: 
the N-hydroxysuccinimide, present in the reaction mixture, lead nucleophilic attack on 
ketone function at C-4 position. The generated anion can provide an intramolecular 
lactonization, entropically favored, leading to the formation of γ-lactone 9 and N-
hydroxysuccinimide that 
O
O
O
BocHN
N
O
O
O-
N OO O
O
-O
BocHN
N
O
O
OSu
O-
N OO +
OSuO O
BocHN
12
345
8
9
Byproduct
can afford even to the complete conversion of 8.  
 
Scheme 3. Hypothesized mechanism for formation of byproduct 9. 
 
Finally, the 5-ALA so activated was used in the coupling reaction with derivatives 4 and 
5 in presence of DCC and Py in DMSO (Scheme 4). In this case, the reaction provided 
the desired FA-5ALA conjugates in quantitative yield.  
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Scheme 4. Synthesis of folate-5ALA 1-2. 
 
Finally treatment of compound 6 and 7 with TFA in THF gave FA-PS 1 and 2 with high 
yield (98%).  
 
 
2.2.2 SYNTHESIS OF CONJUGATE 3 
Folate conjugate 3 contain a pentapeptide linker, consting of β-Alanine (four units) and 
aspartic acid (one unit) linked 5-ALA methyl ester as photosensitizer agent (Figure 3). 
The preparation of FA-PS conjugated was accomplished by solid-phase synthesis and 
involved the main following synthetic steps:  
 preparation of the linker  
 subsequent conjugation of the latter with folic acid  
 detachment from resin and coupling with the photosensitizer.  
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Figure 3. Folate-conjugate 3. 
 
The peptide sequence has been synthesized starting from C-terminal carboxyl group of 
aspartic acid in α-position which was used for anchoring to the solid phase, then the 
amino group was coupled to the group of the first β-alanine unit. β-Carboxyl group of 
aspartic acid was protected as t-butyl ester, an acid-labile group, stable in alkaline 
conditions. Fmoc group was used to protect the β-alanine amino function. Protected 
aspartic acid 10, commercially available at low cost, has been linked to Rink Amide-
MBHA resin (Figure 4) after removal of N-Fmoc protection, as reported in the 
literature.
H3CO
H3CO
NHFmoc
O
H
N
O
CH3
R
polymer
1 
 
Figure 4. Rink Amide-MBHA resin. 
 
Subsequently a Fmoc β-alanine unit was added by a coupling reaction in presence of 
PyBop and DIPEA in NMP. Iterating this technique three more units of β-alanine were 
then added to afford the product 11 in quantitative yield (Scheme 5). Reaction 
monitoring was possible thanks to the presence of β-alanine Fmoc protecting group. 
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Scheme 5. Solid-phase synthesis of polyamide linker 11. 
 
Linker 11 anchored to the resin, was then coupled with FA unit under the same reaction 
conditions allowing to prepare the compound 3. The product 12 so obtained was 
detached from resin by acid hydrolysis (TFA/H2O/TIS) to provide the folate conjugate 
13 with 97% yield (Scheme 6). 
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Scheme 6. Synthesis of folate conjugate 3. 
 
The last step of this synthesis consisted in the conjugation of folate-derivative 13 to 5-
ALA methyl ester 14. This reaction was carried out by treatment with PyBop and 
DIPEA in
 
 DMSO to give the desired compound 3 with 98% yield (Scheme 6).  
                                                 
1 Boussard, C.; Doyle, V. E.; Mahmood, N.; Klimkait, T.; Pritchard, M.; Gilbert, I. H. 
Eur. J. Med. Chem. 2002, 37, 883-890. 
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2.3 CONCLUSION 
Photodynamic therapy is a minimally invasive treatment for the cure of malignant 
diseases. As clearing of the photosensitizer is often a limiting factor in PDT, the study 
of 5-aminolevulinic acid and its derivatives, has been receiving increasing attention. In 
an attempt to improve cell selectivity of ALA and its derivatives, in this work we 
realized an easy methodology to synthesize new folate-based carrier linked prodrugs (1-
3) that will be subjected, in the laboratory of Prof. Giuseppe Palumbo (Department of 
Biology, Cellular and Molecular Pathology “L. Califano” University of Napoli Federico 
II), to experiments of fluorescence spectroscopy on different cell lines in order to obtain 
useful information on the biocompatibility and on cellular internalization of our 
molecular systems. In addition, further studies will be conducted to demonstrate the 
actual release of 5-ALA and of 5-ALA methyl ester in the tumor site, verifying the 
possible application of the derivatives in photodynamic therapy. 
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2.4 EXPERIMENTAL SECTION  
All moisture-sensitive reactions were performed under a nitrogen atmosphere using 
ovendried glassware. Solvents were dried over standard drying agents and freshly 
distilled prior to use. Reactions were monitored by TLC (precoated silica gel plate 
F254, Merck). Column chromatography: Merck Kieselgel 60 (70-230 mesh); flash 
chromatography: Merck Kieselgel 60 (230-400 mesh). 1H and 13C NMR spectra were 
recorded on NMR spectrometers operating on Varian VXR (200 MHz), Bruker DRX 
(400 MHz) or Varian Inova Marker (500 MHz), using CDCl3
2.4.1 SOLUTION-PHASE SYNTHESIS 
 solutions unless otherwise 
specified. In all cases, tetramethylsilane (TMS) was used as internal standard for 
calibrating chemical shifts (δ). Coupling constant values (J) were reported in Hz. 
Combustion analyses were performed by using CHNS analyzer. 
OH
O
O
BocHN
3
 
Compound 3. To a stirring solution of 5-aminolevulinic acid (200 mg, 1.53 mmol) in 
H2O (2.4 mL), at 0 °C, a solution of NaOH (0.1 N) was added dropwise until pH 8-10. 
After a few minute Boc2O (6.2 g, 8.07 mmol) in 1,4-diossano (2.4 mL) was added. The 
mixture was stirred at room temperature for 24h, and then was acidified with a solution 
of HCl 1M until pH ~ 4. The solution was extracted with EtOAc and washed with H2O. 
The organic phase was dried on Na2SO4 and the solvent evaporated under reduced 
pressure, to offer the pure 9 (278 mg, 80% yield) without further purification: 1H NMR 
(500 MHz, CDCl3) δ: 1.43 (s, 9H, C(CH3)3), 2.71 (bs, 4H, H-2, H-3), 4.11 (bs, 2H, H-
5).13C NMR (50 MHz, CDCl3) ppm: 27.4, 28.7, 34.0, 50.1, 79.9, 84.8, 155.6, 176.9, 
204.0. Anal. calcd for C10H17NO5: C, 51.94; H, 7.41; N, 6.06. Found: C, 51.78; H, 
7.44; N, 6.08. 
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Compound 8. At a stirring solution of 3 (200 mg, 0.87 mmol) and TEA (0.18 mL, 1.3 
mmol) in dry CH2Cl2 (7.7 mL) at room temperature, NHS (200 mg, 1.74 mmol) and 
DCC (359 mg, 1.74 mmol) was added. After 16 h a white precipitate was formed due to 
the formation of dicyclohexylurea. After filtration the solvent was evaporated under 
reduced pressure and the crude residue purified by precipitation with cold Et2O to 
provide the pure 8 (203 mg, 71% yield): 1H NMR (400 MHz CDCl3) δ: 1.44 (s, 9H, 
C(CH3)3), 1.90-1.96 (m, 4H, CH2 OSu), 2.84 (t, 2H, J = 6.4 Hz, H-2), 2.97 (t, 2H, J = 
6.4, H-3), 4.02 (bd, 2H, J = 4.4 Hz, H-5). 13C NMR (50 MHz): ppm 24.8, 25.5, 28.2, 
33.8, 49.1, 80.2, 157.1, 168.1, 169.1, 203.0. Anal. calcd for C14H20N2O7
O O
SuO
BocHN
s
9
: C, 51.22; H, 
6.14; N, 8.53. Found: C, 51.38; H, 6.12; N, 8.50. 
 
Compound 9. The lactone 9 was prepared under the same conditions for preparation of 
8, but for prolonged reaction time (3h) with 97% yield. 1H NMR (400 MHz, CDCl3) δ: 
1.44 (s, 9H, C(CH3)3), 2.42-2.52 (m, 2H, H-2), 2.51-2.62 (m, 1H, H-3), 2.72-2.84 (m, 
4H, CH2OSu), 2.93-3.05 (m, 1H, H-3) 3.22 (dd, 1H, J = 4.4, J=15.6, H-5), 3.80 (dd, 
1H, J = 9.3, J = 15.6, H-5), 5.78 (bd, 1H, J = 5.3, NH). 13C NMR (100 MHz): ppm 25.3, 
27.1, 28.2, 29.2, 43.1, 79.9, 113.1, 156.0, 172.0, 174.3. Anal. calcd for C10H16NO4
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: C, 
56.06; H, 7.53; N, 6.54. Found: C, 56.21; H, 7.50; N, 6.52. 
 
Compound 6. To stirred solution of derivate 4 (19 mg, 0.023 mmol) in DMSO (1.2 
mL) Boc-5-ALA-OSu (15mg, 0.046 mmol) and DIPEA (4 µl, 0.023 mmol) was added. 
After 16h at room temperature, cold Et2O (4 mL) was added dropwise to the mixture, 
after a few minutes acetone (2 mL) was added until the desired product was precipitated 
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as yellow crystals, which were recovered and dried under vacuum (98% yield): pf. 210-
214°C, 1H NMR (200 MHz, DMSO-d6) δ: 1.36 (s, 9 H, C(CH3)3), 1.51-1.72 (m, 4H, H-
3II, H-10II), 1.80-2.10 (m, 2H, H-β), 2.15-2.40 (m, 6H, H-13II, H-14II, H-γ), 3.00-3.20 
(m, 4H, H-2II, H-11II), 3.25-3.40 (m, 4H, H-4II, H-9II), 3.41-3.52 (m, 8H, H-5II, H-6II, H-
7II, H-8II), 3.70-3.80 (m, 2H, H-15II), 4.20-4.42 (m, 1H, H-α), 4.45 (bd, 2H, J = 5.4, H-
9), 6.63 (d, 2H, J = 7.6, H-2I, H-5I), 6.75-7.00 (m, 2H, H-3, H-10), 7.63 (d, 2H, J = 7.6, 
H-3I, H-6I), 7.72-7.84 (m, 2H, H-1II, H-2II), 7.90-8.00 (m, 1H, J = 8.4, H-16II), 8.02-
8.10 (m, 1H, NHGlu), 8.30 (s, 2H, NH2) 8.62 (s, 1H, H-7), 11.4 (s, 1H, COOH). 
MALDI-TOF MS: m/z 856.41 (calcd); 880.22 [M+Na]+, 896.20 [M+K]+ (found). 
Anal. calcd for C39H56N10O12
γ
β
α
COOH
N
H
NHGlu
O
1I
6I
5I
2I
3I
4I
N
H
10
9
6
N
5
4a4
O
HN
3
2
H2N N
1
8a N
8
7
H
N1
II
O
2II
3II
4II
O
5II
6II
O
7II8II
O9II
10II
11II
H
N
12II
13II
14I I
O
15II
O
H2N
16II
1
: C, 54.66; H, 6.59; N, 16.35. Found: C, 54.52; 6.61; N, 
16.40. 
 
Compound 1. Compound 1 was prepared starting 6 with the same procedure reported 
in Chapter 1 for compound 8 (97% yield). 1H NMR (200 MHz, DMSO-d6) δ: 1.80-2.00 
(m, 2H, H-β), 2.18-2.38 (m, 10H, H-3II, H-6II, H-9II, H-12II, H-γ), 2.44 (dd, 1H, J = 7.7, 
J = 16.2, H-14II), 2.69 (dd, 1H, J = 6.1, J = 16.2, H14II), 3.15-3.32 (m, 8H, H-2II, H-5II, 
H-8II,H-11II), 4.24-4.38 (m, 1H, H-α), 4.45-4.58 (m, 2H, H-13II, H-9), 6.64 (d, 2H, J = 
8.7, H-3I, H-5I), 7.08 (bs, 1H, H-10), 7.25 (bs, 1H, H-3), 7.63 (d, 2H, H-2I, H-6I), 7.80-
7.95 (m, 6H, H-1II, H-4II, H-7II, H-11II, NH2C=O), 8.12 (d, 1H, NHGlu), 8.12 (d, 1H, J = 
8.2, NHGlu) 8.73 (s, 1H, H-7), 11.98-12.30 (m, 2H, 2xCOOH).  
MALDI-TOF MS: m/z 756.36 (Calcd); 757.19 [M+H]+, 780.21 [M+Na]+, 796.23 
[M+K]+ (Found). Anal. calcd for C34H48N10O10: C, 53.96; H, 6.39; N, 18.51. Found: C, 
54.12; H, 6.37; N, 18.45 
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Compound 7. Under the same conditions used for compound 6, the compound 7 was 
obtained with 98% yield. 1H NMR (200 MHz, DMSO-d6) δ: 1.36 (s, 9H, CH3t-Bu), 1.82-
2.08 (m, 2H, H-β), 2.12-2.32 (m, 10H, H-3II, H-8II, H-γ, H-11II, H-12II), 2.98-3.18 (m, 
4H, H-2II, H-9II), 3.21-3.42 (m, 4H, H-5II, H-6II), 3.75(bd, 2H, J= 5.4, H-13II), 4.31 (bs, 
1H, H-α), 4.52 (bd, 2H, J= 5.9, H-9), 6.62 (d, 2H, J = 7.5, H-3I, H-5I), 6.88-6.96 (m, 
3H, H-4II, H-7II, H-10), 7.65 (d, 2H, J = 7.5, H-2I, H-6I), 7.81 (bs, 2H, H-1II, H-10II), 
7.95 (m, 2H, NHGlu, H-14II), 8.12 (m, 1H, H-3), 8.69 (s, 1H, H-7), 11.42 (bs,1H, 
COOH). 
MALDI-TOF MS: m/z 737.37 (calcd); 760.31 [M+Na]+, 776.29 [M+K]+ (found). 
Anal. calcd for C33H43N11O9
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Compound 2. Under the same conditions used for compound 1, the compound 2 was 
obtained from 7 with 98% yield. 
1H NMR (200 MHz, DMSO-d6) δ: 1.82-2.08 (m, 2H, H-β), 2.12-2.32 (m, 10H, H-3II, 
H-8II, H-γ, H-11II, H-12II), 2.98-3.18 (m, 4H, H-2II, H-9II), 3.21-3.42 (m, 4H, H-5II, H-
6II), 3.75(bd, 2H, J= 5.4, H-13II), 4.31 (bs, 1H, H-α), 4.52 (bd, 2H, J= 5.9, H-9), 6.62 (d, 
2H, J = 7.5, H-3I, H-5I), 6.88-6.96 (m, 3H, H-4II, H-7II, H-10), 7.65 (d, 2H, J = 7.5, H-
2I, H-6I), 7.81 (bs, 2H, H-1II, H-10II), 7.95 (m, 3H, NHGlu, H-14II), 8.12 (m, 1H, H-3), 
8.69 (s, 1H, H-7), 11.42 (bs,1H, COOH). Anal. calcd for C32H42N12O9: C, 52.03; H, 
5.73; N, 22.75. Found: C, 52.18; H, 5.71; N, 22.68. 
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2.4.2 SOLID-PHASE SYNTHESIS 
The synthesis of the pentapeptide 11 and the subsequent coupling reaction with folic 
acid were carried out in a reactor equipped with a plastic filter, PTFE (Teflon), a 
stopcock and a cap. The resin (MBHA-Rink Amide) was deprotected from Fmoc group 
by treatment with piperidine (30%) in DMF for 30 min. The efficiency of coupling of 
monomers was monitored by UV Fmoc test (absorbance of the Fmoc group: 7800 = 
ε301), so as to estimate the yield of incorporation of each residue. During the solid-
phase synthesis, the capping of unreacted amino acid is achieved with Ac2O 
(20%)/DIPEA (5%) in DMF, while the efficiency of coupling was monitored by 
measuring the absorbance of the released Fmoc group (7800 = ε301
N
H
O
O-tBu
OHN
O
N
H
O
N
H
O
N
H
O
H2N
11
 ). 
 
Compound 11. To the resin (0.5 mmol, 300 mg), previously deprotected by Fmoc 
group and washed with NMP, an acid solution of aspartic acid 10 (1 mL of a 0.5 M in 
NMP solution, 2.69 mmol, 358 mg) PyBOP (1 mL of a 0.5 M solution in NMP, 0.85 
mmol) and DIPEA (295 μL, 1.69 mmol) were added in to the reactor. After 20 min the 
mixture was removed from resin that was washed with NMP. To ensure peptide 
homogeneity the capping of unreacted amino acid was achieved using Ac2O 
(20%)/DIPEA (5%) in NMP for 15 min. Deprotection of Fmoc group was achieved 
with pyperidine (30%) in DMF (15 min). After that, a mixture of Fmoc-β-alanine (1 mL 
of a 0.5 M solution in NMP, 0.88 mmol) and PyBOP (1 mL of 0.5 M solution in NMP, 
0.85 mmol) and DIPEA (295 μL, 1.69 mmol) were added into the reactor. Iterating this 
technique, three more units of β-alanine were then added to give the compound 11 in 
quantitative yield (calculated by UV detector). 
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Compound 12. To the linker 11, anchored to the resin, folic acid (1 mL of a 0.5 M 
solution in DMSO, 0.91 mmol, 400 mg), PyBOP (1 mL of a 0.5 M solution in DMSO, 
0.90 mmol) and DIPEA (158 μL, 0.91 mmol) were added. After 16h the product 12 was 
detached from the resin with a solution of TFA/TIS/H2O (95%:2.5%:2.5%) (1.5 mL) 
for 2h. TFA was removed under nitrogen atmosphere. The pure 12 (0.88 mmol, 741 mg, 
97% yield) was obtained by precipitation with cold Et2O, centrifugation and subsequent 
lyophilization. 1H NMR (300 MHz DMSO-d6) δ: 1.82-2.00 (m, 2H, H-β), 2.18-2.25 (m, 
10H, H-3II, H-6II, H-9II, H-12II H-γ), 2.39 (dd, 1H, H-14II); 2.67 (dd, 1H, H-14II); 3.18-
3.25 (m, 8H, H-2II, H-5II, H-8II, H-11II), 4.30 (bs, 1H, H-α); 4.58 (bs, 2H, H-9), 6.62 (d, 
2H, H-3I, H-5I), 7.15-7.22 (m, 3H, H-4II, H-7II, H-10), 7.65 (d, 2H, H-2I, H-6I), 7.00-
7.22 (m, 2H, H-1II, H-3), 8.10 (m, 1H, NHGlu), 8.65 (m, 1H, H-7). 
ESI-MS: m/z 839.33 (calcd); 841.03 [M+H]+, 864.34 [M+Na]+, 881.91 [M+K]+ 
(found). Anal. calcd for C35H45N13O12
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: C, 50.06; H, 5.40; N, 21.68. Found: C, 50.22; 
H, 5.38; N, 21.59. 
 
Compound 3. The compound 3 was obtained with 96% yield under the same conditions 
used for compound 1 described in Chapter 1, starting from 14. 1H NMR (500 MHz 
DMSO-d6) δ: 1.82-2.00 (m, 2H, H-β), 2.18-2.25 (m, 10H, H-3II, H-6II, H-9II, H-12II H-
γ), 2.39 (dd, 1H, H-14II); 2.67 (dd, 1H, H-14II); 2.76-2.79 (bt, 1H, H-19II), 3.12, (m, 1H, 
H-18II), 3.18-3.25 (m, 8H, H-2II, H-5II, H-8II, H-11II), 3.56-3.58 (m, 3H, OCH3) 4.30 
(bs, 1H, H-α); 4.58 (bs, 2H, H-9), 6.62 (d, 2H, H-3I, H-5I), 7.15-7.22 (m, 3H, H-4II, H-
7II, H-10), 7.65 (d, 2H, H-2I, H-6I), 7.00-7.22 (m, 2H, H-1II, H-3), 8.10 (m, 1H, NHGlu), 
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8.46 (s, 1H, H-16II), 8.65 (m, 1H, H-7). Anal. calcd for C41H54N14O14: C, 50.93; H, 
5.63; N, 20.28; O, 23.16. Found: C, 50.75; H, 5.64; N, 20.36. 
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3.1 INTRODUCTION 
Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune 
system caused by the human immunodeficiency virus (HIV).1
HIV-1 and HIV-2 are RNA viruses belonging to the retroviruses family
 The disease interferes 
with the immune system making AIDS infected individuals much more likely to get 
infections, including opportunistic infections and tumors that do not affect people with 
working immune systems. 
2 and so 
they are duplicated in a host cell by reverse transcriptase enzyme to produce DNA from 
its RNA genome.3
1. HIV binds to a CD4 receptor and then fuses with the host cell; 
 The human immunodeficiency virus has a spherical shape with a 
diameter of about 100 nm and is composed by a capsid (glycoproteins membrane) on 
which gp41 trans-membrane protein, and gp120 surface glycoproteins are present. 
Within the membrane there is an nucleocapsid (protein envelope) which encloses the 
genetic material (two copies of single strand RNA) and enzymes necessary for virus 
replication: protease, integrase, reverse transcriptase and ribonuclease.  
As shown in Figure 1, the life cycle of HIV consists of following steps: 
2. after fusion, the virus releases its genetic material into the host cell (uncoating); 
3. the reverse transcriptase enzyme converts the single-stranded viral RNA to 
double-stranded viral DNA;  
4. the newly formed viral DNA is transported in the cellular nucleus and integrates 
into the host DNA by integrase enzyme (integration); 
5. new viral RNA and viral proteins are formed (transcription and trasduction
6. new viral RNA and proteins move to cell surface to form a new mature HIV.
); 
4 
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Figure 1. HIV life cycle. 
 
 
3.1.1 ANTI-HIV CHEMOTHERAPY  
The gained knowledge about HIV replication cycle has led to the development of 
several classes of chemotherapeutic agents5 like, for example, nucleoside and nucleotide 
reverse transcriptase inhibitors (NRTIs, NtRTIs), non-nucleosides reverse transcriptase 
inhibitors (NNRTIs), co-receptor inhibitors (CRIs), fusion inhibitors (FIs), integrase 
inhibitors (INIs), protease inhibitors (PIs).6 In particular, nucleosides reverse 
transcriptase inhibitors (NRTIs) received over the years the greater attention. The 
reverse transcriptase is an asymmetric heterodimer consisting of two subunits of 66 kDa 
(p66) molecular mass  and 51 kDa (p51), with identical residues in their first 428 amino 
acid positions. The p66 subunit is 560 residues in lenght, with its DNA polymerase and 
RNase H domains in the amino and carboxylterminal portions, respectively. Based on 
an examination of crystal forms of HIV-1 RT, the anthropomorphic shape of a hand has 
been used to describe the polymerase domain, with subdomains made up of the fingers, 
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palm, thumb, and connection to the RNase H domain. The p51 subunit comprises the 
same subdomains, but lacks the RNase H portion. The fingers, thumb, palm, and 
connection of the two subunits can be approximately superpositioned, pairwise, 
between p66 and p51. However, the tertiary packing of the subdomains within the 
subunits differs: p66 is described as an open hand, with a large cleft for binding double-
stranded nucleic acids between the thumb and fingers subdomains, while p51 is 
considerably more compact, with no nucleic acid binding cleft. 
 
 
3.1.1.1 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
NRTIs, analogues of natural nucleosides, explicate their pharmacological action after 
phosphorylation steps7 by host cell kinases and phosphotransferases to form 
deoxynucleoside triphosphate8,9 analogues capable of viral inhibition.10 In particular, 
they act on the process of virus replication by blocking the transcription of viral RNA 
into DNA, as once incorporated, the lack of OH prevents the formation of the bond 
3',5'-phosphodiester bond with the next nucleotide in crescent DNA chain, thus 
blocking its growth. 
 
Figure 2. Chain termination mechanism. 
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Currently, there are eight NRTIs approved for HIV treatment by Food and Drug 
Administration (Figure 3).5 As cartooned in Figure 3 this drugs have as common 
feature the lack of 3’-OH group, even if they present different structures. Indeed, in the 
case of nucleosides ddI and ddC the OH-group is substituted by on H-atom, in the case 
of AZT, instead there is a 3’-azido function. In Abacavir drug the saccharide unit is 
replaced by a carbocyclic ring with a double bond, while 3TC and FTC present a sulfur 
atom in C3’. It’s also important to note a particular saccharide portion modification of 
drugs 3TC, FTC, and TFV. Indeed regarding 3TC and FTC, in addition to the 
oxathiolane ring, they have the unnatural L-enantiomeric ribose form. Note that L-
nucleoside analogues are often privileged anti-HIV agents because their activity is often 
associated to minor toxicity.11 TFV, instead, is the only nucleotide analogue among 
approved NRTIs that has an acyclic linker attached to a modified phosphate. 
Furthermore, some of currently approved NRTIs present a modified nucleobase such as 
FTC that contains a fluorine at C5 position of cytosine and ABC has a modified 
diaminopurine ring.12
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Figure 3. NRTIs currently used in HIV-1 and HIV-2 treatment. 
 
 
3.1.1.2 ANTIVIRAL AND ANTITUMOR NUCLEOSIDES 
The structural requirements of antiviral and antitumor nucleosides to be recognized by 
cellular/viral enzymes rely on three key elements:  
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a) the hydroxymethyl group, necessary for nucleoside phosphorylation,  
b) the heterocyclic base moiety, involved in the main recognition processes through 
specific hydrogen bonds, and  
c) the sugar moiety, which can be considered as a spacer to connect the 
hydroxymethyl group and the nucleobase in the correct orientation. 
 
A wide number of structural modifications at the carbohydrate moiety have been 
devised, with the aim to replace the furanose ring with units resembling the 
conformational features of natural nucleosides. Particularly, replacement of the sugar 
skeleton with acyclic moieties, n-membered rings (with n=3,4,5,6,7), equipped in some 
cases with exo- or endocyclic double bonds, has been reported. Such systems quite 
often contain carbon, one or more heteroatoms in place of/or along with endocyclic 
oxygen, resulting in major functional changes in the nucleoside subunits. Such a wide 
structural diversity in nucleoside architectures has led, over the years, to the 
development and approval of several molecules on the antiviral market in both racemic 
or enantiomerically pure form.
3.1.2 HIV DRUG RESISTANCE  
  
 
 
In the last years, combination chemotherapy or highly active antiretroviral therapy 
(HAART) (Figure 3) using two or more NRTIs has improved the life quality of HIV-
infected patients. Unfortunately the application of these compounds is clinically limited 
due to their cytotoxicity through inhibition of the host DNA polymerases and the rapid 
development of drug-resistant HIV variants. Two basic types of NRTI-resistance 
mechanisms known for HIV-1 reverse trascripatase are: NRTI exclusion and NRTI 
excision. 
NRTI exclusion. This resistance mechanism involves enhanced discrimination when 
triphosphate form of a NRTI is incorporated. The M184V/I mutations are a clear 
example of the exclusion mechanism because it selectively reduce the incorporation of 
3TC and FTC by steric hindrance.13 Also the mutations L74V (ddI resistance),14 K65R 
(TFV and ddI resistance)15 and several variants that involved Q151M (resistance to 
most NRTIs)16 cause resistance by the exclusion mechanism.  
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NRTI excision. The excision mechanism involves the selective removal of the 
NRTI from the end of the viral DNA after its incorporation by RT. For example the 
combinations of mutations M41L, D67N, K70R, L210W, T215F/Y, K219E/Q17
3.1.2.1 4’-SUBSTITUTED NUCLEOSIDE ANALOGUES 
 adduce 
high levels of resistance to AZT and to much lower levels of resistance to some other 
NRTIs.  
Therefore, the development of new compounds with reduced cytotoxicity and that 
are active against drug resistant HIV-1 variants and that prevent or delay the emergence 
of resistant HIV-1 variants is urgently needed.  
 
 
Among new classes of nucleoside analogues endowed of the above mentioned features 
4’substituted nucleosides are currently under investigation. Some candidates for 
chemoterapeutic treatment of drug-resistant HIV strains and selected results of their 
antiviral assays are reported below.18 
The first discovered 4’-substituted deoxynucleoside provided with potent anti-HIV 
activity is 4’-azido-thymidine.19 This compound showed better antiviral potency than 
AZT, but also higher cytotoxicity. Among a wide range of subsequently synthesized 4’-
substituted NRTIs,20 2’-deoxy-4’-C-ethynyl-2-fluoroadenosine (EFdA) (Figure 4) 
stands out as one of the most potent NRTIs.21
The 4’-substituted nucleosides (4′-SdNs) in Figure 4 are characterized by presence 
of 3′-OH which makes them acceptable by RT, therefore, they are incorporated into the 
proviral DNA chains. As reported in literature,
 It is up to 100-fold more potent than AZT, 
reaching even better in vitro activity than some HIV protease inhibitors. 
22 the 4′-substituents cause severe steric 
hindrance16,23 to the neighbouring cis 3′-OH group due to restricted rotation around the 
C3′-C4′ single bond. For this reasons 3′-OH results less reactive and it was expected 
that enzymatic chain elongation of DNA proceed slowly. Consequently, 4′ -substituted 
nucleosides could be considered kinetic chain terminators24 for proviral DNA 
biosynthesis. Furthermore 4′ -SdNs would be more stable than 2′ -deoxynucleosides and 
2′,3′-dideoxynucleosides against catabolism because of the steric repulsion between 3′ -
OH and 4′ -substituents changes the conformation of their furanose ring, preferably to 
Introduction                                                                                                         Chapter 3 
92 
 
C3′-endo conformation; this results in 4′ -SdNs being less susceptible to enzymatic 
degradation.
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Figure 4. Anti-HIV-1 Activity of Nucleoside Analogues: 4’-Substituted-D- and L-
nucleosides. 
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Figure 4. Anti-HIV-1 Activity of Nucleoside Analogues: 4’-Substituted-D- and L-
nucleosides (continued). 
 
Among the 4’-substituted nucleosides under investigation at present, an important class 
of this biologically active compounds are nucleosides possessing an unsaturated26 or 
saturated sugar moiety.  
The novel derivatives of d4T, like 2’,3’-didehydro-3’deoxy-4’-ethynylthymidine 
(4’-Ed4T) represent an interesting example (Figure 5).27 Compared with its parental 
compound d4T, 4’-Ed4T is fivefold more potent against HIV-1 replication. It also 
showed much less cytotoxicity than d4T in cell culture studies because triphosphate 4’-
Ed4T had no or only a weak inhibitory effect on major host DNA polymerases. 
Moreover, 4’-Ed4T was found to be active against many drug-resistant HIV-1 strains. 
Drug susceptibility studies showed that HIV-1 strains with the M184V single mutation 
and the P119S/T165A/M184V triple mutations in RT conferred three- to fivefold and 
130-fold resistance to 4’-Ed4T, respectively.28  
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Figure 5. Anti-HIV-1 activity of nucleoside analogues: 2’,3’-dideoxy-2’3’-dideydro-4’-
substituted-D and L-nucleosides, 2’,3’- dideydro-4’-substituted-D and L-nucleosides 
 
Great attention in this field also received the exploration of new 4’-substituted 
nucleosides containing a sulfur atom sugar ring yielded potent inhibitors of HIV with 
EC50 values ranging from 0.37 to 100 µM (Figure 6). In this series, 4’-azido- and 4’-
cyanothionucleosides were approximately 10-fold more potent than the 4’-ethynyl-
containing compounds. Unlike most of the other 4’-substituted NRTIs, the 
thiothymidine series appeared to maintain potent activity against viruses with the 
M184V mutation.29  
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Figure 6. Anti-HIV-1 activity of nucleoside analogues: 2’,3’-dideoxy-2’3’-dideydro-4’-
substituted-D and L-nucleosides 
 
With the aim to prepare new compound able to overcome drug resistance, in the next 
section, it will described novel synthetic strategy to design more specific and selective 
antiviral agents. In particular, our attention was focused on the synthesis of sulfur-
containing six-membered nucleosides30 with structural similarity with natural 
nucleosides and 4’-substituted nucleosides to be tested as antiviral agents for treatment 
of HIV-infected individues. 
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3.2. RESULTS AND DISCUSSION 
On the basis of considerations and data reported in the previous section, this work 
concerns the synthesis of novel nucleoside analogues endowed with potential antiviral 
property. In particular a novel class of nucleosides in which the sugar moiety that 
usually acts as a spacer between the two other unit (CH2OH group and heterocyclic 
base) hase been replaced by a dithinyl one. Moreover a new methodology for the 
synthesis of 4’substituted nucleosides has been realized. Both synthetic approach made 
use of the same starting material 
S
S
HO
S
S
HO
Base
Base
S
S
HO
O
HO Base
CH3O
1) coupling reaction
2) domino reaction
3) desolforation and
nucleobase insertion
1) sulfoxidation reaction
2) Pummerer-type
glycosidation
5,6-dihydro-1,4-dithiin compound depicted in the 
square of Figure 1. 
 
Figure 1. 1,4-Dithiinyl and 4’-Substituted Nucleosides. 
 
 
3.2.1 SYNTHESIS OF 2,3-DIHYDRO-1,4-DITHIINYL NUCLEOSIDES 
In this context, our interest in sulfur-containing nucleosides1 and six-membered 
nucleoside analogues2 took us to open up a synthetic study on the preparation of 
heterocyclic nucleosides 1 and 2, in which the sugar moiety is substituted by a 5,6-
dihydro-1,4-dithiin ring (Figure 2). Such a system has long been at the centre of our 
investigations regarding the development of novel de novo synthetic methodologies for 
the preparation of natural and unnatural compounds by three-carbon homologation of 
various electrophiles.3 Differently from its common employ as elongating system,31,4 
herein we report the use of dithiinyl moiety as sugar scaffold in place of the furan ring 
of natural nucleosides to produce novel analogues endowed with potential antiviral 
activity. 
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Figure 2. Dithiin nucleoside analogues 1 and 2. 
 
In spite of the unusual shape of the dithiine skeleton, we evaluated its capacity to work 
as a good spacer to place the nucleobase and the hydroxymethyl group in the 
appropriate orientation and distance for recognition by viral/cellular enzymes. With this 
aim, some preliminary Hyperchem calculationsi were carried out, overlapping the 
structures of nucleosides 1 and 2 with those of natural nucleosides, as well as of other 
potent antiviral agents. The 1,4-dithiinyl system demonstrated to possess fairly good 
structural features, showing the best superimposition of both the hydroxymethyl group 
and the nucleobase when cytosine analogue (S)-2 was overlapped with the potent 
antiretroviral agent Lamivudine (3TC, 3) frozen in its bioactive N conformation5
(S)-2 Lamivudine
[anti-HIV and
anti-HBV]
3
N
O
OH
S
N
NH2
O
S
S OH
N
N
NH2
O
 
(Figure 3). 
 
Figure 3. Superimposed structures of analogue (S)-2 and Lamivudine (3). 
 
Such studies prompted us to evaluate the biological properties of such nucleoside and to 
develop an expeditious procedure for its preparation as well as that of its regioisomer 1 
(Figure 3). Moreover, given the relaxed enantioselectivity displayed by of some key 
enzymes involved in the activation of deoxycytidine analogues,6 
                                                 
i The models were generated by energy minimization with the Amber force field of the structures using 
the HYPERCHEM 8.0 software package (Hypercube Inc.) 
 a comparable activity 
of both enantiomers should be expected. In this communication, the synthesis of target 
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compounds 1 and 2 as R/S mixture has been performed, as the antiviral evaluation of the 
racemic nucleosides would give results regarding both enantiomers in one procedure.  
Synthesis of dithiinyl nucleosides 1 and 2 was envisioned to be carried out through 
a Pummerer-type glycosylation reaction on sulfoxides 8 and 9, in turn obtained from 
our bis-thioenol ether 5 (Scheme 1). As already documented,31
S
S
RO
5 R = H
6 R = Ac
7 R = PMB
S
S
RO
O
S
S
RO
ORef. 31H3C OCH3
O
984
O
Ac2O/Py
98%
MCPBA,
CH2Cl2, 0 °C
PMBCl, NaH,
0 °C to rt
96%
f r om 5, 6 and 7
see Table 1
a) R = H, b) R = Ac, c) R = PMB
1
2
3
4
60-78%
 preparation of the 5,6-
dihydro-1,4-dithiin ring was easily carried out in four steps from methyl pyruvate 4 
(Scheme 1).  
 
Scheme 1. Synthesis of sulfoxides 8-9. 
 
The synthesis began with the protection of free alchol 5 (Ac2O, pyridine) and 
subsequent thioether oxidation of the acetate 6 with m-CPBA in CH2Cl2
Sulfoxidation reaction was also attempted using dithiin 5 and its derivative 7 in 
presence of various oxidizing agents.
 to give a 55:45 
mixture of two regioisomers 8b and 9b in 78% yield. 
ii,7 As shown in Table 1, use of m-CPBA gave 
similar results on all substrates, affording the two regioisomeric sulfoxides 8a and 9a in 
approximatively 1:1 mixture (R=H) with a slight prevalence for 8 over 9 when R=Ac or 
PMB. The preference for the oxidation at S-4 of the dithiine ring was observed in most 
cases; only the use of a bulkier oxidizing agent, such as pyridinium dichromate (PDC), 
in the oxidation of dithiin 7, led to a greater excess of regioisomer 8c (entry 2). Even the 
use of Kagan-Modena sulfoxidation conditions8 (L-DET or D-DET/tBuOOH/Ti(O-iPr)4
 
) 
did not affect the reaction outcome (entries 4 and 5). Sulfoxidation reaction seemed to 
be essentially driven by steric hindrance reasons at allylic position, even though an 
additional electronic contribute was found. 
 
                                                 
ii All substrates did not exibit any reactivity when in situ generated TFDO [methyl 
(trifluoromethyl)dioxirane] was used. 
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Table 1. Sulfoxidation of dithiins 5-7. 
Entry Conditions 8/9 ratio (% yield) a 
R = H R = Ac R = PMB 
1 m-CPBA (1.0 equiv), -20°C 50:50 (60) 55:45 (78) 60:40 (74) 
2 PDC (1.0 equiv), -20°C ND 65:35 (82) b 85:15 (84) 
3 PDC (1.0 equiv), rt ND 65:35 (80) b --c 
4 
(41) 
L-DET/tBuOOH/Ti(O-iPr)4 50:50 (87) ,  
(2:1.2:1.0 equiv), -20 °C 
60:40 (90) 65:35 (85) 
5 D-DET/tBuOOH/Ti(O-iPr)4 50:50 (89) ,  
(2:1.2:1.0 equiv), -20 °C 
57:43 (91) 68:32 (86) 
a CH2Cl2 used as solvent in all reactions. 
b ND: not determined (concurrent oxidation of primary hydroxyl group occurred). 
c
S
S
O
10
m-CPBA
CH2Cl2, 0 °C
S
S
11
O OCH3OCH3
O
86%
 Further S-4 oxidation led to formation of a sulfone as the only product of the reaction. 
 
It is worthy to note that a full electronic contribution has been observed when the 
sulfoxidation reaction was performed on methyl ester derivative 10, in which the 
electron withdrawing group at C-2 position made S-4 atom a weak nucleophile (Scheme 
2).  
 
Scheme 2. Synthesis of sulfoxide 11. 
 
However 10 could not be used for providing nucleoside 2, owing to fair instability of 
sulfoxide 11 to subsequent reaction conditions. 
Indeed, energy calculation (B3LYP/6-31G*)iii
                                                 
iii Theoretical calculations were performed by SPARTAN '08 Quantum Mechanics Program. 
 performed on 6 and 7 provided 
consistent explanation for the greater oxidability of S-4 compared to S-1. For both 6 and 
7, the HOMO molecular orbital is more localized on S-4 rather than on S-1, and 
coefficient value difference is grater in 7 (Table 2). 
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Table 2. Homo coefficients in 6 and 7 
Atom dithiin 6 dithiin 7 
S-1 0.36824 0.28018 
S-4 0.44799 0.40612 
 
As sulfoxides 8 and 9 were obtained, preparation of target nucleoside analogues was 
carried out by a Pummerer-type glycosidation reaction.9 First attempts carried out on 
sulfoxide 8c, under the same conditions previously reported29 with N4-acetylcytosine, 
TMSOTf and TEA in CH2Cl2
S
S
PMBO 8c
TMSOTf, TEA,
N4-AcCy
S
S
12O
O
S
S
HO
O
S
S
HO
OTMS
H
S
S
HO H
S
S
O
HH+
CH2Cl2,
0 °C to rt
, led as the only product of the reaction to the unexpected 
α,β-unsaturated aldehyde 12. This is probably the result of an intramolecular oxido-
reduction process and, as depicted in Scheme 3, it can be conjectured to occur after 
PMB protecting group removal, sulfoxide trimethylsilylation, thionum ion formation by 
TEA-mediated elimination, and concurred oxidation of free hydroxyl group, to give 
aldehyde 12. 
 
Scheme 3. α,β-unsaturated aldehyde 12 formation. 
 
On the other hand, as depicted in Scheme 4, under the same conditions the use of the 
more stable acetylated sulfoxide 8b allowed to obtain the desired dihydrodithiin 
nucleoside derivative 13 as a racemic mixture and in good yield (78%). Similarly to 
what observed in Scheme 3, the reaction proceeds through thionum ion intermediate 
mediated by TMSOTf and TEA and subsequent attack of silylated nucleobase on 
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thionum ion. Replacement of CH2Cl2 with CH3
8b S
S
13MeONa
MeOH
98% 1
N
N O
NHAc
AcO
78%
TMSOTf,
TEA,
CH2Cl2,
0 °C to rt
S
S
AcO
N
N OTMS
NAc
TMS
TMSO
CN led to the final product with 
approximately the same yield, but prolonged reaction times were required. 
 
Scheme 4. Dihydrodithiinyl nucleoside 1 via Pummerer-type glycosidation of 8b. 
 
Deprotection under common Zemplèn conditions (MeONa/MeOH) afforded the final 
target compound 1 in 98% yield. Analogously the same reactions, carried out starting 
from sulfoxide 9b, led to desired nucleoside analogue 2 in 71% o.y. (Scheme 5). 
9b
TMSOTf, TEA,
N4-AcCy
CH2Cl2, 0 °C
S
S
AcO
14MeONa
MeOH
95%
2
N N
O
AcHN
75%
 
Scheme 5. Dihydrodithiinyl nucleoside 2 via Pummerer-type glycosidation of 9b. 
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3.2.1.1 CONCLUSION 
In this context a straightforward procedure for the preparation of dithiinyl nucleoside 1 
and 2 has been accomplished in four steps by our readily available heterocyclic system 
5. Regioselectivity of sulfoxidation reaction of bis-thioenolethers 6-7 was rationalized 
on the basis of both steric and electronic effects. Nucleobase insertion was carried out 
by direct addition of N4-acetylcytosine to sulfoxide 8b-9b via Pummerer-type 
glycosidation reaction. Evaluation of racemic 1 and 2 as potential antiviral agents is 
currently in progress. In case, further development of asymmetric Pummerer 
rearrangements19 and/or enantiomeric resolution of our mixtures by chiral HPLC will be 
considered to provide enantiopure (S)- and (R)-1, as well as their regioisomers (S)- and 
(R)-2. 
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3.2.1.2 EXPERIMENTAL SECTION 
All moisture-sensitive reactions were performed under a nitrogen atmosphere using 
ovendried glassware. Solvents were dried over standard drying agents and freshly 
distilled prior to use. Reactions were monitored by TLC (precoated silica gel plate 
F254, Merck). Column chromatography: Merck Kieselgel 60 (70-230 mesh); flash 
chromatography: Merck Kieselgel 60 (230-400 mesh). 1H and 13C NMR spectra were 
recorded on NMR spectrometers operating on Varian VXR (200 MHz), Bruker DRX 
(400 MHz) or Varian Inova Marker (500 MHz), using CDCl3
S
S
AcO 6
 solutions unless otherwise 
specified. In all cases, tetramethylsilane (TMS) was used as internal standard for 
calibrating chemical shifts (δ). Coupling constant values (J) were reported in Hz. 
Combustion analyses were performed by using CHNS analyzer. 
 
Compound 6. To a stirring solution of alcohol 5 (0.71 g, 4.8 mmol) in dry pyridine, 
acetic anidride was added at room temperature. After 3h TLC (hexane/EtOAc = 8/2) 
analysis showed the complete formation of final compound. The solvent was evaporated 
under reduced pressure and the crude residue purified by chromatography on silica gel 
(hexane/EtOAc = 9/1) to give the pure 6 (0.834 g, 98% yield). Oily; 1H NMR (400 
MHz): ppm 2 (s, 3H, CH3) δ 3.08-3.20 (m, 4H, CH2S), 4.49 (s, 2H, CH2O), 6.22 (s, 1H, 
CH=). 13C NMR (200 MHz): ppm 20.63, 25.91, 26.42, 68.09, 115.89, 122.41, 170.31. 
Anal. calcd for C7H10O2S2
S
S
AcO
O S
S
AcO
O
98
: C, 44.18; H, 5.30; S, 33.70. Found: C, 44.34; H, 5.28; S, 
33.61. 
 
Compound 8 and 9. To a stirred solution of compound 6 (0,8 g, 4,2 mmol) in dry 
CH2Cl2 (18 mL), at 0 °C, m-chloroperoxybenzoic acid (0.361 g, 2.1 mmol) was added 
in one portion. After 3h the mixture was neutralized with aq NaHCO3, and then 
extracted with CH2Cl2. Organic phase was dried on Na2SO4 and the solvent evaporated 
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under vacuum. The crude residue obtained purified by chromatography on silica gel 
(EtOAc/CH3OH) gave the pure compounds 8 and 9 (in 6/4 ratio, 98%). 
Data for compound 8. Oily; 1H NMR (300 MHz, CDCl3): ppm 2.00 (s, 3H, CH3) 
2.60 (ddd, 1H, CHS), 2.91-3.02 (d, 1H, CHS), 3.31-3.42 (d, 1H, CHS), δ 3.43-3.62 (t, 
1H, CHS), 4.70 (s, 2H, CH2O), 6.80 (s, 1H, CH=). 13C NMR (50 MHz, CDCl3): ppm 
16.20, 20.62, 42.49, 65.64, 118.28, 143.39, 170.42. Anal. calcd for C7H10O3S2: C, 
40.76; H, 4.89; O, 23.27; S, 31.09. Found: C, 40.92; H, 4.87; S, 31.00. 
Data for compound 9. Oily; 1H NMR (300 MHz, CDCl3): ppm 2.00 (s, 3H, CH3) 2.52-
2.68 (t, 1H, CHS), 2.75-2.90 (d, 1H, CHS), 3.31-3.50 (m, 2H, CHS), 4.80 (s, 2H, 
CH2O), 7.00 (s, 1H, CH=). 13C NMR (50 MHz, CDCl3): ppm 13.71, 20.73, 42.65, 
65.39, 128.87, 133.50, 170.44. Anal. calcd for C7H10O3S2
S
S
N
N
O
NHAc
AcO 13
: C, 40.76; H, 4.89; O, 23.27; 
S, 31.09. Found: C, 40.90; H, 4.91; S, 30.99. 
 
Compound 13. To a suspension of N4-acetylcytosine (0.30 g, 2.0 mmol) in CH2Cl2 (10 
mL) TEA (0.8 mL, 6.1 mmol) and TMSOTf (1.1 mL, 6.1 mmol) were added at 0 °C and 
under N2 atmosphere. The mixture was left at room temperature for 30 min, after this 
time the mixture was cooled at 0 °C and a solution of sulfoxide 8b (0.28 g, 1.36 mmol) 
was added dropwise. The reaction was warmed at room temperature for 2h, then 
saturated aq NaHCO3 was added until neutrality. The mixture was extracted with 
EtOAc and washed with water; the organic layers were dried (Na2SO4) and evaporated 
under reduced pressure to give a crude product whose chromatography afforded the 
pure 11 (78% yield). 1H NMR (500 MHz, CDCl3): δ 2.11 (s, 3H, OCOCH3), 2.24 (s, 
3H, NHCOCH3), 3.26 (dd, J = 2.3, 14.6 Hz, 1H, CHaS), 3.40 (dd, J = 4.4, 14.6 Hz, 1H, 
CHbS), 4.61 (d, J = 12.7 Hz, 1H, CHaO), 4.65 (d, J = 12.7 Hz, 1H, CHbO), 6.40 (dd, J 
= 2.3, 4.4 Hz, 1H, CHS), 6.47 (s, 1H, HC=), 7.44 (d, J = 7.3 Hz, 1H, H-5), 7.84 (d, J = 
7.3 Hz, 1H, H-6), 8.42 (s, 1H, NH). 13C NMR (50 MHz, CDCl3): ppm 20.7 (CH3CO), 
24.9, 30.6, 53.0, 67.4, 96.2, 114.1, 124.3, 147.4, 155.1, 162.5, 170.5. Anal. calcd for 
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C13H15N3O4S2
S
S
AcO
N
N OAcHN
14
: C 45.73, H 4.43, N 12.31, S 18.78. Found: C 45.65, H 4.44, N 12.26, S 
18.84. 
 
Compound 14. Under the same conditions, starting from 9b compound 14 was 
obtained (75% yield). 1H NMR (400 MHz, CDCl3): δ 2.13 (s, 3H, OCOCH3), 2.25 (s, 
3H, NHCOCH3), 3.26 (dd, 1H, J = 2.0, 13.9 Hz, 1H, CHaS), 3.35 (dd, 1H, J = 4.6, 13.9 
Hz, 1H, CHbS), 4.70 (d, J = 12.7 Hz, 1H, CHaO), 4.73 (d, J = 12.7 Hz, 1H, CHaO), 
6.45 (s, 1H, HC=), 6.48 (dd, J = 2.0, 4.6 Hz, 1H, CHS), 7.47 (d, J = 7.5 Hz, 1H, H-5), 
7.80 (d, J = 7.5 Hz, 1H, H-6), 8.35 (s, 1H, NH). 13CNMR (50 MHz, CDCl3): ppm 20.8, 
24.9, 28.8, 53.8, 67.2, 96.4, 116.0, 123.1 (C=CH2), 147.2 (C-6), 154.8, 162.7, 170.6. 
Anal. calcd for C13H15N3O4S2
S
S
N
N
O
NH2
HO 1
: C 45.73, H 4.43, N 12.31, S 18.78. Found: C 45.80, H 
4.44, N 12.28, S 18.70.  
 
Compound 1. To a stirring solution of compound 13 (0.100 g, 0.4 mmol) in 10 mL of 
CH3OH, CH3ONa (21.6 mg, 0.4 mmol) was added. After 2 h at mixture of reaction 
AcOH dropwise was added  until neutral. The solvent was evaporated under reduced 
pressure to give a crude residue that purified by chromatography on silica gel 
(CHCl3/MeOH = 9:1) provided the pure 1 (98% yield). 1H NMR (200 MHz, CD3OD): 
δ 3.18-3.25 (m, 2H, CH2S), 4.12 (dd, J = 0.9, 13.0 Hz, 1H, CHaOH), 4.21 (dd, J = 0.9, 
13.1 Hz, 1H, CHbOH), 5.87 (d, J = 7.6 Hz, 1H, H-6), 6.34 (dd, J = 2.8, 3.8 Hz, 1H, 
CHS), 6.39 (d, J = 0.9 Hz, 1H, HC=), 7.66 (d, J = 7.6 Hz, 1H, H-5). 13CNMR (50 MHz, 
CD3OD): ppm 30.6, 55.2, 67.2, 95.5, 113.1, 130.6, 145.2, 157.8, 167.8. Anal. calcd for 
C9H11N3O2S2: C 42.01, H 4.31, N 16.33, S 24.92. Found: C 41.94, H 4.30, N 16.28, S 
25.00. 
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Compound 2. Under the same conditions, starting from 14 compound 2 was obtained 
(97% yield). 1H NMR (200 MHz, CD3OD): δ 3.15-3.34 (m, 2H, CH2S), 4.05 (d, J = 
13.1 Hz, 1H, CHaOH), .4.07 (d, J = 13.1 Hz, 1H, CHbOH), 5.84 (d, J = 7.6 Hz, 1H, H-
6), 6.25 (dd, J = 2.5, 4.8 Hz, 1H, CHS), 6.46 (d, J = 0.9 Hz, 1H, HC=), 7.63 (d, J = 7.6 
Hz, 1H, H-5). 13CNMR (75 MHz, CD3OD): ppm 31.8, 54.0, 67.2, 95.3, 112.0, 130.5, 
145.4, 157.6, 167.4. Anal. calcd for C9H11N3O2S2: C 42.01, H 4.31, N 16.33, S 24.92. 
Found: C 41.90, H 4.32, N 16.37, S 24.99. 
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3.2.2 SYNTHESIS OF 2’,3’-DIDEHYDRO-2’,3’-DIDEOXY-4’-
METHOXY NUCLEOSIDES 
Current status of organic synthesis is hampered by time-consuming, costly protecting 
group-based strategies and lengthy purification procedures after each synthetic step. To 
circumvent these inconveniences, the potential of multistep protocols including domino1 
or cascade2 reactions has been exploited for the efficient and elegant construction of 
complex molecules from simple precursors in a single process. In this context, our 
ongoing efforts working toward the de novo synthesis of novel molecular systems with 
pharmacological potential took us to explore the versatile reactivity profile of our 1,2-
bis thioenol ether synthon 1 in combination with 2,3-dichloro-5,6-dicyanobenzoquinone 
(DDQ) (Scheme 1). 
 
Scheme 1. De novo synthetic strategy to bicyclic furans 5. 
 
Whereas heterocyclic system 1 brought on C3-homologation of various electrophiles3 2, 
in many cases in stereoselective fashion,3,4 use of the resulting homologation products 3 
with DDQ laid the ground for new efficient domino reactions for further elaboration of 
the carbon skeletons. As proof-of-concept of this methodology, we successfully 
developed an expeditious procedure for the synthesis of the whole series of rare L-
hexoses4,5 as well as other structurally related compounds.6 In all cases, rapid assembly 
of pyranosyl scaffolds 4 was found a consequence of the combined electron-transfer, 
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oxidative and acidic properties of DDQ, which enabled sequentially PMB group 
deprotection of allyl ethers 3, oxidation of the resulting primary alcohols and formyl 
groups activation, finally leading to six-membered cyclization by a suitably unprotected 
hydroxyl function (Scheme 1). 
Along this line, synthetic access to dihydrofurans 5 has been herein explored 
(Scheme 1), mainly in view of their potential application in the synthesis of bioactive D- 
and L-(didehydro)furanosyl nucleosides.7 The synthesis starts from coupling reaction of 
thioenol ether 1 with synthetically available methyl glycolate 6, previously protected 
with a TBDPS-group. Under known conditions reported for comparable electrophile23 
unfortunately we didn’t obtained the expected product with highly yields (scheme 2). 
Scheme 2. Synthesis of coupling compound 7 using several conditions. 
 
Particularly, treatment of heterocyclic homologating agent 1 with n-butyl lithium in 
anydrous THF at -78 °C, followed by addition at the same temperature of electrophile 6, 
provided, along with small amounts of ketone 7 (10%), almost exclusive formation of 
tertiary alcohol 9 (80%) resulting from the further nucleophilic addition by the n-butyl 
lithium on C-4 position. The aldehyde 8 was also isolated as another byproduct of the 
reaction (10%), which seem to be formed by consumption of the coupling product 7. 
This byproduct was already obtained in our laboratories, as previously reported, under 
same reaction conditions, during the synthesis of L-hexoses5, however the mechanism of 
such reaction in the current synthesis is still under investigation. On the basis of these 
findings, we decided to prove different basis, poor nucleophiles, like potassium 
hexamethyldisilazide (KHMDS) and lithium diisopropylamide (LDA). While the use of 
KHMDS was unsuccessful, LDA, led to more satisfactory results. This reagent was 
prepared in situ from a solution of diisopropylammine (DIPA) and n-BuLi, in dry THF, 
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at -78 °C. The subsequent addition of 1 and then 6 at the same temperature, finally 
provided the ketone 7 as main product (80%), instead aldehyde 8, under these 
conditions, was isolated only in small amounts (6%) (Scheme 2). With the product 7 in 
hand, our interest was focused on the achievement of key intermediate 13 by carbon 
skeleton cyclization via domino reaction (Scheme 3). After reductioni of 7 to the 
corresponding sec-alcohol 10 (BH3.THF, 86%), direct conversion of the latter into 
methyl glycosides 11 was achieved treating 10 with DDQ (1.2 equiv) in a 95/5 
CH2Cl2/MeOH solution to afford, already after only 30', a mixture of isomers α-11 and 
β-11 in moderate selectivity (α:β = 1:3.3) and fairly good overall yield (83%). 
 
Scheme 3. Domino approach to (dihydro)furans 11-13. 
 
Surprisingly, minimal changes of reaction conditions provided a number of other 
synthetically relevant in situ transformations (Schemes 3 and 4). Under optimized 
conditions, treatment of 10 with DDQ (1.85 eq) in a 3/1 C6H6
                                                 
i As we were first interested to explore reactivity profile of our compounds, rather than their preparation 
as pure enantiomers, starting alcohol 10 was achieved in racemic form. Study of the reaction conditions 
enabling synthesis of 10 in both enantiomeric forms is currently ongoing. 
/MeOH mixture directly 
led, overall after 3h at rt, to the formation of bis-acetals 13 (α:β = 1:4) in an excellent 
90% o.y. (Scheme 3). This process was amenable to be considered a domino reaction, 
as it proceeded across the following six sequential transformations, carried out in a 
single step: a) PMB group removal, b) oxidation of the resulting primary alcohol, c) 
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aldehyde acetalation, d) ring closure, e) MeOH elimination, and f) double acetalation 
(Scheme 3). It’s worth noting that, although furan 12 acted as simple intermediate under 
these conditions, it could be also smoothly isolated as the main product (75% yield) by 
further appropriate tuning of the amount of DDQ and MeOH [DDQ (1.2 eq), 
C6H6/MeOH 3/1, rt, 3h]. 
 
Scheme 4. Domino conversion of ketone 7 into α/β-13. 
 
Not fully unexpected, bis-acetals 13 could be obtained in a single process, albeit by a 
different sequence of synthetic transformations, even starting directly from ketone 7 
(Scheme 4). As a matter of fact, after addition of DDQ (1.2 eq) to a CH2Cl2/MeOH 
solution of 7, acetals 13 (α:β = 1:4) were produced after 3h in a very good 87% yield. 
Although none of the synthetic intermediates could be isolated, we reasonably assumed 
that 13 was the result of five sequential transformations, including oxidative 
deprotection of 7 leading to aldehyde 14, its double acetalation and concurrent 
cyclization (Scheme 4). 
It’s worth mentioning that replacement of MeOH with H2O under the above 
conditions provided even more unexpected reactivity, as it led to furfural derivative 18 
(83%). Analogously to Scheme 4, reaction was supposed to proceed through formation 
of bis-hemiacetal 16, then undergoing H3O+-mediated double elimination affording 18 
even after seven synthetic steps. However, 18 was not enough stable for further 
synthetic manipulations. 
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Scheme 5. Synthesis of furfural derivatives 18. 
 
Excellent synthetic potential of the above processes rely on a combination of versatility 
of DDQ and intriguing chemical properties of the 1,4-dithiinyl scaffold. Given the 
apparent synthetic applications of the domino products, their formation and especially 
that of bis-acetals 13 was investigated in greater detail. We started observing that last 
step of the domino process depicted in Scheme 3 closely resembles the well known 
Clauson-Kaas reaction,8
R = Piv
Pt Ni
MeOH, 91%
[ref. 10]O
RO
O
RO
MeO
OMe
R = TBDPS
DDQ (1.8 eq)
CH2Cl2/MeOH 3/1
reflux, 24h, 50%
(R = Piv) 19
(R = TBDPS) 20
21 (R = Piv)
α:β = 0.7:1
22 (R = TBDPS)
α:β = 1:1
 providing substituted 2,5-dialkoxy-2,5-dihydrofurans 21 from 
corresponding furans 19 under electrochemical conditions (Scheme 5).  
 
Scheme 6. (Modified) Clauson-Kaas approach to acetals 21-22. 
 
Herein, we established that the same transformation could be analogously carried out by 
DDQ (Scheme 5). However, compared to the above domino process, reaction of 
Scheme 6 was less efficient (50%), requiring harder conditions (24h at reflux) and even 
resulting in a worst stereoselectivity (α:β = 1:1). Therefore, a crucial influence of the 
dithiodimethylene bridge on reaction rate and stereoselectivity became apparent.  
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Scheme 7. Conversion of furans 12 and 19 into bis-acetals 13 and 22: hypothesized 
reaction mechanism. 
 
We hypothesized that reaction mechanism underlying conversion of both furans 12 and 
19 into corresponding bis-acetals 13 and 22 follow a common path (Scheme 7). 
However, in case of furan 12, we reasoned that unusual stability of oxocarbenium ions 
28 and 30, owing to deep delocalization of the positive charge by sulfur atoms at both 
C2 and C3-positions, significantly contributed to speed reaction up. In addition, since 
identical mechanistic paths involving furans 12 and 19 must be postulated, we assumed 
that, in case of 12, stabilization of oxocarbenium ions 28 and 30 also influenced the 
stereochemical outcome of the reaction, due to a concurrent thermodynamic equilibrium 
between α:β-13 and 28 and 30, not occurring with acetals α:β-22 (Scheme 7). To proof 
the above assumptions, domino reaction converting alcohol 10 into acetal 13 was 
carried out using C6D6/CD3OD as solvent mixture (Scheme 8). As primarily expected, 
reaction monitoring via 1H NMR enabled us to reasonably exclude any mechanistic path 
other than that described in Scheme 2, by recognizing disappearance of distinctive 1H 
NMR signals belonging to 10 (5.14 ppm, Scheme 8a) with those of furan 12 and 
especially the deuterated forms of acetals 11 and 13 (i.e. compounds α:β-31, 5.73 and 
5.96 ppm, and α:β-32, 5.68 and 5.75 ppm; Scheme 8b-c). Most importantly, occurrence 
of an equilibrium between α and β isomers of 13 was proved by changes in α:β ratio of 
acetals 32 (Scheme 8b-c).  
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Scheme 8. 1H NMR monitoring of domino reaction. 
 
A practical experimental evidence was also produced by simply treating pure β-13 with 
DDQ in a 3/1 CDCl3/CD3OD solution: complete conversion (>99% by 1H NMR) after 
16h at rt of the latter into corresponding bis-trideuteromethoxy acetal 32 as a α:β = 1:4 
mixture of isomers further confirmed, on one hand, existence of a thermodynamic 
equilibrium between the two isomers. On the other hand, it demonstrated that  
bis-thioenol ether moiety enabled effective activation of neighboring acetal functions, 
even under extremely mild acidic conditions. As expected, the same reaction did not 
proceed using acetal 22.  
Finally, the double bond of 13α was easily unmasked by dithioethylene bridge 
removal treating the most abundant α-anomer, preaviusly separated from β-anomer by 
cristallization from methanol, with raney-Ni in acetone at 0 °C affording the saturated 
furanosides 31 in good yield (82%) (Scheme 9). 
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Scheme 9. N-glycosidation reaction: Vorbrüggen one-pot protocol. 
 
Then, the key intermediate 33 was coupled with the heterocyclic bases 34 , using the 
well-known Vorbrüggen one-pot protocol, in which the glycosidic bond was achieved 
by Lewis acid-catalyzed N-glycosidation reaction of 33 with in situ silylated bases by 
BSA. In fact, treatment of compound 33 with cytosine 34, trimethylsilyl 
trifluoromethanesulfonate (TfOMTS) and N,O-bis[trimethylsilyl]acetamide (BSA) in 
acetonitrile, at room temperature for 48h, allowed to obtain a mixture of α- and β- 
nucleoside derivatives 35α/β (1/2) which were easily separated by silica gel column 
chromatography (65% yield) (Scheme 9). 
At last simple removal O-silyl and N-acetyl-protected groups, respectively with 
TBAF in THF and 6M NH3/CH3OH at room temperature, offered the final target 
compounds 36α and 36β, with high overall yields (98% and 92% respectively). 
Evaluation of racemic 36α and 36β as potential antiviral agents is currently in progress. 
In case, further development of asymmetric reaction will be considered to provide 
enantiopure nuclosides. 
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3.2.2.1 CONCLUSION 
A DDQ-mediated domino reaction, enabling synthesis of a number of substituted furans 
and 2,3-dihydrofurans from a common acyclic starting material containing the 5,6-
dihydro-1,4-dithiin moiety, has been developed. Analysis of reaction mechanism 
highlighted a crucial role of the heterocyclic unit in influencing rate and 
stereoselectivity of the process. This domino approach represents the key step of the 
straightforward synthesis of novel D- and L-4’-substituted nucleosides. 
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3.2.2.2 EXPERIMENTAL SECTION 
All moisture-sensitive reactions were performed under a nitrogen atmosphere using 
ovendried glassware. Solvents were dried over standard drying agents and freshly 
distilled prior to use. Reactions were monitored by TLC (precoated silica gel plate 
F254, Merck). Column chromatography: Merck Kieselgel 60 (70-230 mesh); flash 
chromatography: Merck Kieselgel 60 (230-400 mesh). 1H and 13C NMR spectra were 
recorded on NMR spectrometers operating on Varian VXR (200 MHz), Bruker DRX 
(400 MHz) or Varian Inova Marker (500 MHz), using CDCl3
H3CO
OTBDPS
O
6
 solutions unless otherwise 
specified. In all cases, tetramethylsilane (TMS) was used as internal standard for 
calibrating chemical shifts (δ). Coupling constant values (J) were reported in Hz. 
Combustion analyses were performed by using CHNS analyzer. 
 
Compound 6. To a stirred solution of methyl glycolate (0.500 g, 5.5 mmol) in dry DMF 
(8 mL), imidazole (0.453 g, 6.66 mmol) and TBDPSCl (1.7 mL, 6.6 mmol) was added 
at room temperature. After 3h (TLC: Hexane/EtOAc 9:1) the solvent was evaporated 
under reduced pressure at room temperature; the residue was transferred in a separatory 
flask with CHCl3 and washed with ice-cold water. The organic layer was dried on 
Na2SO4 and the solvent was evaporated under vacuum. The crude residue was purified 
by silica gel column chromatography to give the pure 6 (1,76 g, yield 98%): oily. 1H 
NMR (200 MHz, CDCl3): δ 1.09 (s, 9H, C(CH3)3 ), 3.68 (s, 3H, OCH3), 4.25 (s, 2H, 
CH2), 7.38-7.42 (m, 6H, Arom-H), 7.66-7.71 (m, 4H, Arom-H). 13C NMR (50 MHz, 
CDCl3): ppm 19.5, 26.9, 51.8, 62.4, 128.0, 130.2, 133.01, 135.8, 171.9. Anal. calcd for 
C19H24O3
S
S
PMBO
O
OTBDPS
7
Si: C 69.47, H 7.36, Si 8.55. Found: C 69.67, H 7.33. 
 
Compound 7. To a stirring solution of DIPA (0.32 mL, 2.23 mmol) in dry THF (4 mL), 
at -78 °C under nitrogen atmosphere, n-BuLi (1.6 M, 0.21 mL, 2.23 mmol) was added 
to generate lithium diisopropylamide in situ. After 10 min, to the mixture a solution of 1 
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(0.50 g, 1.86 mmol) in dry THF (2 mL). The solution was stirred for 30 min at -78 °C, 
then a solution of electrophile 6 (0.612 g, 1.86 mmol) in THF (2 mL) was added. After 
20 min TLC (hexane/EtOAc 9:1) showed the complete formation of final product and 
the reaction mixture was carefully quenched with 10% aq NH4Cl. The mixture was 
extracted with EtOAc, and the combined organic phases were washed with brine, dried 
(Na2SO4) and evaporated under reduced pressure to give a crude residue from which 
chromatography over silica gel column (hexane/AcOEt=8:2) gave the pure 7 (0.840 g, 
yield 80%): oily. 1H NMR (200 MHz, CDCl3): δ 1.09 (s, 9H, C(CH3)3), 2.99-3.05 (m, 
2H, CH2S), 3.19-3.22 (m, 2H, CH2S), 3.79 (s, 3H, OCH3), 4.34 (s, 2H, PhCH2O ), 4.38 
(s, 2H, CH2OSi), 4.57 (s, 2H, OCH2C=), 6.85 (d, 2H , PMB-Horto), 7.25 (d, 2H, PMB-
Hmeta), 7.34-7.43 (m, 6H, Arom-H), 7.65-7.71 (m, 4H, Arom-H). 13C NMR (50 MHz, 
CDCl3): ppm 19.2, 26.4, 28.2, 29.6, 55.1, 68.6, 71.1, 72.2, 113.6, 122.6, 127.6, 129.5, 
129.7, 132.9, 135.5, 140.5, 159.2, 195.4. Anal. calcd for C31H36O4S2
S
S
PMBO
O
8
Si: C 65.92, H 
6.42, S 11.35, Si 4.97. Found: C 66.11, H 6.40, S 11.30. 
S
S
PMBO
OTBDPS
HO CH2(CH2)3CH3
9
 
Compound 8 and 9. BuLi (1.6 M in hexane, 0.35 mL) was added dropwise to a stirred 
solution of 1 (0.1 g, 0.37 mmol) in anhydrous THF (0.5 mL) at -78° C and under 
nitrogen atmosphere. After 10 min a solution of electrophile 6 (0.122 g, 0.37 mmol) in 
the same solvent (0.5 mL) was added. The reaction mixture was stirred for 2h at -78 °C, 
then carefully quenched with 10% aq NH4Cl. The mixture was extracted with EtOAc, 
the combined organic phases washed with brine, dried (Na2SO4) and evaporated under 
reduced pressure. Chromatography of the crude residue over silica gel (hexane/EtOAc = 
9:1) gave the two separated product 8 (10% yield) and 9 (80% yield).  
Data for compound 8. Oily; 1H NMR (500 MHz, CDCl3): δ 3.10-3.18 (m, 2H, 
CH2S), 3.28-3.32 (m, 2H, CH2S), 3.81 (s, 3H, OCH3), 4.41 (s, 2H, PhCH2O), 4.52 (s, 
2H, OCH2=), 6.89 (d, J = 8.3 Hz, 2H, PMB-Horto), 7.26 (d, J = 8.3 Hz, 2H, PMB-
Hmeta), 9.82 (s, 1H, CH=O). 13C NMR (125 MHz, CDCl3): δ 25.5, 30.2, 55.3, 68.9, 
72.2, 114.0, 129.0, 129.6, 148.8, 159.6, 183.5. Anal.calcd for C14H16O3S2: C, 56.73; H, 
5.44. Found: C, 56.90; H, 5.42. 
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Data for compound 9. Oily; 1H NMR (200 MHz, CDCl3): δ 1.07 (s, 9H, C(CH3)3), 
1.24-1.55 (m, 5H, CH2CH3), 1.61-1.82 (m, 2H, CH2), 2.95-3.05 (m, 2H, CH2S), 3.18-
3.24 (m, 2H, CH2S) 3.56 (d, Ja-b= 10, 1H, CHHaOSi), 3.78 (s, 3H, OCH3), 4.05 (d, Jb-
a= 10, 1H, CHHbOSi) 4.23 (d, Ja-b= 11.2, 1H, CHHaCOH) 4.50 (s, 2H, CH2Ph), 4.62 
(d, Ja-b= 11.2, 1H, CHHaCOH), 6.84 (d, J = 8.6, 2H, PMB-Horto), 7.25 (d, J = 8.6, 2H, 
PMB-Hmeta), 7.36-7.52 (m, 6H, Arom-H), 7.63-7.81 (m, 4H, Arom-H). 13C NMR (50 
MHz, CDCl3): ppm 14.3, 19.25, 19.64, 23.28, 25.7, 26.8, 27.1, 29.6, 32.5, 36.8, 55.5, 
71.1, 72.1, 72.4, 77.5, 82.8, 116.9, 124.3, 127.6, 128.8, 129.5, 129.6, 132.8, 135.3, 
159.0. Anal. calcd for C36H48O4S2
S
S
PMBO
OH
OTBDPS
10
Si: C 67.88, H 7.60, S 10.07, Si 4.41. Found: C 
67.90, H 7.58, S 10.05. 
 
Compound 10. To a stirring solution of ketone 7 (0.50 g, 0.89 mmol) in dry THF (15.5 
mL) at room temperature, under nitrogen atmosphere, a 1M solution of BH3-THF (2.2 
mL, 2.2 mmol) was added dropwise. After 5h to the mixture of reaction CH3OH (5 mL) 
was slowly added, then the solvent was evaporated under reduced pressure. Column 
chromatography of crude residue over silica gel (hexane/EtOAc 9/1) gave the pure 10 
(0.43 g 86% yield): oily. 1H NMR (400 MHz, CDCl3): δ 1.11 (s, 9H, C(CH3)3), 2.94-
3.29 (m, 4H, CH2S), 3.70-3.89 (m, 5H, CH2OSi, OCH3), 3.92 (d, Ja-b = 12.2, 1H, 
CHHaO), 3.96 (d, Jb-a = 12.2, 1H, CHHbO), 4.31 (d, Ja-b = 11.6, 1H, CHHaPh), 4.36 (d, 
Jb-a = 11.6, 1H, CHHbPh), 4.86 (dd, J = 5.0, J = 7.8, 1H, CH), 6.87 (d, J = 8.6, 2H, 
PMB-Horto), 7.25 (d, J = 8.6, 2H, , PMB-Hmeta), 7.36-7.52 (m, 6H, Arom-H), 7.63-7.81 
(m, 4H, Arom-H). 13C NMR (50 MHz, CDCl3): ppm 19.0, 26.6, 27.0, 29.1, 54.9, 64.6, 
66.4, 69.4, 71.4, 113.5, 124.3, 127.6, 128.8, 129.5, 129.6, 132.8, 135.3, 159.0. Anal. 
calcd for C31H38O4S2Si: C 65.68, H 6.76, S 11.31, Si 4.41. Found: C 65.72, H 6.80, S 
11.25. 
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Compound 11α e 11β. To a stirred CH2Cl2/CH3OH (95/5) solution (8.75 mL) 
containing the alcohol 10 (0.50 g, 0.88 mmol) DDQ (0.28 g, 1.06 mmol) was added in 
one portion at room temperature. After 30 min the reaction was stopped, H2O was 
added, and the mixture extracted with CH2Cl2. The organic layer was dried (Na2SO4), 
and the solvent evaporated under reduced pressure. Chromatography of the crude 
residue over silica gel (hexane/EtOAc:95/5) gave a mixture of anomers α/β:3.3/1 (0.335 
g, 83% yield). Data for major isomer 11α: 1H NMR (200 MHz, CDCl3): δ 1.04 (s, 9H, 
C(CH3)3), 3.17-3.26 (m, 4H), 3.27 (s, 3H), 3.55 (s, 3H), 3.70 (d, J= 10.5, 1H), 3.80 (d, J 
= 10.25, 1H) 5.46 (s, 1H), 7.34-7.42 (m, 5H), 7.66-7.72 (m, 5H). 13C NMR (100 MHz, 
CDCl3): ppm 19.2, 25.9, 26.0, 26.5, 49.7, 55.7, 65.6, 99.4, 107.4, 113.9, 127.4, 129.4, 
135.4, 135.5. Anal. calcd for C24H30O3S2
O
S S
TBDPSO
12
Si: C 62.84, H 6.59, S 13.98, Si 6.12. Found: 
C 62.68, H 6.56, S 14.03. 
 
Compound 12. To a stirred C6H6/CH3OH (95/5) solution (8.75 mL) containing the 
alcohol 10 (0.50 g, 0.88 mmol) DDQ (0.28 g, 1.06 mmol) was added in one portion at 
room temperature. After 3h the reaction was stopped, H2O was added, and the mixture 
extracted with EtOAc. The organic layer was dried (Na2SO4), and the solvent 
evaporated under reduced pressure. Chromatography of the crude residue over silica gel 
(hexane/EtOAc:98/2) gave the pure compound 12 (0.285 g, 75% yield). 1H NMR (200 
MHz, C6D6): δ 1.12 (s, 9H, C(CH3)3), 2.34 (s, 4H, CH2S), 4.56 (s, 2H, CH2OSi), 6.77 
(s, 1H, H-4), 7.17-7.21 (m, 5H, Arom-H), 7.74-7.80 (m, 5H, Arom-H). 13C NMR (100 
MHz, C6D6): ppm 19.2, 25.8, 26.1, 26.3, 26.6, 29.7, 57.0, 128.1, 129.4, 129.6, 133.2, 
134.9, 135.7, 136.3. Anal. calcd for C23H26O2S2Si: C 64.75, H 6.14, S 15.03, Si 6.58. 
Found: C 65.00, H 6.12, S 15.08. 
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Compound 13α. To a stirred C6H6/CH3OH (3/1) solution (8.75 mL) containing the 
alcohol 10 (0.50 g, 0.89 mmol) DDQ (0.37 g, 1.65 mmol) was added in one portion at 
room temperature. After 3h the reaction was complete, H2O was added, and the mixture 
was extracted with CH2Cl2. The organic layer was dried (Na2SO4), and the solvent was 
evaporated under reduced pressure. Chromatography of the crude residue over silica gel 
(hexane/EtOAc:95/5) gave a mixture of anomers α/β=4/1 (0.39 g, 90% yield). The α-
anomer was separated from β-anomer by crystallization from CH3OH. Data for major 
anomer 13α 1H NMR (200 MHz, C6D6): δ 1.16 (s, 9H, C(CH3)3), 2.31-2.54 (m, 4H, 
CH2S), 3.24 (s, 3H, OCH3), 3.37 (s, 3H, OCH3), 4.04 (d, Ja,b = 9.7, 1H, 5-Ha), 4.15 (d, 
Jb,a = 9.7, 1H, 5-Hb) 5.61 (s, 1H, 1-H), 7.01-7.27 (m, 6H, Arom-H), 7.74-7.87 (m, 4H, 
Arom-H). 13C NMR (100 MHz, CDCl3): ppm 19.2, 25.9, 26.0, 26.5, 49.7, 55.7, 65.6, 
99.4, 107.4, 114.0, 127.4, 129.4, 133.5, 135.4, 135.5. Anal. calcd for C25H32O4S2
O
TBDPSO
CH3O
33
OCH3
Si: C 
61.44, H 6.60, S 13.12, Si 5.75. Found: C 61.20, H 6.63, S 13.16. 
 
Compound 33. A solution of 13α (0.30 g, 0.61 mmol) in acetone (7 mL) was added in 
one portion to a stirred suspension of Raney-Ni (W2) (2.25 g, wet) in the same solvent 
(7 mL) at 0 °C. The suspension was stirred for 5h, then the solid was filtered off and 
washed with EtOAc. The filtrate was evaporated under reduced pressure to afford a 
crude residue which chromatography over silica gel (hexane/EtOAc = 98/2) gave the 
pure 33 (0.20 g, 82% yield) white crystals (from CH3OH). 1H NMR (400 MHz, C6D6): 
δ 1.25 (s, 9H C(CH3)3), 3.35 (s, 3H, OCH3), 3.38 (s, 3H, OCH3), 4.09 (d, Ja-b = 10.3, 
1H, 5-Ha), 4.13 (d, Jb-a = 10.3, 1H, 5-Hb) 5.52 (dd, J1,2=J1,3 = 0.8, 1H, 1-H), 5.77 (dd, 
J2,1 1.0, J2,3 5.8, 1H, 2-H), 5.88 (dd, J3,1 = 0.8, J3,2 = 5.8, 1H, 3-H), 7.21-7.30 (m, 5H, 
Arom-H) 7.78-7.88 (m, 5H, Arom-H). 13C NMR (50 MHz, C6H6): ppm 19.3, 26.8, 
50.3, 56.2, 67.0, 107.5, 113.7, 127.6, 129.6, 132.0, 133.4, 134.8, 135.6, 135.7, 135.8. 
Anal. calcd for C22H30O4Si: C 69.31, H 7.59, Si 7.05. Found: C 69.52, H 7.56. 
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Compound 35α e 35β. Cytosine (0.22 g, 1.4 mmol) and glycosyl donor 33 (0.5 g, 1.3 
mmol) was dried by coevaporation with anhydrous toluene, and resuspended in 
anhydrous CH3CN (5 mL). To this N,O-bis(trimethylsilyl)acetamide (BSA, 1.25 mL, 
5.0 mmol) was added and the reaction mixture was kept at room temperature for 20 min 
under nitrogen atmosphere. When a homogenous solution was observed TMSOTf (0.05 
mL, 0.13 mmol) was added. After 24h at room temperature, to reaction mixture 
NaHCO3 aq was added. After 10 min the solution was extracted with EtOAc and 
washed with brine. Organic phase was dried (Na2SO4) and evaporated under reduced 
pressure; chromatography (hexane/EtOAC : 1/1) of the crude residue over silica gel 
afforded protected nucleosides 34α e 34β (0.439 g, 65%) as a 1:2 anomeric mixture. 
Anal. calcd for C25H33N3O5Si: C 64.71, H 6.40, N 8.09, Si 5.40. Found: C 64.99, H 
6.38, N 8.06. 
Data for 35α: white crystals; 1H NMR (400 MHz, CDCl3): δ 1.06 (s, 9H, 
C(CH3)3), 2.27 (s, 3H, COOCH3 ), 3.28 (s, 3H, OCH3), 3.76 (d, Ja-b = 10.9, 1H, 5’-Ha), 
3.93 (d, Jb-a = 10.9, 1H, 5’-Hb), 6.22 (dd, J2’,1’ = 1.2, J2’,3’ = 5.9, 1H, 2’-H), 6.26 (d, 
J3’,2’ = 5.9, 1H, 3’-H), 6.89 (s, 1H, 1’-H), 7.37-7.46 (m, 7H, 5-H, Arom-H), 7.64-7.66 
(m, 4H, Arom-H), 7.86 (d, J = 7.5, 1H, 6-H ), 9.76 (bs, 1H, NH) . 13C NMR (125 MHz, 
CDCl3): ppm 19.2, 24.9, 26.8, 51.0, 64.8, 89.9, 97.1, 114.7, 127.8, 129.8, 129.9, 130.3, 
132.9, 133.9, 135.5, 135.6, 144.6, 155.3, 162.9, 171.0.  
Data for 35β: white crystals; 1H NMR (200 MHz, CDCl3): δ 1.09 (s, 9H, 
C(CH3)3), 2,23 (s, 3H, COOCH3), 3.18 (s, 3H, OCH3), 3.92 (d, Ja-b = 11.2, 1H, 5’-Ha), 
4.05 (d, Jb-a = 11.2, 1H, 5’-Hb), 5.92 (dd, J2,1 = 1.8, J2’,3’ = 5.8, 1H, 2’-H), 6.37 (dd, 
J1’,2’ = 0.7, J2’,3’ = 5.8, 1H, 3’-H), 7.15 (s, 1H, 1’-H), 7.37-7.48 (m, 7H, 5-H, Arom-H), 
7.55-7.64 (m, 4H, Arom-H), 8.23 (d, J = 7.5, 1H, 6-H), 9.0 (bs, 1H, NH). 13C NMR 
(125 MHz, CDCl3): ppm 19.3, 25.0, 26.9, 27.0, 29.7, 49.7, 66.7, 90.7, 116.2, 127.8, 
127.9, 130.0, 130.1, 132.0, 132.3, 135.4, 135.6, 145.2, 156.2, 162.6, 170.6.  
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Compound 36β. To a stirred solution of 35β (0.05 g, 0.10 mmol) in THF (670 µL) 
TBAF (11 µL, 1 M solution in THF, 0.11 mmol) was added at room temperature. The 
reaction was stirred for 18h, then the solvent was evaporated under vacuum. The crude 
residue was treated with 1 mL of NH3/CH3OH 6M at room temperature. After 2h the 
solvent was evaporated and the crude residue purified by chromatography on silica gel 
(CHCl3/CH3OH 8/2) affording the unprotected nucleoside 36β as white crystals (0.023 
g, 97 % o.y.). 1H NMR (400 MHz, CD3OD): 3.26 (s, 3H, OCH3), 3.58 (d, Ja-b = 11.8, 
1H, 5-Ha), 3.74 (d, Jb-a = 11.8, 1H, 5-Hb), 5.90 (d, J = 7.5, 1H, 5-H), 6.26 (dd, J2’,1’ = 
1.3, J2’,3’= 5.9, 1H, 2’-H), 6.32 (d, J3’,2’= 5.9, 1H, 3’-H), 6.83 (bs, 1H, 1’-H), 7.59 (d, J 
= 7.5, 1H, 6-H). 13C NMR (100 MHz, CD3OD): ppm 55.0, 65.2, 90.1, 96.6, 115.5, 
131.8, 135.3, 142.8, 158.6, 167.9. Anal. calcd for C10H13N3O4
O
HO
CH3O N
N
O
NH2
36α
: C 50.39, H 5.46, N 
17.50. Found: C 50.39, H 5.46, N 17.50. 
 
Compound 36α. The nucleoside 36α was obtained (92% o.y.) under the same 
conditions reported for the synthesis of compound 36β.White crystals; 1H NMR (400 
MHz, CD3OD): 3.21 (s, 3H, OCH3), 3.59 (d, Ja-b = 11.9, 1H, 5-Ha), 3.74 (d, Jb-a = 11.9, 
1H, 5-Hb), 5.84 (d, J = 7.5, 1H, 5-H), 6.12 (dd, J2’-1’  = 1.7, J2’-3’ = 5.8, 1H, 2’-H), 6.30 
(d J3’-2’ = 5.8, 1H, 3’-H), 7.13 (s, 1H, 1’-H), 7.88 (d, J = 7.5, 1H, 6-H). 13C NMR (100 
MHz, CD3OD): ppm 50.0, 65.7, 91.7, 96.3, 117.0, 133.3, 135.3, 143.1, 158.7, 167.8. 
Anal. calcd for C10H13N3O4: C 50.39, H 5.46, N 17.50. Found: C 50.39, H 5.46, N 
17.50. 
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4.1 INTRODUCTION 
Modified oligonucleotides MOs, are synthetic compounds devised to have a structural 
resemblance with their corresponding natural counterparts, and occupy a privileged 
position in antiviral and anti-tumor drug design. Compared to nucleoside analogues 
(NAs), which are well established lead compounds for the treatment of a large number 
of human diseases, on the other hand, given their more relatively recent birthdate, only a 
few MOs are currently undergoing advanced clinical trials as drug candidates; however, 
they have potentially much wider and safer therapeutic applications. 
By virtue of their obvious biochemical link, NAs and MOs share a common overall 
pharmacological effect, as they are both able to inhibit viral/cellular replication by 
selectively blocking the information flow enclosed in the viral/human genome. 
However, they use different action mechanisms. On one side, NAs are enzymatically 
converted into their triphosphate forms (NA-TPs), acting as building blocks for nucleic 
acid biosynthesis and usually preventing further viral nucleic acid chain elongation by 
means of various mechanisms as reported in the chapter 3. On the other side, MOs 
interact with nucleic acid complements, with a subsequent involvement of enzymatic 
machineries, which provide the eventual pharmacological effect. The discovery by 
Zamecnik and Stephenson1 (1978) that gene expression can be modified by exogenous 
nucleic acids, sets the basis for so called “gene silencing strategies” in human therapy, 
stimulating the development of technologies that use modified nucleic acids to 
manipulate gene expression.  
Some of the most common approaches for gene silencing2 are briefly discussed 
below (Figure 1). 
Antisense strategy. Short MOs are designed to bind to specific sequences of a 
specific mRNA strand via Watson–Crick duplex formation, the resulting complex being 
recognized by hydrolytic enzymes, such as the RNase H, which cleaves the RNA strand 
releasing the MOs.3 
Antigene strategy. MOs bind sequence selectively to genomic, double stranded 
DNA and interfere with transcription and the DNA processing machinery via triple 
helix formation.4  
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RNA interference. This approach is based on the use of a double helix of a short stretch 
of synthetic RNA (known as siRNA, small interfering RNA). siRNA is introduced into 
the cell and then incorporated into the RNA-induced silencing complex (RISC), 
resulting in the cleavage of the sense strand of RNA by argonaute 2 (AGO2). The 
activated RISC–siRNA complex seeks out, binds to and degrades complementary 
mRNA, which leads to the silencing of the target gene. The activated RISC–siRNA 
complex can then be recycled for the destruction of identical mRNA targets.5  
Figure 1. Action mechanism of MOs as therapeutic agents. 
 
 
4.1.1 FEATURES OF SYNTHETIC OLIGONUCLEOTIDES. 
With the aim of ensuring active therapeutic efficacy in vivo, the MOs must have 
appropriate structural features. 
High affinity and specificity of an oligonucleotide to its mRNA target. MOs 
consisting of 13 nucleotides have the minimum sequence of bases to form hybrids 
(double, triple helices, or more complex structures) with specific complementary strand 
mRNA/DNA, because statistically there are not two strand of this length with the same 
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sequence of bases. In contrast, oligomers of shorter length can theoretically form double 
helices with more of a complementary sequence and so they are less selective.  
Stability of the hybrid. Synthetics MOs are designed to form stable hybrids with 
complementary DNA/mRNA. The stability of a hybrid, whether formed by natural and 
synthetic sequences, can be observed by melting temperature Tm, i.e. the temperature at 
which half of the DNA strands are in the double-helical state and half are in the random 
coil states. Obviously, the oligomer with a better specificity for the complementary 
treatment target is characterized by a higher Tm. It’s also clear that the latter must be 
higher than body temperature, in order to allow his obligation to perform its therapeutic 
activity in vivo. 
Bioavailability. Although an oligonucleotide strand too "short" could lead to a weak 
selectivity for the MO target, the choice to synthesize an oligomer consisting of many 
nucleotide units could make the molecule highly polar (due to the large number of 
phosphate groups), preventing an efficient across cell membranes and nuclear. The best 
choice for determining the length of an ON adapter must therefore represent a 
compromise between specific factors and bioavailability. 
Biostability. MO units consisting of (deoxy)ribonucleotide chemically identical to 
natual (i.e. those studied in vitro by Zamenick and Stephenson) have limited 
applicability in vivo due to rapid degradation by cellular nucleases.1
4.1.2 STABILITY IN VIVO OF 
 In the modern 
development of strategies for gene silencing plays, therefore, a very important role in 
the design of analogues of natural nucleic acids, provided with appropriate changes in 
the chemical structure of the nucleotide base unit in order to improve the stability of the 
biological medium. 
 
 
SYNTHETIC OLIGONUCLEOTIDES: 
SUGAR-MODIFIED NUCLEIC ACIDS 
Three main types of chemical modifications are under investigation in oligonucleotide 
antisense, antigene or RNAi experiments: a) modified nucleobase,6 b) modified sugar,7 
c) modified phosphate group.3,8  
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Figure 2. Chemically-modified nucleic acids. 
 
In particular, the study of oligonucleotide sequences containing chemical modified 
sugar units is a line of research of great interest. Over the last few years an huge number 
of variations of the native furanoside skeleton has been achieved, like simple 
functionalization of the hydroxyl group on C2' of ribonucleotide ring3b or complete 
replacement of the latter with at six-membered rings,7c bi/tricyclic4,7a or acyclic7b 
structures (Figure 2). In many cases, the resulting nucleic acids have shown excellent 
potential as therapeutic agents.
Resistance to nucleases. The replacement of furanoside ring of natural nucleic acids 
with other saccharide units (or their analogues) makes the resulting MOs typically more 
stable to nucleases because the substrate is not recognized as a natural.
3 
The replacement of the (deoxy) ribofuranoside unit of DNA and RNA with 
variously modified monosaccharides is generally devised relying on three important 
factors for the stability and efficacy of the resulting MO analogues: a) resistance to 
nucleases, b) mimicking of natural nucleic acids, c) structural preorganization of the 
nucleotide strand. 
7c In some cases, 
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the ability of MOs to limit the degradative action of cellular nucleases was also obtained 
by replacing the more labile functional groups of natural nucleic acids with chemically 
more stable groups one.
Mimicking natural nucleic acids. The complete definition of the conformation of a 
nucleoside usually involves the determination of three groups of structural parameters: 
a) the orientation about the glycosyl bond as syn or anti, which is more accurately 
defined by the value of the angle χ, b) the orientation of the hydroxymethyl group, 
determined by the value of the angle γ, and c) the deviation from planarity of the sugar 
ring, measured by the angle of pseudorotation P.
9 
10 Particularly, the pseudorotation angle 
has been introduced to describe the continuous interconversions among a (virtually) 
infinite number of puckered forms related to the furanose ring of natural 
(deoxy)ribonucleotides. Thus, furanose ring conformations (mainly envelope and 
twisted) can be conveniently described by the value of phase angle P in the 
pseudorotational cycle (Figure 3). 
 
Figure 3. Structural parameters defining the conformation of a (deoxy)ribonucleoside. 
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By convention, P = 0° corresponds to a C-3'-endo puckering, while P = 180° 
corresponds to the C-2'-endo antipode; they are also generically described, respectively, 
as N (North) and S (South) conformations. In ribose and deoxyribose nucleosides, sugar  
moieties fluctuate between these two extremes, because the crossing energy barrier 
between N and S forms is relatively small (ΔG ~ 20 kJ mol-1). Crystallographic data of 
individual nucleosides revealed that the puckering modes of the furanose ring cluster 
near one of these two antipodal regions:11 N domain between 342° and 18°  
(2E → 3T2→ 3E) and antipodean S area between 162° and 198° (2E → 2T3→ 3E)  
(Figure 3). 
When the sugar rings of natural D-(deoxy)ribonucleotides occupy N and S domains 
in polymeric structures (e.g. RNA and DNA) they lead, respectively, to two common 
right-handed helices, known as A- and B-type forms.12 These two different puckering 
modes are favored because they best alleviate the steric clashes of sugar substituents. 
However, the preference for one conformation or for another one seems to derive from 
the nature of the C-2' group. In the presence of a withdrawing (e.g. OH) group, the C-3'-
endo (N) pucker is the only conformation observed (such as in dsRNA, A-type helix); if 
it is absent, the C-2'-endo (S) pucker is preferred (such as in dsDNA, B-type helix)[1]
O O
B
O
P
O
O
O
OH
O
O
B
O
P
O
O
O
C3'-endo C2'-endo
A-type helix B-type helix
ds-RNA ds-dNA
North South
 
(Figure 4). 
 
Figure 4. A- and B-type duplex conformations reported, respectively, for dsRNA and 
dsDNA. 
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The structural preorganization of the nucleotide strand. It is now well established that 
biological events relying on host-guest recognition processes require appropriate 
structural features of both components.13 The formation of these kind of complexes is 
thermodynamically unlikely for two main reasons. First of all, three degrees of 
translational and rotational entropy are lost while forming a complex from two separate 
molecules. Moreover, if each molecule has free internal bond rotations to be locked for 
the complex, several degrees of freedom for each bond will be lost. Even though the 
first effect is mostly an unavoidable feature of molecular recognition, guest-molecular 
design can overcome the last one.14
4.1.3 THE CRITICAL ROLE OF SUGAR CONFORMATION IN THE 
THERAPEUTIC POTENTIAL OF OLIGONUCLEOTIDE ANALOGUES 
 Particularly, if a guest molecule is designed to be 
“frozen” in the binding conformation before the recognition process, then any entropy 
cost, due to fixing bond rotations, will not be necessary in binding. This assumption 
introduces the concept of “preorganization”, coined by Donald Cram to explain host-
guest interactions in supramolecular chemistry. In few words, reduction of all possible 
conformational states of a guest molecule to those fitting with the geometric and 
stereochemical requirements of a host molecule may lead to an entropic benefit of 
complex formation, and thus to enhanced complex stability. As reported below, the 
concept of molecular preorganization (particularly, that of sugar preorganization within 
nucleoside or oligonucleotide structures) has been profitably exploited to gain insight 
into the structural details underlying both enzyme-NAs recognition events and the 
hybridization properties of MOs to be efficiently annealed with natural complementary 
strands. 
 
 
To be successful, most MOs must rely on efficient hybridization with natural RNA and 
DNA complements. This goal is usually attained by designing structurally-preorganized 
MOs, able to keep the potential for communication (via WC or any other alternative 
base-pairing system) resembling the natural A-type or B-type duplexes without entropy 
penalty involved in the binding process.15 In particular, MOs having sugar units 
restricted into the N conformation, thus forming A-type duplexes, resulted into the 
highest duplex stabilities.16 On the other hand, examples of MOs with mononucleotide 
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units resembling the S sugar pucker, thus leading to B-type duplexes, are much more 
sporadic. An accurate structural similarity with natural nucleic acids is of key relevance 
in some strategies, such as in the antisense approach. Thus, a convincing way to 
improve the binding proprieties of a MO toward the desired duplex conformation has 
been to apply conformational restrictions of the furanose ring of nucleotide units toward 
one of the two C3'-endo and C2'-endo sugar conformations. Hereafter, the potential of 
the most relevant sugar modified MOs will be briefly discussed. 
 
 
4.1.4 SIX-MEMBERED NUCLEIC ACIDS 
1',5'-D-Anhydrohexitol Nucleic Acids (HNA). As above discussed, replacement of a 
furanose ring with a pyranose one involves differences in flexibility, causing 
conformational preorganization of the corresponding oligonucleotide system.17 This was 
the rationale behind the design of a great amount of (pento and hexo)-pyranosyl 
oligonucleotides, which have been investigated over the years to consider their potential 
in therapy,18 diagnostics,19 synthetic biology20 and etiology-oriented research.21 In this 
context, it was thought that nucleobase positioning at the axial or equatorial C2' site of 
an hexopyranosyl unit could bring the extra methylene group of the six-membered ring 
in the minor groove site, where it should not influence the conformational freedom of 
nucleobases in the neighboring residues. This assumption led to the design of 
conformationally restricted pyranose ONs such as 1',5'-anhydro-D-ribo/arabino-hexitol 
nucleic acids (respectively α- and β-HNA).22 Particularly, the β-isomer (corresponding 
to the axial orientation of the nucleobase) demonstrated most accurate mimicking of 
natural nucleic acids. Indeed, as already mentioned for the anhydrohexitol nucleosides, 
the nucleotide unit of β-HNA (hereafter HNA) closely resemble that found in natural 
nucleic acids inducing A-type duplexes, such as RNA.39 
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Figure 5. 1',5'-D-Anhydrohexitol Nucleic Acids (HNA). 
 
Because of these features, the HNA system represented one of the most prominent 
examples of hexopyranose nucleic acids with capability for cross-communication with 
natural complements (DNA: ∆Tm/mod up to +1.3 °C; RNA: ∆Tm/mod up to +3 °C).24 
CD analysis demonstrated that HNA strands of both HNA:RNA and HNA:DNA 
hybrids adopted a winding very close to the A-type helix (Figure 5). However, this 
could also be the reason why HNA:RNA duplexes were resistant to RNase H 
activation.[39] Nonetheless, HNA could be used to control gene expression, as 
demonstrated by the inhibition of P-glycoprotein expression in a cell system.23 
The intriguing properties of HNA stimulated the development of further analogues 
(Figure 6) based on modifications in both structure and configuration of the sugar 
ring.44 For example, the hydroxylated versions of HNA, namely ANA (Altritol Nucleic 
Acids) and MNA (Mannitol Nucleic Acids) were prepared and evaluated (Figure 6). 
The complexes between ANA and RNA or DNA were reported to be even more stable 
than those between HNA and natural complements (e.g., RNA: ∆Tm/mod up to +7 
°C).24 This was evidently due to the introduction of the axially-oriented hydroxyl group, 
with more accurate RNA mimicking. Hybridization ability of ANA enabled to consider 
it as an efficient tool in gene expression inhibition25 and in nucleic acid-based 
diagnostics and nanotechnology.26 Conversely, the diastereoisomeric MNA displayed 
considerably minor affinity to RNA, compared to ANA or HNA.27 Molecular modelling 
studies identified the reason for such reduced affinity in the intrastrand inter-residue H-
bond formation between the equatorial C3'-positioned OH group and the O6' of the 
phosphodiester group of the following nucleotide unit, tying the MNA single strand into 
a non-pairing conformation.28 
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Figure 6. HNA derivatives. 
 
CNA (Cyclohexanyl Nucleic Acids). An interesting example of saturated six-
membered nucleic acids derived from HNA, is Cyclohexanyl Nucleic Acids (CNA).29 
The rigidity of the chair conformation of cyclohexane of CNA gives a high structural 
preorganization to corresponding oligonucleotide strands.  
However, the CNA drew attention because they represent a  first example of 
oligonucleotides existing in two extreme forms. In fact solution phase analysis reveals 
that this nucleosides adopt a) an A-type helix (corresponding to a 4C1 conformation of 
pseudosaccharide portion) superimposable to HNA structure and b) a quasi-linear 
structure (corresponding to a 1C4 conformation of pseudosaccharide portion).7c In 
particular, the single-strand of CNA is present in a non-helical conformation as the 
cyclohexane ring adopts a 1C4 conformation due to unfavorable 1,3-diaxial interactions 
between the nucleobase and the atoms of hydrogen on C1' and C3' in the 4C1 
conformation (Figure 7). The presence of a complementary strand (DNA or RNA) can, 
however, involve a significant thermodynamic advantage by promoting the inversion of 
the chair (1C4 → 4C1) in the adequate conformation for base pairing.12 
 
Figure 7. Conformation of CNA systems. 
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The formation of one of the two conformational states may depend on the type of 
sequence complementary. In fact, it was found that the CNA is able to hybridize with 
orthogonal complementary sequences (D-and L-oligonucleotides) using the two different 
conformations of the nucleotide monomer unit.30 The ability of hybridization of CNA 
with orthogonal complement represents a rare case of modified oligonucleotide systems 
studied until now.7c If pairing with natural DNA and RNA showed the possible use of 
CNA in therapeutic systems,27 its ability to hybridize with orthogonal nucleic acids to 
natural ones has applications in diagnostic field,7c and even in prebiotic chemical 
experiments.28 
On the basis of the above and the study of oligonucleotide systems with limited 
conformational freedom, (in particular of the CNA system), the conformation of the 
saccharide unit of a nucleotide is very important in the development of efficient and 
versatile applicability oligonucleotide drugs. However, it still remains to clarify the 
precise reasons why structural conformational changes, such as modified saccaride unit 
of the CNA, may determine the pairing of a nucleotide respect to two orthogonal 
complements. This justifies the conformational studies currently under way in this field, 
in particular the studies based on nucleic acids having six-membered (pseudo-) 
saccharide units, carried out in order to make new oligonucleotide systems with 
remarkable therapeutic potential. 
Cyclohexenyl Nucleic Acids (CeNA). One of the most effective six-membered 
MOs is indeed represented by cyclohexenyl nucleic acids (CeNA), a DNA mimic 
having the deoxyribose replaced by a cyclohexenyl moiety31 (Figure 8). Although this 
system holds minor flexibility than that of a natural nucleotide (constraints are 
introduced by the rigid double bond within the six-membered ring), conformational 
equilibria and thermodynamic parameters of a cyclohexenyl nucleoside [∆E between 
3H2 (N-type) and 2H3 (S-type) is 1.8 kJ/mol with a barrier of 10.9 kJ/mol] were very 
similar compared to a natural ribonucleoside (∆E between N-type and S-type 
conformers is 2 kJ/mol with a barrier of 4-20 kJ/mol).32 The flexibility of the 
cyclohexenyl nucleotide was further demonstrated by the fast equilibrium between two 
conformational states adopted when the NA was incorporated in ds-DNA sequences.33 
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Figure 8. Cyclohexenyl Nucleic Acids (CeNA). 
 
CeNA were capable of forming hybrids with natural complements (average ∆Tm/mod 
+1.2 °C), CeNA/RNA duplexes being more stable than the corresponding DNA/RNA 
hybrids.34 In view of the selective interaction with RNA complements and the 
preservation of RNaseH recognition of a CeNA:RNA hybrid, CeNA currently 
represents one of the most promising antisense candidates. Moreover, it has recently 
been demonstrated that CeNA could be incorporated in siRNA duplexes, with retention 
of potent biological activity.35 
The above results highlighted how, among the most relevant examples of 
conformationally restricted NAs, those bearing a six-membered moiety drew most 
attention, as they demonstrated to enable precise positioning of functional groups (in 
ways otherwise thermodynamically disfavored) in recognition events dealing with the 
development of both efficient NAs and MOs. This justifies the longstanding efforts in 
the field, as well as the still ongoing studies aimed to explore other six-membered NAs 
endowed with broad therapeutic activity. 
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4.2 RESULTS AND DISCUSSION 
Considering the results discussed in the previous section, during my PhD, an efficient 
synthetic routes to prepare a new class of carbocyclic nucleic acid, identifiable with 
acronym “ribo-CNA” (ribo-configured D-Cyclohexanyl Nucleic Acids) has been 
developed. They were been designed on the basis of structural analogy with CNA and 
ANA modified oligonucleotides (Figure 1a-b). As in the case of ANA (Figure 1a), the 
sugar unit of ribo-CNA should be able to mimic the RNA structure locked in its 
bioactive conformation (C3'-endo or 3E), in order to make MOs able to form stable 
double and triple helices. As in the case of CNA (Figure 1b), it will be evaluated the 
capacity of ribo-CNA to adopt different conformations of saccharidic unit to study the 
geometric relationships that exist between this latter and the ability of hybridization of 
corresponding nucleic acid sequences compared to their complementary sequences. 
 
Figure 1. ribo-CNA, a new class of carbocyclic nucleic acids. 
 
This work concerned the preparation of the nucleosides 1 and 2 (B = T, ABz), through a 
versatile procedure applicable also for the preparation of the remaining nucleosides 3-4 
(B = GiBu, CBz, Scheme 1). Compounds 1-4 constitute the building blocks for the 
subsequent oligonucleotide synthesis of ribo-CNA, whose ability to form stable 
double/triple helices with complementary sequences of natural mRNA and dsDNA will 
be evaluate. 
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Scheme 1. Nucleoside monomers 1-4: retrosynthetic path. 
 
 
4.2.1 SYNTHESIS OF NUCLEOSIDE UNITS. 
The structure of nucleosides 1-4 consists of a six-membred carbocyclic skeleton whose 
configuration of stereogenic centers mimics the D-altrosie. As indicated by 
retrosynthetic analysis (Scheme 1), the preparation of this compounds can be achieved 
through an enantioselective synthetic procedure using an economical starting material 
cyclohexanone (7), via the intermediates 5 and 6. The synthesis of the nucleosides 1-2 is 
described below. 
 
SYNTHESIS OF (2R)-2-(HYDROXYMETHYL) CYCLOHEXAN-1-ONE (17) 
The first step of the syntesis is represented by the enantioselective reaction of α-
hydroxymethylation of cyclohexanone (7), resulting in the formation of a new chiral 
center that will determine the steric series (D- or L-) of nucleoside unit target. In 
particular α-hydroxymethylation of 7 was conducted through an organocatalytic 
reaction. It’s know that organocatalysis1 is a branch of asymmetric catalysis in which 
the catalytic activity, often associated with a high stereoselectivity, uses available 
commercially organic molecules (such as natural amino acids)2 or easily synthesized 
molecules (modified pyrrolidines chiral or monosaccharides derivatives)3,4 without the 
use of transition metals. For this reason, organocatalysis associates a significant eco-
compatibility and low toxicity of the reagents with a high efficiency and versatility. 
From a synthetic point of view, organocatalysts commonly act on carbonyl compounds 
(mainly aldehydes and ketones), leading to generally products of α-functionalization5 
via aldolic condensation reactions6 or Mannich reactions.7 
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The organocatalytic procedure8 used to allow the insertion of hydroxymethyl group on 
the cyclohexanone (7) (Scheme 2) involved the use of D-proline, enantiomer of natural 
L-proline. i,9 A product with the (R)configuration  required by the target nucleoside was 
obtained. Specifically, treatment of a solution of 7 in dimethyl sulfoxide (DMSO), with 
an aqueous solution of formaldehyde (15) and a catalytic amount (10%) of D-proline 
(13) took to the formation, after 16h at room temperature, of alcohol 17, obtained with 
complete enantioselectivity (ee = 99%), albeit with a modest yield (28%). The 
mechanism of this reaction involves the initial formation of the enamine intermediate 
14, by reaction of the carbonyl group of 7 with proline 13, with leakage of a water 
molecule. The reaction of 14 with the electrophile 15 led to imino intermediate 16. 
Finally, the attack of H2O estabilished again the carbonyl function, giving the α-
hydroxymethyl cyclohexanone (17) (Scheme 2). 
 
Scheme 2. α-Hydroxymethylation of cyclohexanone (7). 
 
The complete stereoselectivity of this reaction is due to formation of intramolecular 
hydrogen interaction in enamine intermediate 14, (Scheme 2), the Re face of 14 
presents more steric hindrance that obstructs a possible nucleophilic attack. The high 
enantiomeric excess of reaction makes this method particularly useful for our synthetic 
                                                 
i Amino acids, especially proline, have taken a leading role because they have been among the best 
catalysts in this reactions, presenting in the same molecule, the amino group and the carboxyl function; 
see ref. 1. 
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purposes, although this reaction is characterized by a low chemical yield (this problem 
is not important in virtue of the large commercial availability of starting materials). 
 
SYNTHESIS OF (2R)-2-(BENZYLOXYMETHYL) CYCLOHEXAN-1-ONE (6) 
The primary alcohol 17 was then protected; over a wide range of protecting groups (t-
butyldiphenylsilyl- TBDPS; monomethoxy trityl- MMT; p-methoxybenzyl- PMB) 
tested only benzyl group proved to be sufficiently stable in subsequent synthetic 
transformations and it was hence selected for the protection of primary alcoholic 
function of 17. Common conditions of benzylation (NaH/BnBr) did not afford the 
desired protected compound (Scheme 3). On the other hand the use of benzyl-2,2,2-
trichloroacetimidate 18 (easily prepared from benzyl alcohol (BnOH), 1,8-diazabicyclo 
[5,4,0] undecane-7-ene (DBU) and trichloroacetonitrile)10 and triflic acid
O
OH
BnOH
DBU, CCl3CN
CH2Cl2
NH
CCl3BnO
O
OBn
TfOH, THF
17 6
18
52%
NaH/BnBrno
reactivity
 (TfOH) gave 
the desired product 6 with a satisfactory yield (52%; Scheme 3). 
 
Scheme 3. Synthesis of (2R)-2-(benzyloxymethyl) cyclohexan-1-one (6). 
 
SYNTHESIS OF (6R)-6-(BENZYLOXYMETHYL)-2-CYCLOHEXEN-1-ONE (20) 
Benzyl ether 6 was further functionalized with introduction of a double bond in not 
chiral α-position, in view of installation of the remaining chiral centers of target 
nucleoside unit. The preparation of 20 proceeded through the formation of trimethysilyl 
enol ether 19, obtained by treatment of ketone 6 with lithium diisopropylamide (LDA) 
and trimethylsilyl chloride (TMSCl) in tetrahydrofuran at -78 °C (Scheme 4). The 
reaction was carried out using LDA generated in situ by treatment of diisopropylamine 
(DIPA) with n-butyllithium (Buli). The silyl enol ether 19 is not sufficiently stable to be 
stored, anyway it could be isolated for its 1H NMR characterization, so it was used 
directly in subsequent reaction. In particular, treatment of 19 with palladium acetate in 
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anhydrous acetonitrile led, after 2 h at room temperature,  with complete conversion to 
20 (96% overall yield starting from 
O
OBn
BuLi, THF
- 78°C
OTMS
OBn
TMSCl
THF, -78 °C6 19
LDA
96% (f rom 6)
N
H
DIPA
N
O
OBn
20
Pd(OAc)2
CH3CN
2h, r.t.
6). 
 
Scheme 4. Synthesis of (6R)-6-(benzyloxymethyl)-2-cyclohexen-1-one (20). 
 
SYNTHESIS OF (1AS, 2R, 3R, 5AS)-2-HYDROXY-3-(BENZYLOXYMETHYL) 
PERHYDRO-1-BENZOXIRENE [SYN-(ANTI-5)] 
With the compound 20 in hand, the possibility to insert nucleobase exploiting the 
presence of an electrophilic center on the carbocyclic skeleton was then examined. As 
reported on similar substrates,11 the electrophilic center is commonly achieved through 
the installation of an epoxy function (as in 21) able to undergo nucleophilic attack by 
nucleobase, to obtain the desired nucleoside 22 in the right configuration (Scheme 5). 
However, a stereoselective epoxidation reaction is necessary; indeed only the epoxide 
with appropriate stereochemistry (anti to hydroxymethyl group) allow the addition of 
nucleobase in the desired position and with appropriate axial orientation. 
Preliminary tests of epoxidation of 20 were carried out using a wide range of 
reagents (H2O2/NaOH, UHP/NaOH, Triton B/H2O2). However, in all conditions used 
no satisfactory results were dotained (Scheme 5) probably due to the presence of 
carbonyl group near the chiral center. In fact, under common basic conditions, required 
for the epoxidation of a α,β-unsaturated ketone, the carbonyl function may be subject to 
enolization by proton removal on chiral carbon leading to racemization of the substrate 
and loss of stereoselectivity. 
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Scheme 5. Epoxidation for nucleobase insertion. 
 
On the basis of these considerations, an alternative strategy was chosen. Firstly 
reduction of the carbonyl group was carried out, and then stereoselective epoxidation of 
the corresponding allyl alcohol was attempted (Scheme 6). The reduction of the 
carbonyl group of 20 was realized using a wide range of reducing agents (NaBH4, 
LiAlH4, Na(AcO)3BH, LiBH4, DIBAL-H, Red-Al, Li(MeO)3AlH), to study the most 
favorable conditions for the stereoselective formation of the required anti-product. As 
recently reported in the literature on similar substrates,12 best conditions were found by 
the use of lithium aluminum hydride (LiAlH4) in anhydrous THF (Scheme 6); indeed 
after 3.5h at -100 °C, a mixture of anti-23 and syn-23 diastereomers was isolated (84% 
overall yield), with a satisfactory preference for the anti-product (dranti /syn = 75:25). 
 
Scheme 6. Reduction and epoxidation reactions. 
 
Unfortunately, reduction products (anti-23 and syn-23) were not separable by 
chromatograpy: therefore the mixture of diastereoisomers was directly used in the next 
epoxidation step. 
It’s known that epoxidation reactions on chiral allylic alcohols with peroxy acids 
are typically associated to high stereoselectivity of the oxidation process, 13 thanks to the 
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a hydrogen bond established between the allylic hydroxyl group and peracid, which 
guides the formation of a single stereoisomer predominantly. Hence, the epoxidation 
reaction was carried out starting from the mixture of alcohols knowing that four 
possible diastereoisomeric oxiranes could be obtained. In fact, treatment of alcohols 
anti/syn-23 with a slight excess of m-chloroperoxybenzoic acid (m-CPBA) in anhydrous 
CH2Cl2
SYNTHESIS OF CARBOCYCLIC NUCLEOSIDE ANALOGUES 1 AND 2.  
 gave, after 3 h at -20 °C, only three epoxides, the syn-(anti-5) being the most 
abundant (70% yield; easily purified by flash chromatography). On the other side, it is 
reasonable to hypothesize that treatment of syn-23 with m-CPBA has not led to any 
stereoselectivity, leading to the formation of a 1/1 mixture of syn-(syn-5) and anti-(syn-
5) epoxides (20% yield), due to the steric hindrance of the benzyl ether group on Re 
face which is typically involved in the formation of the epoxy function. (Scheme 6). 
 
At this point our attention was focalized on synthesis of the nucleosides 25a and 25b 
from the most abundant oxirane syn-(anti-5) through the steps shown in Scheme 7. The 
alcohol syn-(anti-5) was further protected with a benzyl group: in this case the most 
common benzylation conditions (NaH/BnBr) were suitable to achieve the desired 
benzyl ether 24 (98%). 
The regioselective14 ring opening of the epoxide 24 with nucleobases was achieved 
in reasonable yields in the presence of DBU,ii affording the desired carbocyclic 
nucleosides.15 Indeed, trans-diaxial ring opening
                                                 
ii DBU was preferred to other commonly used bases, such as NaH or LiH, because not strictly anhydrous 
conditions were required. 
 of 24 with thymine (T) and DBU in 
dry DMF at 120 °C for 7 h afforded protected nucleoside 25a, in 80% yield, with “D-
altro” configuration to the newly formed stereogenic centers (Scheme 7). Analogously, 
the reaction of 24 with adenine (A), under the same conditions, gave nucleoside 25b 
with more satisfactory 90% yield.  
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BnO
O
OBn
24
DMF
120°C, 7hBnO
OH
BnO
25a B = T
25b B = A
B
HO
O
OBn
5
NaH, BnBr
DMF, 0 °C
98%
B
 
Scheme 7. Synthesis of  nucleosides 25a-b: trans-diaxial ring opening of epoxide 24. 
 
Finally, protection of hydroxyl function of 25a using a catalytic amount of 4-
dimethylamino pyridine (DMAP) and benzoyl chloride in pyridine for 4h, led to the 
desired nucleoside 1 with 98% yield. Under the same conditions and through the 
subsequent in situ mono-N6-debenzoylation (by treatment of reaction mixture with 
concentrated ammonia) nucleoside 2 was obtained with a satisfactory 95% yield 
(Scheme 8). 
It’s noteworthy to note that nucleoside 1 and 2 adopt a 1C4-like conformation due to 
the steric hindrance of 3’-OBz group and the nucleobase in axial position (Scheme 8).iii 
Inversion of conformation was verified by coupling costants analysis of 1H NMR for 
compounds 1 and 2 which showed a J3’,4’ (J = 3.05 Hz), J3’,2’ (J = 11.2 Hz) for 1, and  
J3’,4’ (J = 2.8 Hz), J3’,2’
BnO
OH
OBn
25a B = T
25b B = A
B
BzCl/Py BnO
OBz
OBn
1 B = T
2 B = ABz
B
OBn
BnO
BzO
B
H
H
H
1C44C1
rt1'2'3'
4'
5'
6'
7'
1 J3' ,2' = 11.2 Hz
2 J3' ,2' = 10.6 Hz
1 J3',4' = 3.05 Hz
2 J3',4' = 2.8 Hz
 (J = 10.6 Hz) for 2. 
 
Scheme 8. Synthesis of nucleosides 1-2. 
 
Even though they adopt the 1C4 in the form of nucleosides, it’s reasonable to 
hypothesize that the corresponding nucleotides will adopt the 4C1
                                                 
iii Starting from compounds 25a-b, numbering was attributed on the base of analogy with natural 
nucleosides. 
 one, because 
otherwise they should resemble the “forbidden” C2’-endo super puckering of RNA. 
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4.2.2 OLIGONUCLEOTIDE SYNTHESIS 
Nucleosides 1 and 2 represent the building blocks for the next oligonucleotide synthesis 
(Scheme 10), which will be assembled into oligomers of different sequences, each 
consisting of 13 nucleotide units, containing the ribo-CNA-T, and ribo-CNA-A 
monomers. 
 
Scheme 10. Oligonucleotide synthesis by phosphoramidite method. 
 
The stage of nucleoside incorporation into oligomeric sequences,16 after deprotection of 
hydroxyl groups in C-4’ and C-6’ position, will be accomplished by using the common 
phosphoramidite method17 on a solid support in laboratories of Professors Piet 
Herdewijn and Arthur van Aerschot of the Rega Institute for Medical Research, 
Katholieke Universiteit Leuven (Belgium). 
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4.3 CONCLUSION 
At the beginning of last century, the Nobel prize Paul Ehrlich, medical microbiologist, 
immunologist and pioneer of chemotherapy, theorized the existence of magic bullets 
capable of locked the action of toxic substances in infected organisms, reducing 
dramatically the occurrence of side effects. The advent of gene silencing strategies 
based on the development of synthetic MOs promises to achieve the specificity and 
efficacy that Ehrlich thought. This strategies for regulating the expression of a gene 
results completely selective, and of universal applicability, compared to traditional 
therapies. 
For more than two decades, chemists have explored the chemical space in search 
for analogs of natural nucleic acids (NAs) endowed with certain desirable properties, 
such as increased stability against nucleolytic degradation and improved binding 
affinity toward natural complements. Strong motivations for this research have been the 
therapeutic promises of antisense, antigene, aptamer, and, in more recent times, RNAi 
and miRNA strategies. In addition, chemically modified NAs, and particularly those 
equipped with a sugar moiety in the backbone deviating from the natural D-
(deoxy)ribose, have been considered for a plethora of other potential in vitro and in vivo 
applications: they have been used, inter alia, as chemical probes in NA diagnostics or in 
the analysis of protein-NA interactions; as (potential) unnatural carriers of genetic 
information; as building blocks for the assembly of higher-order nanostructures; as 
synthetic models of alternative basepairing systems, aimed at potentially yielding 
insights into the origin and uniqueness of DNA and RNA. Over the years, slight 
modifications of the original furanose moiety  or replacement of the five-membered ring 
with six-membered, bicyclic, tricyclic, or even acyclic structures have been conceived, 
resulting, in many cases, in excellent candidates for cross-pairing with natural 
complements.  
In this work an enantioselective procedure for the synthesis of ribo-configured 
cyclohexanyl nucleic acids starting from economical cyclohexanone 7, has been 
conveniently reported. Further experiments aimed to incorporate nucleosides 1 and 2 in 
oligonucleotide strands, will determine their hybridization aptitude with natural mRNA 
and dsDNA sequences. 
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4.4 EXPERIMENTAL SECTION 
All moisture-sensitive reactions were performed under a nitrogen atmosphere using 
ovendried glassware. Solvents were dried over standard drying agents and freshly 
distilled prior to use. Reactions were monitored by TLC (precoated silica gel plate 
F254, Merck). Column chromatography: Merck Kieselgel 60 (70-230 mesh); flash 
chromatography: Merck Kieselgel 60 (230-400 mesh). 1H and 13C NMR spectra were 
recorded on NMR spectrometers operating on Varian VXR (200 MHz), Bruker DRX 
(400 MHz) or Varian Inova Marker (500 MHz), using CDCl3
O OH
17
 solutions unless otherwise 
specified. In all cases, tetramethylsilane (TMS) was used as internal standard for 
calibrating chemical shifts (δ). Coupling constant values (J) were reported in Hz. 
Combustion analyses were performed by using CHNS analyzer. 
 
(2R)-2-(hydroxymethyl) cyclohexan-1-one (17). To a solution of cyclohexanone 7 
(10.0 g, 0.10 mmol) and (D)-proline 13 (1.2 g 0.01 mmol) in DMSO (120 mL), 
formaldehyde 15 (4 mL, 0.05 mmol, 37% in H2O) was added at room temperature. 
After 16 h, the reaction mixture was quenched by the addition of brine and extracted 
with EtOAc. The combined organic extracts were concentrated and the crude product 
purified by silica gel column chromatography (hexane/ EtOAc 6:4) affording the pure 
17 in 28% yield with >99% ee; [α]D25 -11.9 (c 0.41, CHCl3). 1H NMR (200 MHz, 
CDCl3): δ 1.39–1.50 (m, 2H, H-4); 1.56–1.73 (m, 2H, H-5); 1.86–1.92 (m, 1H, OH); 
1.97–2.12 (m, 2H, H-3); 2.25-2.41 (m, 2H, H-6); 2.42–2.53 (m, 1H, H-2); 3.57 (dd, Ja,b 
= 11.5, Ja,2 = 3.8, 1H, CHHaOH); 3.72 (dd, Jb,a = 11.5, Jb,2 = 7.5, 1H, CHHbOH). 13C 
NMR (50 MHz, CDCl3) δ: 24.9, 27.7, 30.2; 42.4; 52.5, 63.0; 215.0. Anal. calcd for 
C7H12O2: C, 65.60; H, 9.44. Found: C, 65.38; H, 9.47. 
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O OBn
6  
(2R)-2-(benzyloxymethyl) cyclohexan-1-one (6). To a solution of 17 (0.5 g, 3.9 mmol) 
in dry CH2Cl2 (16 mL) BnOC(NH)CCl3 18 (1.97 g, 7.8 mmol) in dry THF (3.25 mL) 
and triflic acid (40 µl, 0.39 mmol) was added at -10 °C. After 2 h to the mixture of 
reaction NaOHaq (3%) was added. The mixture was washed three times with H2O 
extracted with CH2Cl2 and the organic phase dried on dry Na2SO4. The solvent was 
evaporated under vacuum, crude product obtained was purified by chromatography on 
silica gel (1:30, hexane/Et2O, 8:2) to give the pure 6 (0.4 g, 52% yield). Oily; 1H NMR 
(300 MHz, CDCl3): δ 1.48-1.52 (m, 2H, H-4), 1.66-1.71 (m, 2H, H-5), 2.07–2.08 (m, 
2H, H-3), 2.32–2.38 (m, 2H, H-6), 2.65–2.70 (m, 1H, H-2), 3.46 (dd, JHa,Hb = 9.50, 
JHa,H-2 = 7.40, 1H, CHaHOBn), 3.86 (dd, Ja,b = 9.50, Jb,2 = 5.10, 1H, CHHbOBn), 4.52 
(d, Ja,b = 11.9, CHHaPh,1H), 4.57 (d, Jb,a = 11.9, CHHbPh,1H), 7.35 (m, 5H, Arom- 
H). 13C NMR (75 MHz, CDCl3): ppm 24.7, 27.6, 31.4, 42.0, 50.8, 69.3, 73.2, 69.3, 
127.4, 127.5, 128.22, 138.3, 211.5. Anal. calcd for C14H18O2
O OBn
20
: C, 77.03; H, 8.31. Found: 
C, 76.92; H, 8.35. 
 
(6R)-6-(benzyloxymethyl)-2-cyclohexen-1-one (20). To a stirred solution of DIPA 
(312 µl, 2.2 mmol) in dry THF (4 mL), at -78 °C, n-BuLi (1.6 M in hexane, 1.81 mL, 
1.94 mmol) was added to prepare LDA in situ. After 10 min, to the mixture ketone 6 
(0.4 g, 1.84 mmol) in dry THF (4 mL) was added. The mixture was stirred for further 30 
min at this temperature, and then TMSCl (400µl, 3.13 mmol) was added. After 3 h the 
solvent was evaporated under reduced pressure and the crude residue was filtered on 
celite and washed with pentane. To a solution of Silyl enol ether 19 so obtained was in 
CH3CN (20 mL) Pd(OAc)2 (408 mg, 1.84 mmol) was added. After 2 h the mixture was 
filtered on celite and eluted with CH2Cl2, the eluate was washed with brine. The crude 
residue purified by chromatography on silica gel gave the pure compound 20 (381 mg, 
96% o.y.). Oily; 1H NMR (200 MHz, CDCl3): δ 1.80-2.06 (m, 2H, H-5), 2.22-2.47, (m, 
2H, H-4), 2. 56–2.70 (m, 1H, H-6), 3.62 (dd, Ja,b = 9.52, Ja,2 = 7.57, 1H, CHaHOBn), 
3.87 (dd, Ja,b = 9.53, Jb,2 = 4.15, 1H, CHHbOBn), 4.53 (s, 2H, CH2Ph), 6.52 (dt, J = 
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1.96, J = 2.15, 1H, H-3), 6.92-7.01(m, 1H, H-2), 7.28-7.34 (m, 5H, Aromat-H). 13C 
NMR (50 MHz, CDCl3): ppm 23.0, 25.5, 25.9, 26.3, 38.05, 47.4, 61.1, 69.4, 73.5, 
127.8, 127.9, 128.6, 130.0, 138.6, 146.7, 150.5, 200.8. Anal. calcd for C14H16O2
OH OBn
5
O
: C, 
77.75; H, 7.46. Found: C, 77.65; H, 7.49. 
 
(1aS, 2R, 3R, 5aS)-2-hydroxy-3-(benzyloxymethyl) perhydro 1-benzoxirene (5). To 
a stirring solution of 20 (0.02 mg, 0.92 mmol) in dry THF (4.5 mL), at -100 °C under 
nitrogen atmosphere LiAlH4 (9.0 mg, 0.23 mmol) was added. After 3.5h, the mixture 
was cooled at 0 °C, diluted with EtOAc and NaHCO3 aq (7.5 mL). After 15’, the 
solution was extracted with EtOAc. The organic phase was dried on Na2SO4 and 
evaporated under vacuum. The crude residue, purified by chromatography on silica gel 
(hexane/EtOAc = 8:2), gave a mixture of alcohols syn-23 e anti-23 (164 mg, 84% yield, 
anti/syn:75/25). To a stirred solution of olefins syn-23 e anti-23 (0.10 g, 0.46 mmol) e 
NaHCO3 (40 mg, 0.46 mmol) in dry CH2Cl2 (3 mL), at -20 °C, under nitrogen 
atmosphere, m-CPBA (0.97 g, 0.46 mmol) was added in one portion. After 3h, the 
mixture was extracted with CH2Cl2 and washed with brine. The organic phase was 
dried on Na2SO4 and evaporated under vacuum to give a crude residue which was 
purified by flash chromatography (hexane/ EtOAc = 8:2), affording the pure syn-(anti-
5) (82 mg, 70% yield). Oily; 1H NMR (300 MHz, CDCl3): δ 1.02–1.19 (m, 2H, H-4), 
1.35–1.49 (m, 2H, H-5), 1.89-1.90 (m, 2H, H-3, OH), 3.33 (bs, 2H, CH2OBn), 3.51 (m, 
2H, H-1a, H-5a), 3.95 (d, 1H, H-2), 4.55 (bs, 2H, CH2Ph), 7.35 (m, 5H, Arom-H). 13C 
NMR (75 MHz, CDCl3) δ: 22.2, 23.1, 37.4, 54.7, 56.0, 72.1, 73.1, 73.5, 127.5, 127.6, 
128.3, 137.7. Anal. calcd for C14H16O2
OBn OBn
24
O
: C, 77.75; H, 7.46. Found: C, 77.65; H, 7.49. 
 
(1aS,2R,3R,5aS)-2-benzyloxy-3-(benzyloxymethyl) perhydro-1-benzoxirene (24). 
To a stirred solution of alcohol 5 (0.82 g, 0.35 mmol) in dry DMF (3 mL) at 0 °C, under 
nitrogen atmosphere, BnBr (0.72 g, 0.46 mmol) and NaH (8.4 mg, 0.35 mmol) were 
added. After 1.5h, the mixture was extracted with AcOEt and washed with brine. The 
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organic phase was dried on Na2SO4 evaporated under reduced pressure. 
Chromatography of crude residue over silica gel (hexane/EtOAc = 9:1) gave the pure 24 
(0.11 g, 98% yield). Oily; 1H NMR (300 MHz, CDCl3): δ 1.28-1.35 (m, 2H, H-4), 1.58-
1.69 (m, 2H, H-5), 1.85-195 (m, 1H, H-3), 3.33 (m, 2H, H-1a, H-5a), 3.54 (m, 2H, 
CH2OBn), 3.80 (d, J2,1a= 9.5 Hz,1H, H-2), 4.46 (d, Ja,b= 11.9 Hz, 1H, CHaHPh’), 4.49 
(d, Jb,a = 11.9 Hz, 1H, CHbHPh’), 4.63 (d, Ja,b = 11.7 Hz, 1H, CHHaPh), 4.75 (d, Jb,a = 
11.7 Hz, 1H, CHHbPh), 7.34 (m, 10H, Arom-H). 13C NMR (75 MHz, CDCl3): δ 22.3, 
24.2, 35.9, 53.4, 54.3, 70.5, 70.6, 72.7, 127.2, 127.6, 128.0, 128.1, 138.2, 138.3. Anal. 
calcd for C21H24O3
OBn OBn
25a
HO
T
1'
2 '
3' 4' 5' 6'
7 '
: C, 77.75; H, 7.46. Found: C, 77.64; H, 7.49. 
 
Compound 25a. To a solution of epoxyde 24 (0.10 g, 0.31 mmol) in dry DMF (3 mL), 
under nitrogen atmosphere, thymine (0.89 g, 0.71 mmol) was added at room 
temperature. After 15 min, to the resulting mixture DBU (0.11 g, 0.71 mmol) was 
added. The solution was stirred at 120 °C for 7h; after that the solution was cooled at 
room temperature, extracted with CH2Cl2 and washed with NH4Cl. The organic phase 
dried on Na2SO4 was evaporated under vacuum to give a crude residue that purified on 
silica gel (EtOAc/hexane = 1:1) provided the pure 25 (0.12 g, 80% yield). White 
crystals (from EtOAc); 1H NMR (300 MHz, CDCl3): δ 1.45-1.99 (m, 7H, CH3, H-1’, 
H-7’), 2.51 (m, 1H, H-5’), 3.57-3.62 (m, 3H, H-4’,CH2OBn), 3.85-3.95 (m, 1H, H-2’), 
3.99 (bs, 1H, H-3’), 4.49-4.73 (m, 4H, 2xCH2Ph), 6.77 (s, 1H, H-6), 7.36 (m, 10H, 
Arom-H), 8.54 (s, 1H, NH). 3C NMR (75 MHz, CDCl3): δ 12.3, 22.2, 25.9, 29.6, 36.4, 
69.3, 71.0, 71.7, 73.5, 79.8, 110.5, 127.7, 127.9, 128.4, 128.5, 137.2, 137.7, 137.8, 
151.4, 163.2. Anal. calcd for C26H30N2O5
OBn OBn
25b
HO
A
1'
2 '
3' 4' 5' 6'
7'
: C, 69.31; H, 6.71; N, 6.22. Found: C, 69.18; 
H, 6.74; N, 6.25. 
 
Compound 25b. Under the same conditions used to prepare nucleosides 25a, 
compound 25b was obtained in 90% yield. White crystals (from EtOAc); 1H NMR (300 
MHz, CD3OD): δ 1.66-1.70 (m, 2H, H-7’), 1.83-2.11 (m, 4H, CH3, H-1’), 2.52 (m, 1H, 
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H-5’), 3.65-3.78 (m, 2H, CH2OBn), 4.00 (bs, 1H, H-4’), 4.47 (dd, J3’-4’ = 3.1, J3’-2’ = 
10.6, 1H, H-3’), 4.56 (s, 2H, CH2Ph’), 4.58-4.78 (m, 3H, H-2’,CH2Ph’), 7.28-7.45 (m, 
10H, Arom-H), 8.05 (s, 1H, H-8), 8.14 (s, 1H, H-2). 13C NMR (75 MHz, CD3OD): δ 
12.1, 20.9, 22.0, 26.3, 28.7, 29.0, 31.3, 36.9, 56.9, 68.6, 69.4, 71.6, 72.4, 78.8, 118.7, 
126.9, 127.0, 127.2, 127.4, 127.6, 127.7, 138.1, 138.4, 140.5, 149.3, 151.5, 155.4. Anal. 
calcd for C26H29N5O3
OBn OBn
1
BzO
T
: C, 67.95; H, 6.36; N, 15.24. Found: C, 67.82; H, 6.39; N, 15.30. 
 
Compound 1. To a stirring solution of 25a (0.10 g, 0.23 mmol) in dry pyridine (1 mL), 
benzoyl chloride (276 µL) and a catalytic amount of DMAP (10%) were added at room 
temperature. After 4 h the TLC showed the complete formation of final product. The 
solvent was evaporated under vacuum and the crude residue was extracted with EtOAc 
and washed with brine. Purification by chromatography over silica gel (EtOAc/hexane 
= 1:1) gave the pure 1 (98% yield). White crystals (from EtOAc); 1H NMR (300 MHz, 
CDCl3): δ 1.72 (s, 4H, CH3), 1.77-1.80 (m, 1H, H-7’), 1.86-1.90 (m, 2H, H-1’), 2.37 
(bs, 1H, H-5’), 3.66-3.68 (m, 2H, CH2OBn), 4.15 (bs, 1H, H-4’), 4.55-5.58 (m, 4H, 
CH2Ph’), 5.16 (s, 1H, H-2’), 5.62 (dd, J3’-4’ = 3.05, J3’-2’ = 11.2, 1H, H-3’), 6.87 (d, 1H, 
J6-5= 1.15, H-6), 7.28-7.56 (m, 11H, Arom-H), 7.66 (d, J = 8.25, 2H, Arom-H) 7.98 (d, 
J = 8.25, 2H, Arom-H). 13C NMR (75 MHz, CDCl3): δ 11.95, 21.9, 26.4, 38.2, 71.1, 
72.1, 72.3, 73.5, 110.4, 127.2, 127.6, 127.9, 128.1, 128.2, 128.3, 129.1, 129.4, 129.8, 
133.0, 133.1, 137.7, 137.9, 150.8, 163.3, 165.4. Anal. calcd for C33H34N2O6
OBn OBn
2
BzO
ABz
: C, 71.46; 
H, 6.18; N, 5.04. Found: C, 71.58; H, 6.16; N, 5.03. 
 
Compound 2. To a stirring solution of 25b (0.1 g, 0.21 mmol) in dry pyridine (1 mL), 
benzoyl chloride (274 µL) and a catalytic amount of DMAP (10%) was added at room 
temperature. After 3h concentrated ammonia (0.1 mL), was added to afford selective 
N6-monodebenzoylation. After stirring for 1 h at 0 °C the solvent was removed under 
reduced pressure and residue coevaporated three times with toluene. Chromatography of 
crude residue over silica gel (EtOAc) gave the pure nucleoside 2 (95% yield). White 
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crystals (from EtOAc); 1H NMR (300 MHz, CDCl3): δ 1.12-1.43 (m, 2H), 1.44-1.85 
(m, xH) 2.07-2.22 (m, xH), 2.58 (m, 1H, H-5’), 3.64-3.81 (m, xH, H-6’), 4.25 (bs, 1H, 
H-4’), 4.59-4.69 (m, 2H, CH2Ph), 5.24 (dt, J = 4.2, J = 11.6, 1H, H-2’), 5.91 (dd, J3’-4’= 
2.8, J3’2’= 10.6, 1H, H-3’), 7.16-7.25 (m, xH, Arom-H), 7.30-7.57 (m, xH, Arom-H), 
7.79 (d, J = 8.2, 2H, Arom-H), 7.92 (s, 1H, H-8), 8.00 (d, J = 8.2, 2H, Arom-H), 8.78 (s, 
1H, H-2), 9.05 (s, 1H, NH). 13C NMR (75 MHz, CDCl3): δ 12.3, 22.2, 25.9, 29.6, 36.4, 
69.3, 71.0, 71.7, 73.5, 79.8, 110.5, 127.7, 127.9, 128.4, 128.5, 137.2, 137.7, 137.8, 
151.4, 163.2 . Anal. calcd for C40H37N5O5: C, 71.95; H, 5.58; N, 10.49. Found: C, 
71.85; H, 5.60; N, 10.53. 
